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Endothelial death/dysfunction is a critical process in the development of 
cardiovascular diseases. Finding a source of endothelial cells (ECs) for regenerative 
medicine is a challenging yet fundamental issue. Induced pluripotent stem cells 
(iPSCs) constitute an attractive source of cells for transplantation because of their 
high proliferation and differentiation potential.  
 
We established a protocol using collagen and VEGF to drive the functional 
differentiation of iPSCs into ECs. After 7 days, the cells strongly expressed EC 
markers (VE-cadherin, Flk1, vWF and eNOS) and formed tubes on Matrigel. Next, 
we compared the miRNA signature of undifferentiated and differentiated iPSCs with 
VEGF. Amongst the validated miRNAs, we focused on miR-21 which was 
previously shown to be involved in angiogenesis. Overexpression of miR-21 (Pre-
21) in pre-differentiated iPSCs induced EC marker upregulation and in vitro and in 
vivo capillary formation; accordingly, inhibition of miR-21 (LNA-21) produced the 
opposite effects. Interestingly, miR-21 overexpression increased TGF-β2 mRNA and 
secreted protein level, consistent with the strong upregulation of TGF-β2 during 
iPSC differentiation. In addition, treatment of iPSCs with TGF-β2 induced EC 
marker expression and in vitro tube formation, through induction of VEGF secretion. 
Inhibition of SMAD3, a downstream effector of TGF-β2, strongly decreased VE-
cadherin expression. Furthermore, TGF-β2 neutralization inhibited miR-21 induced 
EC marker upregulation, indicating that TGF-β2/SMAD3 pathway is required during 
iPSC differentiation into ECs. We then confirmed the PTEN/AKT pathaway as a 
direct target of miR-21 and we showed that PTEN shutdown during the 
differentiation of iPSCs increased EC marker expression. 
We demonstrated that miR-21 directly targets the PTEN/AKT pathway, which also 
involves TGF-β2 pathway regulation by miR-21. Moreover the PTEN/AKT pathway 
is required in the VEGF-induced EC differentiation of iPSCs. Thus, the molecular 
mechanisms elucidated in this work might provide the basic information for stem 






I would like to thank my supervisor, Professor Qingbo Xu, for giving me the 
opportunity to study for my PhD degree in his laboratory at King’s College London 
and for his guidance in my project. 
I am grateful to Dr Paola Campagnolo for her daily supervision and support in the 
laboratory work, and for her help during the writing of my thesis.  
 
I would also like to thank Dr John Paul Kirton for training me during the first 
months of my PhD and for his help in teaching me the laboratory techniques. 
 
I also wish to thank Dr Andriana Margariti for her help with the iPSC culture and her 
precious advices for my experiments. 
 
I would then like to thank Dr Anna Zampetaki for her help in performing the miRNA 
arrays. 
 
I finally would like to thank Dr Claire Potter for her help in reading the final version 









I, Elisabetta Di Bernardini, confirm that the work presented in this thesis is my own 
and I have been involved in the design, planning and conduct of all the experiments 
and the thesis writing. This includes the differentiation of iPSCs to ECs, the 
lentiviral particle production, standard molecular biology methods and analysis of 
the results. 
Expert assistance was provided in some aspects of the project by the following 
colleagues from the Cardiovascular Division of King’s College. 
Dr Anna Zampetaki performed the microRNA arrays in the Proteomics laboratory 
directed by Professor Manuel Mayr. 





TABLE OF CONTENTS 
ABSTRACT ................................................................................................................. 3 
ACKNOWLEDGMENTS ........................................................................................... 4 
DECLARATION ......................................................................................................... 5 
TABLE OF CONTENTS ............................................................................................. 6 
LIST OF FIGURES ................................................................................................... 12 
LIST OF TABLES ..................................................................................................... 14 
ABBREVIATIONS ................................................................................................... 15 
CHAPTER 1. INTRODUCTION ........................................................................... 18 
1.1 THE VASCULAR SYSTEM ....................................................................... 19 
1.1.1. ENDOTHELIAL CELL CHARACTERIZATION AND FUNCTION ........... 20 
1.1.2 ENDOTHELIAL CELL DYSFUNCTION....................................................... 25 
1.1.3 ENDOTHELIAL CELLS AND ATHERIOSCLEROSIS ................................ 26 
1.1.4 ANGIOGENESIS IN INFARCTED TISSUE .................................................. 29 
1.1.5 TISSUE ENGINEERING AND VASCULAR GRAFTS ................................. 31 
1.2 SOURCES OF ENDOTHELIAL CELLS .................................................... 34 
1.2.1 EMBRYONIC STEM CELLS (ESCs) ............................................................. 34 
1.2.1.1 ESC SPECIFIC MOLECULAR NETWORKS ......................................... 36 
1.2.1.2 ESCs DIFFERENTIATION INTO MESODERMAL LINEAGE ............. 39 
1.2.2 ADULT STEM CELLS .................................................................................... 40 
1.2.3 INDUCED PLURIPOTENT STEM CELLS (iPSCs) ....................................... 44 
1.2.3.1 iPSC DIFFERENTIATION INTO MESODERMAL LINEAGES ........... 47 
1.3 STIMULI REGULATING ENDOTHELIAL DIFFERENTIATION .......... 50 
1.3.1 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ....................... 50 
7 
 
1.3.1.1 ROLE OF VEGF IN EC DIFFERENTIATION ........................................ 52 
1.3.2 SHEAR STRESS .............................................................................................. 55 
1.3.2.1 ROLE OF SHEAR STRESS IN EC DIFFERENTIATION ...................... 56 
1.3.3 MicroRNA (miRNA) ........................................................................................ 58 
1.3.3.1 ROLE OF miRNAs IN ANGIOGENESIS AND EC DIFFERENTIATION 
AND FUNCTION .................................................................................................. 61 
1.3.3.2 ROLE OF MiRNA-21 IN ANGIOGENESIS AND ECs ........................... 63 
1.3.4 TRANSFORMING GROWTH FACTOR BETA (TGF-β) FAMILY .............. 66 
1.3.4.1 ROLE OF TGF-β IN ANGIOGENESIS, VASCULOGENESIS AND EC 
DIFFERENTIATION AND FUNCTION ............................................................. 70 
1.3.5 SIGNALLING PATHWAYS INVOLVED IN EC DIFFERENTIATION AND 
ANGIOGENESIS ...................................................................................................... 73 
1.3.5.1 VEGF AND SHEAR STRESS SIGNALLING INTERACTION ............. 73 
1.3.5.2 miRNA-21 INTERACTION WITH THE VEGF AND SHEAR STRESS 
SIGNALLING ....................................................................................................... 76 
1.3.5.3 TGF-β INTERACTION WITH THE VEGF AND SHEAR STRESS 
SIGNALLING ....................................................................................................... 77 
1.4 USE OF STEM CELLS IN CARDIOVASCULAR THERAPY ................. 79 
1.5 HYPOTHESIS AND AIMS OF THE STUDY ............................................ 88 
CHAPTER 2. MATERIALS AND METHODS .................................................... 90 
2.1 MATERIALS................................................................................................ 91 
2.2 METHODS ................................................................................................... 92 
2.2.1 CELL CULTURE OF mESC AND iPSCs ....................................................... 92 
2.2.2 GENERATION OF MOUSE iPSCs ................................................................. 92 
2.2.3 DIFFERENTIATION ....................................................................................... 93 
2.2.4 CELL SORTING .............................................................................................. 94 
2.2.5 HARVESTING CELLS .................................................................................... 94 
2.2.6 RNA EXTRACTION ........................................................................................ 94 
2.2.7 REVERSE TRANSCRIPTION ........................................................................ 95 
8 
 
2.2.8 POLYMERASE CHAIN REACTION ............................................................. 96 
2.2.9 QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION (Q-
PCR) ........................................................................................................................... 98 
2.2.11 MiRNA EXTRACTION ............................................................................... 102 
2.2.12 REVERSE TRANSCRIPTION AND PREAMPLIFICATION ................... 102 
2.2.13 TAQMAN miRNA ARRAY ........................................................................ 103 
2.2.14 TAQMAN qPCR ASSAY ............................................................................ 104 
2.2.15 MiRNA TRANSIENT TRANSFECTION ................................................... 104 
2.2.16 PROTEIN EXTRACTION ........................................................................... 105 
2.2.17 WESTERN BLOT ........................................................................................ 105 
2.2.18 INDIRECT IMMUNOFLUORESCENCE ASSAY ..................................... 106 
2.2.19 IN VITRO AND IN VIVO TUBE FORMATION ASSAY ........................... 107 
2.2.20 BACTERIA CULTURE FROM STAB AND PLASMID PURIFICATION108 
2.2.21 LENTIVIRAL PARTICLE PRODUCTION ................................................ 108 
2.2.22 shRNA LENTIVIRAL INFECTION ............................................................ 109 
2.2.23 LUCIFERASE REPORTER ASSAY ........................................................... 109 
2.2.24 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)..................... 110 
2.2.25 PHARMACOLOGICAL INHIBITION OF SIGNALLING PATHWAYS . 112 
2.2.26 STATISTICAL ANALYSIS OF DATA ...................................................... 112 
CHAPTER 3. RESULTS ..................................................................................... 114 
3.1 ROLE OF VEGF AND SHEAR STRESS IN STEM CELL 
DIFFERENTIATION INTO ECs ..................................................................... 115 
3.1.1 VEGF induces functional differentiation of iPSC towards EC lineage .......... 115 
3.1.2 Role of shear stress in stem cell differentiation .............................................. 123 
3.1.3 Synergistic action of shear stress and VEGF in ESC differentiation into ECs124 
3.1.4 Synergistic action of shear stress and VEGF in iPSC differentiation into ECs
 ................................................................................................................................. 126 
3.1.5 Conclusions ..................................................................................................... 127 
9 
 
3.2 CHARACTERIZATION OF miRNA PROFILE DURING VEGF- AND 
SHEAR STRESS- INDUCED iPSC DIFFERENTIATION: MiRNA-21 
REGULATES VEGF-INDUCED iPSC DIFFERENTIATION INTO ECs..... 128 
3.2.1 MiRNA array analysis on iPSCs differentiated with VEGF and undifferentiated
 ................................................................................................................................. 128 
3.2.2 Real time PCR validation of selected miRNAs .............................................. 131 
3.2.3 MiRNA array analysis on iPSCs treated with shear stress for 48h and static . 132 
3.2.4 Analysis of differential expression of selected miRNAs in iPSCs treated with 
shear stress for 48h and untreated ............................................................................ 134 
3.2.5 Study of the role of miRNAs in endothelial differentiation ............................ 135 
3.2.5.1 MiR-20b expression does not affect iPSC endothelial differentiation ..... 136 
3.2.5.2 MiR-21 specifically regulates iPSC differentiation into ECs .................. 138 
3.2.5.3 MiR-21 regulates the functional differentiation of iPSCs into ECs in in 
vitro angiogenesis assay ....................................................................................... 146 
3.2.5.4 MiR-21 regulates the functional differentiation of iPSCs into ECs in an in 
vivo angiogenesis assay ........................................................................................ 149 
3.2.5.5 VEGF stimulation is required in miR-21-induced EC differentiation ..... 155 
3.2.6 Conclusions ..................................................................................................... 158 
3.3 IDENTIFICATION OF THE MOLECULAR TARGETS OF MiRNA-21: 
TGF-β2 PATHWAY IS A DOWNSTREAM TARGET OF MiR-21 AND 
DRIVES iPSC DIFFERENTIATION INTO ECs ............................................ 159 
3.3.1 Screening for the potential target genes of miR-21 ........................................ 159 
3.3.2 TGF-β2 is a downstream target of miR-21 ..................................................... 162 
3.3.3 TGF-β2 pathway is required in the miR-21-inducing iPSC differentiation into 
ECs ........................................................................................................................... 167 
3.3.4 TGF-β2 pathway regulates iPSC differentiation into ECs .............................. 169 
3.3.4.1 TGF-β2 expression is increased during VEGF-induced iPSC differentiation
 ............................................................................................................................. 169 
3.3.4.2 TGF-β2 treatment induces iPSC differentiation specifically towards EC 
lineage ...................................................................................................................... 171 
3.3.4.3 TGF-β2 promotes the functional differentiation of iPSCs ....................... 174 
10 
 
3.3.4.4 Inhibition of SMAD3 abolishes TGF-β2 stimulation of VE-cadherin 
expression ............................................................................................................ 176 
3.3.4.5 TGF-β2 induces EC differentiation of iPSCs through the secretion of 
VEGF ................................................................................................................... 178 
3.3.5 Conclusions ..................................................................................................... 181 
3.4 IDENTIFICATION OF THE MOLECULAR TARGETS OF miRNA-21: 
MiR-21 TARGETS THE PTEN/AKT PATHWAY, WHICH REGULATES 
iPSC DIFFERENTIATION INTO ECs ............................................................ 182 
3.4.1 MiR-21 targets the PTEN/AKT pathway ........................................................ 182 
3.4.1.1 PTEN is a direct target of miR-21............................................................ 182 
3.4.1.2 Phosphorylation of AKT is induced by miR-21 ...................................... 184 
3.4.2 The PTEN/AKT pathway regulates iPSC differentiation into ECs ................ 186 
3.4.2.1 PTEN inhibition leads to AKT activation in the VEGF-induced iPSC 
differentiation ....................................................................................................... 186 
3.4.2.2 PTEN downregulation increases the EC marker expression in 
differentiating iPSCs ............................................................................................ 187 
3.4.3 Conclusions ..................................................................................................... 190 
CHAPTER 4. DISCUSSION ............................................................................... 191 
4.1 ROLE OF VEGF AND SHEAR STRESS IN STEM CELL 
DIFFERENTIATION INTO ECs ..................................................................... 192 
4.2 CHARACTERIZATION OF miRNA PROFILE DURING VEGF- AND 
SHEAR STRESS- INDUCED iPSC DIFFERENTIATION: MiRNA-21 
REGULATES VEGF-INDUCED iPSC DIFFERENTIATION INTO ECs..... 196 
4.3 IDENTIFICATION OF THE MOLECULAR TARGETS OF MiRNA-21: 
TGF-β2 PATHWAY IS A DOWNSTREAM TARGET OF MiR-21 AND 
DRIVES iPSC DIFFERENTIATION INTO ECs ............................................ 202 
4.4 IDENTIFICATION OF THE MOLECULAR TARGETS OF miRNA-21: 
MiR-21 TARGETS THE PTEN/AKT PATHWAY, WHICH REGULATES 
iPSC DIFFERENTIATION INTO ECs ............................................................ 207 
11 
 
4.5 CONCLUSIONS AND FUTURE WORK ................................................. 210 
FUNDING SOURCE ............................................................................................... 212 
CHAPTER 5. PUBLICATIONS AND AWARDS .............................................. 214 





LIST OF FIGURES 
Figure 1 Anatomy of artery ............................................................................................................... 20 
Figure 2 Atherosclerotic development .............................................................................................. 28 
Figure 3 The basic concept of tissue engineering............................................................................. 33 
Figure 4 In vitro and in vivo tests for pluripotency......................................................................... 35 
Figure 5 Mechanisms of ESC self renewal and differentiation ...................................................... 37 
Figure 6 Regulation of Nanog expression in the ESC transcriptional network of pluripotency . 39 
Figure 7 Niches of adult stem cells .................................................................................................... 43 
Figure 8 Generation of iPSCs ............................................................................................................ 46 
Figure 9 Procedure and time course of mESC and iPSC differentiation into ECs and 
cardiomyocytes ................................................................................................................................... 48 
Figure 10 Systematic induction of different cardiovascular cell types from common progenitor 
Flk1+ of mouse iPSCs ........................................................................................................................ 49 
Figure 11 The two types of blood-vessel cells arise from a common progenitor ........................... 53 
Figure 12 miRNA production in cells ............................................................................................... 60 
Figure 13 Mechanisms of TGF-β signalling ..................................................................................... 69 
Figure 14 VEGF activates different signalling pathways leading to angiogenesis ........................ 74 
Figure 15 Potential cell types and mechanism involved in cardiac therapy .................................. 79 
Figure 16 Isolation, culture and differentiation of embryonic stem cells ...................................... 81 
Figure 17 iPSC technology for regenerative medicine and drug screening .................................. 84 
Figure 18 Dose-dependent response of iPSCs to VEGF ................................................................ 115 
Figure 19 Time course study of EC markers expression in iPSCs differentiated with 20ng/ml 
VEGF ................................................................................................................................................ 116 
Figure 20 Time course study of EC marker expression in iPSCs differentiated with 50ng/ml 
VEGF ................................................................................................................................................ 117 
Figure 21 EC marker protein expression in iPSCs differentiated with 50ng/ml VEGF at 
different time points ......................................................................................................................... 118 
Figure 22 Morpholgy of iPSC-derived ECs and undifferentiated iPSCs .................................... 119 
Figure 23 Staining of iPSC-derived ECs treated with 50ng/ml VEGF ........................................ 120 
Figure 24 Staining of iPSC-derived ECs treated with 50ng/ml VEGF ........................................ 121 
Figure 25 In vitro angiogenesis assay in iPSCs differentiated with VEGF ................................. 122 
Figure 26 Effect of shear stress on ESC differentiation ................................................................ 124 
Figure 27 Combined application of shear stress and VEGF improves EC differentiation of ckit+ 
cells .................................................................................................................................................... 125 
Figure 28 Combined application of shear stress and VEGF improves EC differentiation in 
iPSCs ................................................................................................................................................. 126 
Figure 29 Analysis of the expression of selected miRNAs in iPSCs differentiated with 50ng/ml 
VEGF for up to 7 days ..................................................................................................................... 132 
Figure 30 Analysis of the expression of miRNAs selected from the miRNA array performed in 
iPSCs treated with shear stress and static ...................................................................................... 135 
Figure 31 MiR-20b overexpression and inhibition in iPSCs differentiated with VEGF ............ 137 
Figure 32 Analysis of EC marker expression in iPSCs differentiated with VEGF, after miR-20b 
overexpression and inhibition ......................................................................................................... 138 
Figure 33 MiR-21 overexpression and inhibition in iPSCs differentiated with VEGF .............. 139 
Figure 34 Analysis of EC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition ......................................................................................................... 140 
Figure 35 Protein analysis of EC markers in iPSCs after miR-21 overexpression and inhibition
............................................................................................................................................................ 141 
Figure 36 Analysis of SMC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition ......................................................................................................... 142 
Figure 37 Analysis of SMC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition ......................................................................................................... 143 
Figure 38 Analysis of pancreatic and liver marker expression in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition...................................................................... 144 
13 
 
Figure 39 Analysis of neuronal and epidermal markers expression in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition...................................................................... 145 
Figure 40 In vitro angiogenesis assay in iPSCs transfected with miR-21 .................................... 147 
Figure 41 In vitro angiogenesis assay in iPSCs transfected with miR-21 inhibitor .................... 148 
Figure 42 miR-21 overexpression increases the number of CD31-positive capillaries in in vivo 
Matrigel plugs ................................................................................................................................... 150 
Figure 43 miR-21 overexpression induces the number of VE-cadherin-positive capillaries in 
matrigel plaques ............................................................................................................................... 151 
Figure 44 miR-21 inhibition decreases the number of CD31-positive capillaries in Matrigel 
plugs .................................................................................................................................................. 153 
Figure 45 miR-21 inhibition decreases the number of VE-cadherin-positive capillaries in 
Matrigel plugs ................................................................................................................................... 154 
Figure 46 miR-21 overexpression and inhibition in iPSCs differentiated in absence of VEGF 156 
Figure 47 Analysis of the EC marker expression in iPSCs differentiated in the absence of 
VEGF, after miR-21 overexpression and inhibition...................................................................... 157 
Figure 48 Analysis of the expression of potential targets of miR-21 after overexpression ........ 161 
Figure 49 Analysis of the expression of potential targets of miR-21, after its inhibition ........... 162 
Figure 50 Analysis of TGF-βRII and TGF-βI expression after miR-21 overexpression and 
inhibition ........................................................................................................................................... 164 
Figure 51 Analysis of the TGF-β1 and TGF-βRI expression in iPSCs differentiated with VEGF 
after miR-21 overexpression and inhibition ................................................................................... 165 
Figure 52 Analysis of TGF-β2 expression in iPSCs pre-differentiated with VEGF, after miR-21 
overexpression and inhibition ......................................................................................................... 166 
Figure 53 Analysis of TFG-β2 secretion after miR-21 overexpression and inhibition ............... 167 
Figure 54 TGF-β2 is required in miR-21 induced iPSC differentiation into ECs ...................... 168 
Figure 55 Analysis of CD-31 protein expression in iPSCs transfected with miR-21 precursor and 
treated with TGF-β2 antibody ........................................................................................................ 169 
Figure 56 Analysis of TGF-β2 and TGF-β1 gene expression during VEGF induced iPSC 
differentiation ................................................................................................................................... 170 
Figure 57 Analysis of TGF-βRIII, II and I expression during VEGF induced iPSC 
differentiation ................................................................................................................................... 171 
Figure 58 Analysis of EC marker expression in iPSCs treated with TGF-β2 ............................. 172 
Figure 59 Protein expression analysis of EC markers in iPSCs treated with TGF-β2 ............... 173 
Figure 60 Analysis of SMC markers expression in iPSCs treated withTGF-β2 ......................... 174 
Figure 61 In vitro angiogenesis assay in iPSCs differentiated with TGF-β2 ............................... 175 
Figure 62 Inhibition of SMAD3 strongly reduces the baseline expression of VE-cadherin and 
abolished its induction by TGF-β2 .................................................................................................. 177 
Figure 63 Analysis of VEGF secretion in iPSCs treated with TGF-β2 for 7 days ...................... 178 
Figure 64 Protein expression analysis of VE-cadherin in iPSCs treated with TGF-β2 and VEGF 
neutralizing antibody ....................................................................................................................... 179 
Figure 65 Protein expression analysis of PTEN in iPSCs differentiated with VEGF after miR-21 
overexpression and inhibition ......................................................................................................... 183 
Figure 66 Luciferase reporter assay confirms PTEN as a direct target for miR-21 .................. 184 
Figure 67 Protein expression analysis of P-AKT and total AKT in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition...................................................................... 185 
Figure 68 Protein expression analysis of P-AKT, total AKT and PTEN in iPSCs differentiated 
with VEGF, after PTEN chemical inhibition ................................................................................. 187 
Figure 69 PTEN knockdown using lentiviral-mediated shRNA expression................................ 188 
Figure 70 Knockdown of PTEN induces EC marker upregulation in differentiating iPSCs .... 189 
Figure 71 Endothelial lineage differentiation from iPSCs is regulated by miR-21/AKT and 






LIST OF TABLES 
Table 1 Reverse Transcription reaction                                                                    89                                   
Table 2 PCR reaction                                                                                                90 
Table 3 Primer parameters and their sequence                                                          91 
Table 4 Real Time PCR primer sequences                                                                93 
Table 5 Primary antibodies used in Western Blotting                                               99 
Table 6 Primary and secondary antibodies used in immunofluorescence staining 100 
Table 7 Map of the pGL3-Luciferase Basic vector                                                 103 
Table 8 Buffers and their composition                                                                    106 
Table 9 Pool A miRNAs target                                                                                122 
Table 10 Pool B miRNAs target                                                                              123 
Table 11 Pool A miRNAs target                                                                              125 





±SEM standard error of mean 
AKT protein kinase B (PKB) 
AP-1 activator protein 1 
bFGF basic fibroblast growth factor 
BMPs bone morphogenetic proteins 
CD133  cluster of differentiation 133 
CD144 cluster of differentiation 144/VE-cadherin 
CD31 cluster of differentiation 31/PECAM-1 
CD34 cluster of differentiation 34 
CD45 cluster of differentiation 45 
CDK cyclin-dependent kinase 
cDNA complementary deoxyribonucleic acid  
cKit  
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
cMyc  similar to v-MYC (myelocytomatosis viral oncogene) 
DAPI  4',6-diamidino-2-phenylindole 
ECs  endothelial cells 
ELISA  enzyme-linked immunosorbent assay 
EMT epithelial–mesenchymal transition 
EndMT endothelial to mesenchymal transition 
eNOS endothelial nitric oxide 
EPCs endothelial progenitor cells 
ERK extracellular-signal-regulated kinase 
ESCs embryonic  stem cells 
EtBr ethidium Bromide 
FGF fibroblast growth factor 
FACS  fluorescence activating cell sorting 
FITC fluorescein isothiocyanate 
Flk1 vascular endothelial growth factor receptor 2/KDR 
Flt1 vascular endothelial growth factor receptor 1 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GFP  green fluorescent protein 
h hours 
HDACs histone deacetylases 
HE Hematoxylin 
HIF-1α hypoxia-inducible factor 1-alpha 
HRP horse radish peroxidise 
HUVECs human umbilical vein endothelial cells 
IL-6 interleukin 6 
16 
 
iPSCs induced pluripotent stem cells 
JNK c-Jun N-terminal kinase 
KDR kinase insert domain receptor/Flk1 
KLF4 krüppel-like family of transcription factor 4 
LDL low density lipoprotein 
LiCl  lithium chloride 
LIF leukaemia inhibitory factor 
LNA-Ctrl control of miRNA inhibitor  
LNA-21 miR-21 inhibitor  
MAPKs mitogen-activated protein kinases 
MCP-1 monocyte chemotactic protein-1 
MEFs  mouse embryonic fibroblasts 
min minutes 
mRNA messenger ribonucleic acid 
mTOR mammalian target of rapamycin 
NO nitric oxide 
NOS nitric oxide synthase 
OCT4  octamer-binding transcription factor 4 
OSS oscillatory shear stress 
PDCD4 programmed cell death 4 
PCR  polymerase chain reaction 
PDGF platelet derived growth factor  
PI3K phosphatidylinositide 3-kinases 
Pre-Ctrl control of miRNA precursor 
Pre-21 miR-21 precursor 
PTEN phosphatase and tensin homolog 
Q-PCR  quantitative real time polymerase chain reaction 
RhoB ras homolog gene family, member B 
ROS reactive oxygen species 
rpm rounds per minute 
s seconds 
Sca-1 stem cell antigen-1 
SCF stem cell factor 
SCID  severe combined immune deficiency 
SDS sodium dodecyl sulphate 
shRNA  short hairpin ribonucleic acid 
SM22  smooth muscle protein 22-alpha or transgelin 
SMA smooth muscle actin 
SMCs smooth  muscle cells 
SMMHC  smooth muscle myosin heavy chain 
SOX2  SRY (Sex determining region Y)-box2 
STAT3  signal transducer and activator of transcription factor 3 
TGF-β transforming growth factor β 
TGF-βI  transforming growth factor β-induced 
17 
 
TNF tumour necrosis factor 
TRITC  tetramethyl Rhodamine Iso-Thiocyanate 
VCAM-1 vascular cell adhesion molecule 1 
VE-cadherin Vascular endothelial-cadherin/CD144 
VEGF  vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor  
vWF  von Willebrand factor 








1.1 THE VASCULAR SYSTEM 
The cardiovascular system is a complex organ that passes blood around the body, 
bringing nutrients and oxygen to the cells and removing waste products and carbon 
dioxide.   
The main mechanisms leading to blood vessel formation are two, namely 
vasculogenesis and angiogenesis. Vasculogenesis is the formation of new vessels 
from progenitor cells and was historically believed to occur in embryo development, 
during the formation of the primitive vascular network from angioblasts, which 
occurs in several stages.  First, hemangioblasts, the common putative precursors of 
endothelial and hematopoietic cells in the embryo, differentiate from the mesoderm. 
These differentiated cells then aggregate to form blood islands. The inner cells of the 
blood islands become hematopoietic stem cells, or blood-forming cells and the outer 
cells become angioblasts, which give rise to the blood vessels (Gilbert 2000). 
Angiogenesis is the formation of new blood vessels from pre-existing ones and 
occurs both during embryonic development and during physiological and 
pathological conditions in adult life. Angiogenesis can be initiated by several stimuli 
including hypoxia and is pivotal to the development of many diseases, such as cancer 
(Carmeliet 2003). More recently, the discovery of vasculogenic bone marrow and 
tissue resident progenitor cells in the adult has challenged the definition of 
vasculogenesis and extended it into adult life (Garin, Mathews et al. 2005). Finally, 
another form of de novo vascular development is arteriogenesis, which is caused by 
mechanical forces like shear stress and occurs through the remodelling of pre-
existing vasculature and expansion of collateral vessels (Carmeliet 2000, Heil, 
Eitenmuller et al. 2006). 
Large blood vessels are composed of three layers: the innermost is the tunica intima, 
which is composed of a single continuous layer of endothelial cells (ECs) and 
mediates the exchange of nutrients and cells with the circulation. Surrounding the 
intima is the thick layer of smooth muscle cells (SMCs) composing the tunica media, 
which is responsible for the maintenance of the vessel tone and elasticity. Finally, 
adventitia is the external layer mainly composed of fibroblasts and connective tissue 
and incorporating the vasa vasorum, the small network of vessels that provides 
oxygen and nutrients to the cells in the vessel wall (Figure 1). Vessels within the 
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microvascular system (i.e. capillaries and venules) are formed by contractile cells 
called pericytes that wrap around the endothelial cell layer (Carmeliet 2000). 
 
 
Figure 1 Anatomy of artery 
In this schematic representation of the arterial wall the three layers of a blood vessel (intima, media 
and adventitia) are shown together with the cells that compose each layer (endothelial cells, smooth 
muscle cells and fibroblast). http://en.wikipedia.org/wiki/File:Anatomy_artery.png 
 
 
1.1.1. ENDOTHELIAL CELL CHARACTERIZATION AND 
FUNCTION 
Endothelial cells line the blood vessels of the entire circulatory system, from the 
aorta to capillaries, and represent the barrier between circulating blood and the rest 
of the vessel wall. The endothelium is a dynamic and heterogeneous organ with 
secretory, metabolic, synthetic and immunological functions (Fishman 1982). 
Endothelial cells cover a surface in an adult human of approximately 1 to 7 m
2
, 
which is composed of approximately 1 to 6 x 10
13
 cells and weighs approximately 1 
kg (Augustin, Kozian et al. 1994).  ECs, which line the vessels of all organs, regulate 
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the flow of nutrients, biologically active molecules and blood cells through the 
action of membrane-bound receptors, lipid transporting particles, metabolites and 
hormones and specific junctional proteins and receptors that govern cell-cell and 
cell-matrix interactions (Cines, Pollak et al. 1998).  
A unique characteristic of ECs is that, despite their many common functional and 
morphological features, they display a great heterogeneity in different organs or in 
the same organ in the endothelium of large and small vessels, veins and arteries. For 
instance the kidney contains different types of ECs: fenestrated in the peritubular 
capillaries, discontinuous in glomerular capillaries and continuous in other regions 
(Risau 1995). 
As mentioned before, vascular and hematopoietic tissues develop together after 
implantation, with the formation of blood islands within the primitive yolk sac. 
During embryonic development, ECs differentiate from a common precursor called 
angioblast and acquire organ-specific properties. The angioblasts form the outer 
layer of ECs in the blood island, whereas the hematopoietic stem cells compose the 
inner cluster, which gives rise to the first embryonic blood cells (Risau and Flamme 
1995). Angioblasts are primarily found in embryonic mesoderm, arising from the 
lateral mesodermal plate and cardiac crescent and some cells  migrate into the 
forming brain or into the endocardium of the early heart tube (Palis, McGrath et al. 
1995). Other angioblasts differentiate into the ECs of the vitelline vessels, which 
allow the blood cells from the yolk sac to circulate within the body of the embryo 
(Risau and Flamme 1995). Moreover, ECs directly differentiated from the 
surrounding mesenchyme of invading vessels compose the vasculature of the viscera 
(Risau and Flamme 1995). Endodermally-derived cells of the branching airway have 
been shown to induce formation of angioblasts that become part of the pulmonary 
vasculature (Buck, Edelman et al. 1996).  
One of the determinants of EC specific pathways of differentiation is the local 
environment in which the cells differentiate and their interaction with surrounding 
cells, which may occur through the release of soluble mediators, cell-to-cell adhesion 
and the synthesis and assembly of matrix proteins on which the endothelium develop 
(Garlanda and Dejana 1997). Importantly, many recent studies showed that vascular 
development is mediated by the action of two important factors, basic fibroblast 
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growth factor (bFGF) and vascular endothelial growth factor (VEGF) (Beck and 
D'Amore 1997).  
ECs have been shown to express specific markers which are used to identify these 
cells in vivo and in vitro. In the majority of cases these molecules have been 
discovered using monoclonal antibodies directed to ECs. The most identified 
markers for ECs are von Willebrand factor (vWF), platelet–endothelial cell adhesion 
molecule (PECAM-1/CD31), angiotensin-converting enzyme, type I scavenger 
receptor, vascular endothelial cadherin (VE-cadherin), CD34, CD102/ICAM-2, 
CD105/endoglin, CD36 and thrombomodulin (Garlanda and Dejana 1997).  
Detailed studies of endothelial function started in the 1970s with the development of 
techniques to culture ECs in vitro (Jaffe, Nachman et al. 1973, Lewis, Hoak et al. 
1973). 
Endothelium is a semi-permeable barrier that regulates the conduction of blood and 
the passage of fluids and solutes between the blood and the interstitial space; the 
permeability of this barrier and cell adhesion is tightly regulated by intracellular 
junction. The most important intracellular junctions that have been characterized as 
the cell–cell adhesive barrier structures in the microvascular endothelium are the 
adherens junction and the tight junctions; the structural and functional integrity of 
these junctions is a major determinant of paracellular permeability (Michel and 
Curry 1999).  Adherens junctions are found in nearly all types of vascular beds, 
especially in the peripheral microvasculature and are impermeable to albumin (69 
kDa) and other large proteins, indeed representing the major responsible of 
endothelial barrier to macromolecules in many organs and tissues (Mehta and Malik 
2006). Amongst the adherens junctions, VE-cadherin, also known as cadherin-5, is 
believed to be the most important protein in forming the molecular basis and 
regulating the function of adherens junctions. VE–cadherin is a transmembrane 
receptor, whose extracellular domain binds to the extracellular domain of another 
VE–cadherin expressed in the membrane of an adjacent endothelial cell; it is found 
almost exclusively on ECs and promotes cell-cell adhesion by a calcium-dependent 
homotypic mechanism (Dejana, Orsenigo et al. 2008). Intracellularly, VE–cadherin 
is connected to the actin cytoskeleton through binding to β-catenin and γ-catenin, 
which in turn are connected to actin via binding to α-catenin (Mehta and Malik 
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2006). The catenins indeed not only represent a structural linkage between VE–
cadherin and the cytoskeleton, but they can also transduce biochemical signals for 
cell–cell communications; the maintenance of endothelial barrier function is indeed 
ensured by the stability of the VE–cadherin–catenin–cytoskeleton complex (Vincent, 
Xiao et al. 2004). Adherens junctions are also involved in many signalling events 
regulating gene expression (Bazzoni and Dejana 2004). 
There are many other proteins at cell–cell contacts which can interact with adherens 
junctions, such as E-cadherin, junctional adhesion molecules, and PECAM-1, a 
member of the Ig superfamily. Within the vascular compartment, PECAM-1 is 
expressed on leukocytes, platelets, and on ECs mostly at junctions between adjacent 
cells. PECAM-1 is known to bind to integrins on leukocytes to facilitate their 
transmigration across the microvascular endothelium; in addition to its adhesive 
properties, it plays a role in signal transduction, angiogenesis, platelet function, 
thrombosis and endothelial mechanosensing of fluid shear stress (Woodfin, Voisin et 
al. 2007).  
Tight junctions are less common than adherens junctions in the peripheral 
microvasculature, and are mainly found in the microvascular endothelium of some 
specialized tissues, such as the blood–brain or blood–retinal barriers (Hawkins and 
Davis 2005). Tight junctions contribute to endothelial barrier function by impeding 
the passage of much smaller molecules (<1 kDa), such as small inorganic ions (e.g., 
Na
+
). Endothelial tight junctions are based on the interactions of the tight junction 
proteins occludin, claudins (3/5), which are integral membrane proteins, and 
junctional adhesion molecule-A, a member of the immunoglobin superfamily of 
proteins. Occludin, claudins and junctional adhesion molecules-A are connected to 
the actin cytoskeleton through binding to zona occludens proteins (ZO-1, ZO-2) and 
α-catenin (Schneeberger and Lynch 2004, Hawkins and Davis 2005, Abbott, 
Patabendige et al. 2010). 
Additionally, links between the endothelial basolateral membrane and the 
surrounding extracellular matrix of the microvascular wall are maintained by focal 
adhesions (Wu 2005). The main components of focal adhesions are the integrins, 
transmembrane receptors which belong to a family of glycoproteins. Intracellularly 
integrins interact with the cytoskeleton through the linker proteins paxillin, talin, 
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vinculin, or α-actinin, whereas extracellularly they bind to the matrix proteins 
fibronectin, collagen, vitronectin, fibrinogen and laminin (Petit and Thiery 2000, 
Hodivala-Dilke, Reynolds et al. 2003).  
ECs also show an anti-thrombotic function, preventing the progression of the 
thrombotic response after endothelial damage. The release of tissue factor inhibitor 
prevents coagulation.  Furthermore, healthy ECs respond to a number of stimuli, 
such as serotonin from aggregating platelets and thrombin, by releasing nitric oxide 
(NO), which relaxes the underlying vascular SMCs (Kolluru, Siamwala et al. 2010).  
In ECs NO production is mediated by the enzyme nitric oxide synthase (NOS), of 
which there are three isoforms: inducible, neuronal and endothelial (eNOS); eNOS 
activity regulates blood vessel dilatation (van Hinsbergh 2001). Increasing 
concentration of Ca
2+ 
by the action of eNOS agonists such as bradykinin, 
acetylcholine, ATP, ADP, substance P and thrombin, induces the association 
between Ca
2+
 and calmodulin, which binds to and activates eNOS. eNOS activity is 
also increased by phosphorylation and acetylation (Butt, Bernhardt et al. 2000, Jung, 
Kim et al. 2010).  eNOS is expressed in human endothelial progenitor cells (EPCs) 
(Qiao, Niu et al. 2010) and during the differentiation of bone marrow stem cells into 
ECs (Liu, Jiang et al. 2007).  
NO, together with prostacyclin and prostaglandin-E2, inhibits platelet aggregation, 
preventing abnormal constriction (vasospasm) of the coronary arteries and inhibiting 
the expression of endothelial adhesion molecules and thus preventing the adhesion 
and penetration of macrophages.  
The endothelium is also responsible for regulating vascular tone, which is 
maintained by a balance between the production of vasodilatation and 
vasoconstriction factors.  Synthesis of plasminogen activators stimulates fibrinolysis 
to lyse a developing thrombus before it causes damage (van Hinsbergh 2001).  NO 
diffusion from the EC into adjacent vascular SMCs leads to reduced SMC 
contraction. 
Endothelium-derived NO also prevents the proliferation of vascular SMCs and limits 
the formation of oxidised low density lipoprotein (LDL), reducing the risk of 
atherogenesis (Michel and Vanhoutte 2010). 
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Finally vWF, a blood glycoprotein involved in homeostasis, is considered a specific 
EC marker and is produced by ECs and megakaryocytes only; it is heterogeneously 
distributed throughout the vasculature and differently expressed by ECs (Zanetta, 
Marcus et al. 2000). It has been shown that increased plasma levels of vWF are 
involved in a large number of cardiovascular, neoplastic and connective tissue 
diseases, and may contribute to an increased risk of thrombosis (Budde and 
Schneppenheim 2001). 
In vivo, ECs are in contact on their basal surface with the basement membrane, a 
highly specialized extracellular matrix. This matrix covers the ECs and maintains the 
tube-like structures of the blood vessels (Kalluri 2003). Because endothelial cell tube 
formation on basement membrane replicates many steps of angiogenesis, it has been 
established as a method to screen for angiogenic and antiangiogenic factors 
(Auerbach, Lewis et al. 2003). In the past 20 years it has been demonstrated that ECs 
rapidly form capillary-like structures in vitro when plated on a reconstituted 
basement membrane extracellular matrix, such as Matrigel (Grant, Kinsella et al. 
1995). The formation of the capillary-like tubes is indeed specific to ECs and it is 
used as an in vitro angiogenesis assay to confirm the functionality of the ECs. These 
capillary-like tube structures take up acetylated-low density lipoprotein (Ac-LDL), 
which is a marker of differentiation for these cells (Arnaoutova 2009). Ac-LDL is 
taken up by macrophages and ECs via the "scavenger cell pathway" of LDL 
metabolism; the increased metabolism of Ac-LDL in ECs is used to identify these 
cells, using Ac-LDL labeled with the fluorescent probe 1,1'-dioctadecyl-3,3,3',3'-
tetramethyl-indocarbocyanine perchlorate (Dil-Ac-LDL) (Voyta, Via et al. 1984). 
 
1.1.2 ENDOTHELIAL CELL DYSFUNCTION 
Environmental risk factors (LDL levels, smoking, diabetes, hypertension, infection 
and hemodynamic forces), which accelerate cardiovascular diseases result in a 
reduced release of NO, an increase in superoxide, cytokine, prostaglandin-D2 and 
adhesion molecule production and an acceleration of the apoptotic process in the 
endothelium. This process increases inflammation and thrombosis, thus leading to 
progression of the disease. 
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In cases of endothelial damage, growth factors and chemokines are released in order 
to increase EC proliferation and motility and to reduce neointima formation, caused 
by matrix deposition. The apoptotic cells are removed by the blood stream and can 
be replaced by proliferating neighbouring cells and/or circulating EPCs which 
circulate postnatally in peripheral blood. EPCs may be able to target and repair 
damaged endothelial regions (Xu, Zhang et al. 2003, Xu 2008). In a process named 
postnatal vasculogenesis EPCs may be recruited from the bone marrow and target 
sites of active neovascularisation in ischemic hindlimbs or myocardium, tumour 
vasculature and damaged corneas (Asahara, Masuda et al. 1999).  
However, the proliferative capacity of the endothelium is thought to be low, due to 
the presence of senescent cells. Moreover these cells are thought to be unable to 
produce the required amounts of NO, which together with low proliferative capacity 
facilitates the inflammatory response, ultimately leading to the formation of 
atherosclerotic plaques (de Nigris, Lerman et al. 2003). 
Endothelial dysfunction is considered the initial stage of many cardiovascular 
diseases, such as atherosclerosis. 
 
1.1.3 ENDOTHELIAL CELLS AND ATHEROSCLEROSIS 
Cardiovascular disease is the major cause of death worldwide, and current therapies 
can only delay progression of the disease (Segers and Lee 2008). The main forms of 
cardiovascular related mortality develop following atherogenesis, which is thought to 
be initiated by endothelial cell dysfunction. 
Cardiovascular diseases include arteriosclerosis, aneurysms, cerebrovascular disease, 
heart failure, coronary heart disease, myocardial infarction, hypertension and stroke.  
The most common form of arteriosclerosis is atherosclerosis, which is the primary 
cause of cerebrovascular disease and coronary heart disease. Atherosclerosis mainly 
occurs in elastic arteries causing vessel wall thickening and narrowing of the blood 
vessel lumen and loss of elasticity, followed by the ischemia of connected tissue. 
Atherosclerosis is a chronic inflammatory disease, started by endothelial dysfunction 
(Sima, Stancu et al. 2009, Sandoo, van Zanten et al. 2010). ECs dysfunction is a key 
27 
 
early event in the formation of the atherosclerotic plaque.  Atherosclerosis develops 
in specific regions of the vasculature following interactions between modified 
lipoproteins, endogenous SMCs and ECs, macrophages and immune cells and it is 
the result of multiple risk factors.   
In these atheroprone regions, ECs show increased permeability, cytokine production 
and expression of cell adhesion molecules, transcytosis of lipoproteins, secretory 
function and hyperplasia of the basement membrane (Sima, Stancu et al. 2009).  
Furthermore, in atheroprone regions ECs are sensitive to changes in blood flow, such 
as disturbed flow, which modify their morphology and signalling cascade activation 
(World, Garin et al. 2006).  
The pathogenesis of atherosclerosis can be classified into several stages, which were 
initially described by Ross in 1976. Once ECs become damaged, the activation of an 
inflammatory response induces the exposure of adhesion molecules on the apical 
surface of the endothelium; this promotes the adhesion and migration of monocytes 
which can penetrate into the subendothelial space (Figure 2 A).The penetration and 
accumulation of LDL contributes to this process leading to the formation of a fatty-
streak in the vessel. With the progress of the lesion, SMC migration, T-cell 
activation and platelet adhesion and aggregation further contribute to the process. 
The excessive uptake of oxidised LDL by macrophages, through recognition by 
scavenger receptors, results in a morphological change into a foam cell (Figure 2 B).  
Foam cells have high intracellular levels of cholesterol, which induces apoptosis, 
releasing the fatty contents into the subendothelial space and driving the formation of 
the atherosclerotic lesion. Finally, the lesion progresses with the formation of a 
fibrous cap formed from SMC-produced extracellular matrix proteins. The continued 
expansion of the lipid-filled interior leads to the formation of a necrotic core (Figure 





Figure 2 Atherosclerotic development 
Adhesion and migration of leukocytes follow endothelial cell dysfunction (A).  The initial 
development of atherosclerosis is the formation of a fatty streak upon the lumen surface, following 
platelet and leukocyte adhesion, T-cell activation and smooth muscle cell migration. Moreover, 
macrophage engulfment of oxidised LDL leads to foam cell formation (B). As atherosclerosis 
progresses, the lesion forms a fibrous cap, which narrows the lumen and a necrotic core forms (C) 
(Ross 1999).  
 
There are two types of atherosclerotic plaques: stable and unstable, due to their 
position in the vessel and composition.  Stable plaques can grow until the lumen is 
totally occluded; unstable plaques are prone to rupture following proteolytic 
degradation at the edges of the fibrous cap. This results in the formation of a 
thrombus which occludes the lumen at the site of rupture, causing ischemia and 
damage of tissue, such as myocardial infarction.  
Balloon angioplasty and stenting are routinely used in clinical practice to treat 
patients with angina pectoris or myocardial infarction. However, one of the major 
issues of stenting is restenosis, leading to the recurrence of symptoms; balloon 
inflation at high pressure and use of metallic stent struts cause EC loss with 
subsequent SMC proliferation and matrix deposition, thus originating luminal 
narrowing (Xiao, Zeng et al. 2006). It has been reported that after vascular injury 
restenosis development can be prevented through accelerated re-endothelialization 
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by mature ECs, which inhibits SMC migration, proliferation and neointima 
formation (Nowak, Karrar et al. 2004).  
In the past several years, accumulating evidence suggests that embryonic stem cells 
(ESCs), a promising source of pluripotent stem cells with unlimited growth and self-
renewal abilities, are able differentiate into ECs in vitro and in vivo (Levenberg, 
Golub et al. 2002). Understanding of the molecular mechanisms of stem cell 
differentiation into ECs might lead to definition of new methods to produce large 
number of ECs with high purity from ESCs: ESC-derived ECs can be used to treat 
damaged vessels and to avoid restenosis. However, so far still little is known about 
the EC differentiation mechanisms and the therapeutic potential of ESC-derived ECs 
in cardiovascular diseases. 
 
1.1.4 ANGIOGENESIS IN INFARCTED TISSUE 
When myocardium is deprived of blood, ischemia, infarction and myocardium 
remodelling are initiated. Following epicardial coronary artery obstruction, DNA 
synthesis in ECs and SMCs is strongly induced, indicating active neovascularisation 
(White, Carroll et al. 1992). Formation of new blood vessels is fundamental for 
oxygen and nutrient supply to the infarcted myocardium in order to sustain 
metabolism. Neovascularisation is indeed essential to develop collateral blood 
vessels able to compensate for the compromised vascular function. The infarct size, 
the amount of viable myocardium and the prognosis in patients with acute 
myocardial infarction are determined by the amount of coronary collateral blood 
vessels (Sabia, Powers et al. 1992). Recurrent myocardial ischaemia may play an 
active role in inducing EC proliferation essential to expand the myocardial vascular 
network (Banai, Shweiki et al. 1994). 
Angiogenesis in the infarcted tissue occurs through a complex link between 
extracellular matrix, ECs and pericytes, in response to an imbalance of angiogenic 
factors compared to angiostatic factors in the local environment (Ferrara and Alitalo 




Early release of angiogenic factors in the injured areas has been associated with 
myocardial infarction. Many studies have shown that the angiogenic factors VEGF, 
interleukin 8 (IL-8) and bFGF are rapidly induced in the ischemic myocardium and 
may induce infarct neovascularisation (Kukielka, Smith et al. 1995, Lee, Wolf et al. 
2000).  
VEGF is a secreted growth factor that is angiogenic in vivo and specifically targets 
vascular ECs  (Houck, Ferrara et al. 1991). VEGF expression has been shown to be 
increased in vitro in myocardial cells in hypoxia and by myocardial ischemia in vivo; 
indeed VEGF is a likely mediator in the myocardial neovascularisation induced by 
ischemia (Banai, Shweiki et al. 1994). 
Use of angiogenic growth factors to promote new collateral vessel formation in the 
ischemic tissues is now a very exciting frontier of cardiovascular medicine (Ferrara 
and Alitalo 1999, Frangogiannis, Smith et al. 2002). One of the initial attempts in 
this direction was made through the delivery of VEGF recombinant protein in 
patients with coronary artery disease. However, this procedure was not really 
effective due to half-life of VEGF-A in vivo, insufficient myocardial uptake after 
coronary infusion and de-sensitization of chronically ischemic tissues to VEGF 
treatment. Therefore, the next step was trying to deliver VEGF-A gene directly to the 
ischemic tissues. Although the outcome of the clinical trials showed an indication of 
functional improvement in myocardial perfusion and cardiac function, in particular 
at early time points after treatment, the efficiency of naked DNA uptake by muscle 
and cardiac cells was still very low (Giacca and Zacchigna 2012). 
Indeed, there are still many issues related to local delivery of growth factors in the 
infarcted tissues to induce neovascularisation; the aim of this study is to develop a 
differentiation protocol based on the use of the angiogenic growth factor VEGF, to 
induce the differentiation of pluripotent cells into ECs able to heal the damaged 





1.1.5 TISSUE ENGINEERING AND VASCULAR GRAFTS 
Atherosclerosis and stenosis are phenomena that lead to the narrowing of a blood 
vessel and are the cause of several cardiovascular diseases, including myocardial 
infarction. One approach for the treatment of arterial stenoses is the application of a 
vascular bypass performed using the patient’s own saphenous vein or mammary 
artery. When natural vessels are not available, due to concomitant vascular 
complications or earlier procedures, alternative grafts need to be developed. The 
challenge of creating tissue engineered graft (artificial or from decellularized natural 
vessels) is to obtain a result with the mechanical and anti-thrombotic properties of 
the natural vessel, in particular in the case of small diameter vessel (<6mm). 
The concept of tissue engineering is based on three essential components: cells, 
which can either be seeded in vitro or mobilized in vivo; scaffolds, onto which the 
extracellular matrix is organized and signals, which can be classified as humoral and 
mechanical (Bell 1991) (Figure 3). 
An ideal cell source for vascular tissue engineering should be easy to isolate and 
expand in culture; it should be able to differentiate into functional vascular cells and 
be non-immunogenic for recipients. Recent studies showed that adult stem cells, 
ESCs and induced pluripotent stem cells (iPSCs) could be used as a source for 
vascular tissue engineering since they show all the above mentioned characteristics 
(detailed description follows). 
However, there are still limitations in the use of synthetic vascular grafts, such as 
thrombogenicity, risk of infection and lack of growth potential. The first clinical trial 
using tissue engineered vascular grafts by seeding autologous bone marrow-derived 
mononuclear cells onto biodegradable tubular scaffolds has been recently performed; 
approximately 16% of grafts within the first seven years after implantation of this 
tissue engineered vascular grafts showed stenosis, an abnormal narrowing in the 
blood vessel (Naito, Shinoka et al. 2011). 
Despite the numerous studies conducted on ESC differentiation into vascular 
lineages, limited studies have used vascular cells derived from ESC as a source for 
vascular grafts in vitro. In 2003, Shen and his colleagues implanted small diameter 
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tissue engineered vascular grafts (3mm) subcutaneously into nude mice by seeding 
SMCs from rabbit arteries onto a biodegradable polymer scaffold wrapped around a 
silicon tube. After 8 weeks from implantation the graft was retrieved and silicon tube 
removed. Then, ECs derived from mouse ESCs were seeded onto the lumen of the 
graft to form an intimal layer, and the graft was re-implanted subcutaneously for a 
further 5 days. Histological and immunohistochemical staining of this tissue 
engineered graft showed ESC-derived ECs lining the intimal surface and the 
presence of SMCs and collagen in the wall, resembling a vascular structure. Indeed, 
ECs differentiated from mouse ESCs can be used as seed cells for endothelium 
lining in tissue engineered blood vessels (Shen, Tsung et al. 2003). However, this 
tissue engineered vascular graft has not been tested yet in vivo by implanting it into 
the circulatory system; therefore, the mechanical and functional properities of the 
graft still remain to be elucidated. 
In one of the most recent studies, sheets created from iPSC-derived vascular cells 
were used as an alternative and attractive source for tissue engineered vascular grafts 







Figure 3 The basic concept of tissue engineering 
Three essential components are required for the construction of tissue engineering grafts: cells, 
biodegradable scaffold onto which the extracellular matrix is organized to support the neotissue and 
signals such as cytokines, chemokines, gowth factors and mechanical forces such as shear stress, 
required for the formation of an organized tissue (Naito, Shinoka et al. 2011). 
 
 
Following the initial tissue engineering techniques developed, recent studies have 
been trying to improve re-endothelialisation of vascular scaffolds using autogenous 
cells in order to create a tissue engineered vessel with autogenous ECs and SMCs. 
However, the possibility of isolating adequate numbers of functional ECs or SMCs 
from patients with vascular disease is often not possible.  
Developing tissue engineered vascular grafts is now a major challenge for the future 
of medicine. Clinical research studies and innovation of tissue engineering 
techniques, combined with the emerging iPSC technology may represent the future 






1.2 SOURCES OF ENDOTHELIAL CELLS 
 
Recently, the mechanisms involved in the maintenance of endothelial layer integrity 
have become an important focus of research due to their importance in the 
pathophysiology of the vessels. Furthermore, new strategies have been developed to 
allow the isolation, culture and differentiation of cells that can contribute to vascular 
repair (Kirton and Xu 2010). However, current cell transplantation therapies devised 
for the treatment of cardiovascular diseases are hampered by the lack of a viable 
source of committed cells. Indeed, fully mature ECs isolated from patients’ blood 
vessels have limited proliferation and expansion capabilities. Hence, alternatives 
such as the use of ESCs or iPSCs, which have an unlimited self-renewal capability, 
are increasingly sought after for tissue regeneration in the damaged areas.  
In order to fulfil the potential of ESCs or iPSCs as a platform for treating 
cardiovascular diseases, an understanding of their roles and functional biology in 
vasculogenesis is pivotal. As such, the following sections will discuss current studies 
focusing on ESCs and in particular on iPSCs as model systems, and the relevant 
mechanisms that are involved in their differentiation.  
 
1.2.1 EMBRYONIC STEM CELLS (ESCs) 
Embryonic stem cells (ESCs) are derived from the inner mass of the embryonic 
blastocysts and can be cultured in vitro under the appropriate conditions in order to 
maintain their original pluripotency. This pluripotent ability has attracted the interest 
of numerous researchers, both to expand the fundamental understanding of 
developmental biology and for their potential application in regenerative medicine. 
Isolation of ESCs was firstly reported in 1981 from the inner cell mass of mouse 
E3.5 blastocysts (Evans and Kaufman 1981). In in vitro culture, these cells were 
shown to maintain their proliferative and undifferentiated state, growing on a feeder 
layer of mouse embryonic fibroblasts (MEF) or in medium containing leukaemia 
inhibitory factor (LIF) (Conner 2001). 
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Pluripotency is the ability of a cell to differentiate into all the cell types that make up 
an individual. Pluripotency can be tested in vitro, with the capacity of forming 
embryoid bodies, three-dimensional aggregates that are able to recapitulate the three 
germ layers. In vivo, cells can be injected into a blastocyst to assess whether they 
will be able to contribute to the development of a chimeric mouse and be transmitted 
through the germ line. Furthermore, proof of pluripotency can be obtained by 
subcutaneously injecting the cells in immunocompromised mice and monitoring for 




Figure 4 In vitro and in vivo tests for pluripotency 
a) Embryoid body formation. Embryonic stem cells (ESCs) are isolated from the inner cell mass of a 
blastocyst and cultured in suspension in semisolid media without Leukemia inhibitory factor. After 
eleven days, the cells spontaneously differentiate to form three-dimensional multicellular aggregates 
called embryoid bodies (EBs), which comprise the three embryonic germ layers. b) Production of 
chimeric mice. Labelled or mutated ESCs are injected into the diploid blastocyst of a wild type 
mouse. F0 generation chimeric mice are only partially derived from the modified ESCs and are bred 
to obtain F1 generation in which some of the mice are derived from the labelled ESCs c) Teratoma 
formation. ESCs subcutaneously injected into immunodeficient mice spontaneously originate tumours 
comprised of all three germ layers, called teratoma. 
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1.2.1.1 ESC SPECIFIC MOLECULAR NETWORKS  
As mentioned above, pluripotency is the key characteristic of stem cells in general 
and ESCs in particular. Understanding the network of factors that regulates this 
process has been the crucial focus of a large number of recent papers. In ESCs, 
pluripotency is maintained by a transcription factor network, which activates 
pluripotency-associated genes, including themselves, while repressing the 
developmentally regulated genes (Yeo and Ng 2013).  
LIF, a member of the IL-6 family, is a supplement that is necessary to maintain 
ESCs in an undifferentiated state in the absence of a feeder layer. On the cell surface, 
LIF binds to a two-part receptor complex that consists of the LIF receptor and the 
gp130 receptor. This binding leads to the phosphorylation of a signal transducer and 
to the activation of the latent signal transducer and activator of transcription 3 
(STAT3). This event is necessary for the maintenance of a proliferative state in 
mouse ESCs. Activated STAT3 translocates to the nucleus to activate a variety of 
downstream genes like Krüppel-like factor 4 (KLF4), which is involved in the 
regulation of numerous processes including proliferation and differentiation, and 
cMyc, a potent oncogene known to strongly promote proliferation (Figure 5a). 
Src homology-2 domain (SH2)-containing tyrosine phosphatases (SHP-2) and 
extracellular-signal-regulated kinase (ERK) are both components of a signal-
transduction pathway that counteracts the proliferative effects of STAT3 activation, 
influencing the self-renewal of mouse ESCs. SHP-2 is a tyrosine phosphatase that 
interacts with the intracellular domain of the gp130 receptor, and ERK is one of 
several enzymes activated when the gp130 receptor and other cell-surface receptors 
are stimulated. If ERK and SHP-2 are active, they inhibit ESC self-renewal 




Figure 5 Mechanisms of ESC self renewal and differentiation 
a) Promotion of ESC self-renewal via LIF-dependent activation of STAT3. Leukemia inhibitory 
factor (LIF) stabilizes the binding between Leukemia inhibitory factor receptor (LIFR) and 
glycoprotein 130 (gp130) cytokine receptor resulting in the activation of receptor-associated Janus-
associated (JAK) tyrosine kinases. This causes the recruitment, phosphorylation and dimerization of 
the transcription factor signal transducer and activator of transcription 3 (STAT3). When the dimers 
translocate to the nucleus they can regulate the expression of self-renewal genes. b) Ras/MEK/ERK 
signalling pathway induces cell differentiation. The recruitment on cell-surface receptors, such as 
gp130 of a complex containing the growth factor receptor-bound protein 2 (Grb2) adaptor and sos 
guanine-nucleotide-exchange factor, is mediated by src homology-2 domain (SH2)-containing 
tyrosine phosphatase (SHP-2). Subsequent activation of rat sarcoma (RAS) initiates a cascade of 
transphophorylations involving Raf and MAPK kinase (MEK) kinases with the final activation of and 
extracellular-signal-regulated kinase (ERK). Active ERK promotes ESC differentiation after 
phosphorylating cytoplasmic targets and undergoing nuclear translocation. 
 
 
Other important transcription factors involved in the maintenance of pluripotency 
are: sex determining region (SRY) Y-box 2 (Sox2), homeobox protein Nanog 
(Nanog) and octamer-binding transcription factor 4 (Oct4).  
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Sox2 gene, a member of the SOX gene family, encodes for a transcription factor, 
which is initially expressed in the blastocyst inner cell mass and, in later stages of 
development, in the germ cells and in the ectoderm. After gastrulation, Sox2 
expression is detectable in the developing neural tube throughout the early 
neuroepithelium (Wood and Episkopou 1999) and is probably induced by the 
activity of some regionally restricted enhancer elements (Zappone, Galli et al. 2000). 
In vitro, Sox2 is essential for maintaining pluripotency and it has been shown that a 
reduction of its expression induces mouse ESCs to differentiate into cells of the 
trophoectoderm lineage (Masui, Nakatake et al. 2007). 
Nanog is a homeobox-containing transcription factor expressed in the inner cells of 
the morula, prior to blastocyst formation and in the inner cell mass of the blastocyst 
up until the implantation stage (Chambers, Colby et al. 2003). Nanog expression is 
still detectable in the proximal epiblast at embryonic day 6 and in the epiblast as the 
development progresses (Hart, Hartley et al. 2004). In vitro, overexpression of 
Nanog in differentiation-inducing conditions prevents ESCs from exiting their 
pluripotent and self-renewing stage (Chambers, Colby et al. 2003). 
Oct4 is expressed in the mouse zygote, and is required throughout blastocyst 
development to establish and maintain the pluripotency of the inner cell mass and the 
epiblast. Oct4 is also expressed in the primordial and mature germ cells of mice 
(Schöler, Dressler et al. 1990). Oct4 expression in vitro is required to maintain the 
pluripotent, undifferentiated state of ESCs and its expression level is very important 
in the developmental program of mouse ESCs, making the protein a candidate 
"master regulator" of ESCs pluripotency. Indeed, Oct4 regulates gene expression by 
acting in synergy with Sox2 and binding to the Oct-Sox enhancer. This results in 
activation of pluripotency genes and silencing of differentiation-associated genes 
(Rodda, Chew et al. 2005). Furthermore, the binding of Oct4/Sox2 to the proximal 
region of Nanog promoter enhances its expression. LIF, with its downstream 
effectors STAT3 may be also involved in the regulation of Nanog gene expression 
(Pan and Thomson 2007) (Figure 6). 
Therefore, the pluripotency of ESCs is externally regulated through several 
molecules such as LIF, whose signalling pathway activates transcription factors in 
the nucleus. The transcriptional activity of Klf4, cMyc and Nanog, along with Oct4 
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and Sox2, maintains the unlimited proliferative capacity and differentiation potential 
of the cells.  
 
 
Figure 6 Regulation of Nanog expression in the ESC transcriptional network of pluripotency 
Octamer-binding transcription factor 4 (Oct4) regulates gene expression by acting in synergy with sex 
determining region (SRY) Y-box 2 (Sox2) and binding to the Oct-Sox enhancer; the binding of 
Oct4/Sox2 to the proximal region of homeobox protein Nanog (NANOG) promoter enhances its 
expression. Leukemia inhibitory factor (LIF), with its downstream effector signal transducer and 




1.2.1.2 ESCs DIFFERENTIATION INTO MESODERMAL LINEAGE 
Recently ESCs have been successfully differentiated into mesoderm-derived lineages 
using specific stimulations with different substrates and growth factors. For instance, 
mouse ESCs under optimised culture conditions and following serum induction have 
been shown to differentiate into hematopoietic cells (Keller 1995). Moreover, mouse 
ESCs plated on matrigel originated embryonic bodies and differentiated into blood 
vessels spontaneously (Nakagami, Nakagawa et al. 2006). Furthermore, ESCs have 
been differentiated recently into ECs and SMCs (Levenberg, Golub et al. 2002, Xiao, 
Zeng et al. 2007), vascular progenitors (Yamashita, Itoh et al. 2000) and 
cardiomyocytes (Kehat, Kenyagin-Karsenti et al. 2001, Yamashita, Takano et al. 
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2005), offering a wide range of cell lineages for clinical transplantation and 
therapeutic applications, which will be discussed in one of the following sections 
(1.4). 
It has also been shown that CD34
+
 cells isolated from differentiated hESCs act as 
vascular progenitor cells capable of originating both ECs and SMCs (Hill, 
Obrtlikova et al. 2010).  
Generation of vascular ECs, SMCs and cardiomyocytes from ESCs offers a 
prospective source for cardiovascular tissue repair (Gepstein 2002). 
Differentiation potential of stem cells into mesodermal lineages will be better 
discussed in some of the following sections, with a particular focus on iPSCs 
differentiation and the different stimuli inducing stem cell differentiation. 
 
1.2.2 ADULT STEM CELLS 
Adult stem cells, also known as somatic stem cells, are multipotent stem cells, found 
throughout the body after development in specific niches, that multiply by cell 
division to replenish dying cells and regenerate damaged tissues (Yin and Li 2006). 
Scientific interest in adult stem cells is due to their self-renewability and to their 
potential to differentiate into one or more cell types of the organ from which they 
originate. Unlike embryonic stem cells, the use of adult stem cells for therapeutic 
application does not raise ethical issues, since these cells are derived from adult 
tissue samples without the need for destroying human embryos.  
Adult stem cells can be divided into three categories: bone marrow, circulating and 
tissue-resident stem cells. The first application of adult stem cell therapy was 
discovered in the 1950s, with the first bone marrow transplantation study. Stem cells 
present in the bone marrow can be used to replenish the depleted tissue and are able 
to produce all the derived populations. Subsequent studies isolated two main stem 
cell populations in the bone marrow: the hematopoietic stem cells, which form all the 
types of blood cells in the body, and the bone marrow stromal stem cells (also called 
mesenchymal stem cells), which can generate bone, cartilage, fat, cells that support 
the formation of blood, and fibrous connective tissue (Nirmalanandhan and 
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Sittampalam 2009). They have been used for the therapy of blood disorders, such as 
leukemia, multiple myeloma and lymphoma, and disorders with defective genes such 
as severe combined immune deficiency (Papewalis, Topolar et al. 2013). Beside the 
reconstitution of host bone marrow, many other regenerative medicine applications 
of these cells have been progressively discovered. Mesenchymal stem cells have 
been differentiated in vitro into functional cardiomyocytes offering a great potential  
for therapeutic applications in myocardial infarction  (Xu, Zhang et al. 2004). 
Moreover, mesenchymal stem cells have been used in the effective cell therapy of 
the infarcted heart (Pittenger and Martin 2004). Furthermore, mesenchymal stem 
cells have been transplanted in a model of limb ischemia, after artery occlusion and 
their angiogenic potential has been tested, compared to a control cell population 
composed of bone marrow-derived mononuclear cells. Blood flow recovery was 
improved by both cell types and mesenchymal stem cells were able to differentiate 
into ECs and SMCs and to contribute to the sprouting of collateral vessels (Iwase, 
Nagaya et al. 2005). 
Gradually, it has become evident that adult stem cells play an important role in the 
maintenance and repair of tissues and organs during the life span of the individual 
(Nirmalanandhan and Sittampalam 2009, Teo and Vallier 2010).  
Progenitor cells are found in many organs and are unipotent or multipotent with 
limited plasticity. Even though their self-renewability is highly limited, progenitor 
cells are able to repair injury in tissues where they reside. There are many types of 
progenitor cells so far identified, such as osteoblasts and chondrocytes, satellite cells 
in muscles, angioblasts, bone marrow, cardiac, stromal cells and the intermediate 
progenitor cells in the subventricular zone of the brain (Nirmalanandhan and 
Sittampalam 2009).  
Bone marrow cells are recruited to the site of injury and participate in the healing of 
several organs. During the reparative process, progenitor cells are mobilized from 
the bone marrow into the circulation by directed migration along growth 
factor/cytokine gradients, to differentiate into a more mature phenotype and integrate 
in the nascent vasculature. The most widely studied subpopulation of circulating 
progenitor cells so far is represented by the EPCs, which have been shown to offer a 
great potential for angiogenesis applications and atherosclerosis treatment. 
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EPCs are derived from the bone marrow and appear to be implicated in the repair 
and maintenance of the vasculature through re-endothelialisation and 
neovascularisation (Shi, Rafii et al. 1998). It has been shown that the number and 
function of circulating EPCs decrease in response to risk factors associated with 
coronary artery disease (CAD), such as age, diabetes and high levels of blood 
cholesterol, potentially contributing to increased cardiac risk, reduced angiogenic 
capacity, and impaired cardiac repair effectiveness; however, the mechanisms 
underlying this process are not yet fully understood (Vasa, Fichtlscherer et al. 2001). 











 (Asahara, Murohara et al. 1997). EPCs were originally 
characterized as a circulating population carrying the marker CD34 and coexpressing 
hematopoietic antigens (such as CD45). During culture/expansion, EPCs stop 
expressing CD45 (leukocyte common antigen) and start expressing EC markers, 
such as Factor VIII, CD31, UEA-1 (ulex eureopaeus agglutinin-1), eNOS, E-selectin 
and become able to incorporate Dil-labeled acLDL. EPCs injected in a non-
immunocompetent mice model of limb tumour were shown to successfully integrate 
into nascent capillaries (Asahara, Murohara et al. 1997). The therapeutic potential of 
EPC transplantation has been exploited by many studies conducted in mouse and 
rabbit hind limb ischemia models (Takahashi, Kalka et al. 1999, Kalka, Masuda et al. 
2000). Moreover, EPCs expanded ex vivo have been reported to incorporate into foci 





Figure 7 Niches of adult stem cells 
Adult stem cells have been identified in specific niches in the human body, such as in the bone 
marrow, the heart and the brain. These cells show self-renewability and the potential to differentiate 
into all the cell types of the organ from which they originate. 
http://www.kokhucredernegi.org.tr/eng/kok_hucre/eriskin.html 
 
Adult stem cells have been shown to be present in many different adult tissues. For 
instance, vascular progenitor cells such as Sca-1
+
 have been shown to be abundant in 
the adventitia  (Hu, Zhang et al. 2004) and perivascular progenitor cells have been 
identified in the human adult vena saphena (Campagnolo, Cesselli et al. 2010); adult 
stem cells can be also found in the skin (Bickenbach and Grinnell 2004), the liver 
(Kung and Forbes 2009), the muscle (Martin, Russell et al. 2006), the lung 
(Neuringer and Randell 2006) and the heart (Beltrami, Barlucchi et al. 2003).  
Despite the success in the use of stem cells from the bone marrow, adult stem cells 
clinical use is still restricted because of the limited differentiation potential of these 
cells. Furthermore, the identification of adult stem cells in the human body and 
indeed their characterization is still challenging (Teo and Vallier 2010). In addition, 
the therapeutic potential of somatic stem cells might be reduced in pathological 
conditions, since they might be impaired by the disease itself. Finally, using 
44 
 
endogenous stem cells in genetic diseases is not likely to be beneficial, since the 
stem cells would still produce progeny carrying the same phenotype (Teo and Vallier 
2010).  
Mobilization of endogenous somatic stem cells represents the ultimate non-invasive 
objective of regenerative medicine. It has been recently demonstrated that 
stimulation with granulocyte colony-stimulating factor (G-CSF) is able to mobilize 
hematopoietic progenitor cells from the bone marrow (Levesque, Hendy et al. 2003). 
Moreover, populations of progenitor cells can be selectively mobilized from the bone 
marrow as a response to different factors in various pathologies (Pitchford, Furze et 
al. 2009).  
A better environment should be created in order to facilitate a therapeutic use of 
adult stem cells, for instance through the activation and mobilization of resident 
progenitor cells from their niches. Cytokines may be used to mimic the physiological 
situation in which BM cells are mobilized into the circulation, after stimulation from 
damaged tissues. Moreover, in a the study conducted on adult epicardium-derived 
progenitor cells, it has been shown that the actin monomer-binding protein thymosin 
beta4 (Tβ4) is able to induce and revert these resident progenitor cells to their 
embryonic phenotype, giving rise to endothelial cells and vascular smooth muscle 
cells ex vivo. Indeed, through an “endogenous repair,”  Tβ4 promotes cardiac 
neovascularization to sustain the myocardium after ischemic damage (Smart, Risebro 
et al. 2010). 
 
1.2.3 INDUCED PLURIPOTENT STEM CELLS (iPSCs) 
The knowledge of the complex network of transcription factors cooperating to 
maintain the pluripotent state of ESCs has recently been exploited in order to induce 
somatic cell reprogramming. In the past, techniques such as somatic cell nuclear 
transfer have proved successful in inducing cell de-differentiation; however, there 
are technical and ethical issues in applying this type of approach to human cells, for 
example oocyte donor-associated risk of transmissible diseases (Yamanaka 2007).  
In a landmark study, Yamanaka and colleagues showed the generation of induced 
pluripotent stem cells (iPSCs), following retroviral overexpression of four 
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transcription factors, Oct4, Sox2, Klf4, and c-Myc (OSKM) in mouse fibroblasts 
(Takahashi and Yamanaka 2006).  
However, iPSCs could not produce chimeric mice and there were major differences 
between their global gene expression pattern and that of ESCs. Indeed, in 2007 a 
new method to generate mouse iPSCs was described; resultant cells showed  
phenotypes more closely related to ESCs and were able to generate chimeric mice 
and be transmitted through the germline (Meissner, Wernig et al. 2007, Okita, 
Ichisaka et al. 2007, Wernig, Meissner et al. 2007). 
Hence, reprogrammed cells, like ESCs, exhibited unlimited proliferation and 
satisfied all the pluripotency standard assays, such as in vitro differentiation into the 
three germ layers, teratoma formation, contribution to chimeric mice, germline 
transmission (Maherali and Hochedlinger 2008), and tetraploid complementation 
(Woltjen, Michael et al. 2009).  
Moreover, as iPSCs may be obtained from somatic cells, they offer the potential of 
generating patient-specific cell lines and consequently will overcome the immune 
rejection response. Furthermore, being generated from adult cells, iPSCs are not 




Figure 8 Generation of iPSCs 
iPSCs are generated from adult fibroblasts by introducing a cocktail of reprogramming factors. 
Reprogrammed cells are pluripotent and if cultured with different stimuli can originate cells from the 
three germ layers, such as blood cells, gut cells or cardiac cells. 
http://learn.genetics.utah.edu/content/tech/stemcells/quickref/ 
 
Following the publication of the protocol for iPSC generation, a number of research 
groups focused on demonstrating that iPSCs can originate from different types of 
somatic cells derived from all three germ layers: neuronal progenitor cells and 
keratinocytes from the ectoderm (Aasen, Raya et al. 2008, Shi, Tae Do et al. 2008), 
progenitor B cells from the mesoderm (Hanna, Markoulaki et al. 2008) and stomach 
cells and hepatocytes from the endoderm (Aoi, Yae et al. 2008). Furthermore, iPSCs 
were derived from human cells using either the OSKM factors (Takahashi, Tanabe et 
al. 2007, Park, Zhao et al. 2008) or Oct4, Sox2, Nanog and lin-28 (Yu, Vodyanik et 
al. 2007). 
The availability of pluripotent stem cell populations and the understanding of the 
mechanisms that maintain the undifferentiated state, provide a powerful tool to drive 
stem cell differentiation into therapeutically interesting cell types, such as ECs. In 
order to design an efficient protocol of differentiation, it is fundamental to 
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understand the physiological stimuli involved in EC maturation and proliferation 
during development and adulthood. 
 
1.2.3.1 iPSC DIFFERENTIATION INTO MESODERMAL LINEAGES 
As mentioned before, iPSCs are able to differentiate towards cells derived from all 
the three germ layers, such as pancreatic beta-cells from the endoderm (Zhang, Jiang 
et al. 2009), and several neuronal cell types from the ectoderm (Wernig, Zhao et al. 
2008). In particular, in this work we will focus on iPSC differentiation towards 
mesodermal lineages and specifically endothelial cell lineage. 
iPSCs are believed to possess the same characteristics and differentiation potential of 
ESCs. Studies to confirm this statement are of extreme importance and will help to 
elucidate more clearly the degree of similarity between those two cell types. In 
regards to the process of endothelial differentiation, the protocols applied and the 
results obtained so far seem to be comparable. A recent study elucidated the features 
of the directed differentiation of human iPSCs into vascular ECs and mural cells, 
revealing that the properties of human iPSC differentiation into vascular cells are 
nearly identical to those observed in human ESCs (Taura, Sone et al. 2009). 
To initiate the differentiation process, iPSCs are cultured on collagen IV, an 
extracellular matrix protein, which has been reported to direct ESC differentiation to 
mesodermal lineages, including SMCs, ECs, and hematopoietic cells, in both mouse 
(Nishikawa, Nishikawa et al. 1998, Schenke-Layland, Angelis et al. 2007) and 
human cultures (Gerecht-Nir, Ziskind et al. 2003). Fluorescence-activated cell sorter 
(FACS) analysis of collagen IV differentiated iPSCs showed the presence of Flk1
+
 
progenitor cells which, when isolated and cultured in differentiation promoting 
conditions, differentiated into functional SMCs, ECs and spontaneously beating 
cardiomocytes, with concomitant decrease of stem and progenitor cell gene 
expression (Figure 9) (Narazaki, Uosaki et al. 2008, Schenke-Layland, Rhodes et al. 
2008). 
Additionally iPSCs monolayers have been shown to differentiate into functional 





Figure 9 Procedure and time course of mESC and iPSC differentiation into ECs and 
cardiomyocytes 
When undifferentiated induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs) were 
cultured for 4.5 days on collagen IV-coated dishes in differentiation medium, without leukemia 
inhibitory factor (LIF), a mixed population of cells containing vascular progenitor cells arose. 
Vascular endothelial receptor 2 (Flk1
+
) putative vascular progenitor cells were sorted by flow 
cytometry and plated onto collagen IV dish or OP9 stroma cells. Flk1
+
 cells differentiated for one day 
(Flk-d1) or four and five days (Flk-d4-5) give rise respectively to a mixed population of endothelial 
cells (ECs) and cardiomyocytes. Fluorescence-activated cell sorter (FACS) analysis and 
immunostaining were performed at Flk-d3 and Flk-d5 to evaluate the differentiation of ECs and 
cardiomyocytes; electrophysiological studies were carried out on cardiomyocytes at Flk-d8. Adapted 
from (Narazaki, Uosaki et al. 2008). 
 
 
In one particular study, cells derived from Flk1
+
 progenitors were thoroughly 
characterized. Amongst the populations obtained, the authors identified mural cells 
(vascular SMCs and pericytes), lymphatic, vascular ECs (arterial and venous ECs) 
and a novel population of cardiac progenitor cells. From cardiac progenitor cells, a 
population of self-beating cardiomyocytes arose as a mix of atrial, ventricular, 






Figure 10 Systematic induction of different cardiovascular cell types from common progenitor 
Flk1
+
 of mouse iPSCs 
A population of common progenitor cells positive for Flk1
+
 and endothelial cadherin (E-cadherin) is 
selected from pre-differentiated mouse induced pluripotent stem cells (iPSCs), initially positive for 




 cells cultured in presence of vascular endothelial 











 cells give rise to smooth muscle 
actin positive (SMA+) mural cells in presence of platelet-derived growth factor BB (PDGF-BB). On 
the other hand, Flk1
+
 cells cultured on OP9 stroma cells differentiated into a cardiac progenitor cells 
population, positive for Flk1 and chemokine receptor type 4 (CXCR4
+
), that can then be further 
differentiated into cardiomyocytes, which are negative for Flk1 and positive for -myosin heavy 
chain (MHC+) and homeobox protein Nkx2.5.  Adapted from (Narazaki, Uosaki et al. 2008). 
 
In a similar study, using collagen IV culture or EB formation, Flk1
+
 progenitor cell-
derived mouse iPSCs were differentiated into mesodermal lineages, including 
cardiovascular and hematopoietic lineages (Schenke-Layland, Rhodes et al. 2008). 
Finally, mouse iPSCs have been shown to differentiate in vitro into functional 
cardiomyocytes, which have been characterized for the expression of functional 





1.3 STIMULI REGULATING ENDOTHELIAL 
DIFFERENTIATION 
Initial methods to generate vascular progenitors from ESCs tried to mimic the in vivo 
pattern of blood vessel formation. In terms of differentiation both cytokines and 
mechanical forces are able to initiate a signal cascade leading to progenitor cell 
acquisition of phenotypic features typical of ECs.  
 
1.3.1 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
Both vasculogenesis and angiogenesis are regulated by the actions of a series of 
growth factors, such as fibroblast growth factor–2 (FGF-2), vascular endothelial 
growth factor (VEGF) and, in the adult, platelet-derived growth factor (PDGF) and 
transforming growth factor beta (TGF-β).  
VEGF is an EC-specific mitogen that plays an important role in many of the events 
necessary for angiogenesis (Connolly 1991) and other EC functions, such as  
permeability, vascular tone and production of vasoactive molecules (Zachary 1998). 
The VEGF gene is located on the short arm of chromosome 6 and it is composed of 
eight exons and seven introns (Tischer, Mitchell et al. 1991, Vincenti, Cassano et al. 
1996). Hypoxia-mediated control of gene transcription and alternative splicing 
regulate the transcription of VEGF gene and the production of differing isoforms 
(Giles 2001). VEGF transcript is subjected to alternative splicing from exons 5 to 8, 
leading to the production of different isoforms which show variable diffusibility 
depending on their length: VEGF121, VEGF165, VEGF189  represent the main forms 
(Tischer, Mitchell et al. 1991). Exon 6, which is not present in VEGF121 and 
VEGF165, together with exon 7 provide heparin-binding affinity; exon 8, which is 
present in all the active isoforms, is required to stimulate mitosis (Ferrara 2004). The 
smaller isoform VEGF121, which lacks exons 6 and 7, is freely diffusible, whereas 
the longer isoforms are highly basic and remain cell-associated (Houck, Ferrara et al. 
1991). VEGF165, which lacks only exon 6, shows intermediary properties: it is 
largely soluble, with a distinct cell-associated fraction (Houck, Ferrara et al. 1991). 
VEGF165 is the prevailing isoform, and is most biologically active in the 
physiological state (Ferrara 2004). VEGF regulates key cellular events during 
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vasculogenesis, supporting EC proliferation and motility. In particular, low doses of 
VEGF induce EC proliferation while high doses enhance EC motility. This dose-
dependent effect can also explain the abnormal blood vessel formation and lethality 
of embryos lacking only one single VEGF allele (heterozygous VEGF
+/-
). As 
expected, the development of blood vessels is further impaired in homozygous 
VEGF-deficient embryos (VEGF
-/-
) (Carmeliet, Ferreira et al. 1996, Ferrara, Carver-
Moore et al. 1996).  
VEGF exerts its action binding to three different receptors: VEGFR-1, also known as 
fms-related tyrosine kinase (Flt1), VEGFR-2 or kinase insert domain receptor 
(KDR), the human homolog of fetal liver kinase (Flk1), and VEGFR-3 (Flt4) 
(Neufeld, Cohen et al. 1999, Ellis, Takahashi et al. 2000). Both VEGFR-1 and 2 
consist of an extracellular domain composed of seven immunoglobulin (Ig)-like 
domains, a transmembrane domain, a juxtamembrane domain, a long kinase domain 
insert in the middle of the tyrosine kinase domain and a C-terminal tail (Takahashi, 
Yamaguchi et al. 2001). VEGFR-1 can be activated by VEGF-A or placenta growth 
factor-1 in arteriogenesis. Wound healing processes and their signalling pathways 
have been characterized in human monocytes. As a result of VEGFR-1 activation 
there is an induction of chemotactic responses, with the expression of tissue factors, 
cytokines
 
and chemokines (Tchaikovski, Fellbrich et al. 2008).
 
VEGFR-2 is 
expressed in monocytes and ECs and mediates the effect of VEGF on cell motility 
(Gille, Kowalski et al. 2001), vascular permeability and proliferation (Clauss, Weich 
et al. 1996). VEGFR-2 is a major progenitor cell marker for hematopoietic and 
endothelial lineage, expressed from  the hemangioblast to mature ECs (Schatteman 
and Awad 2004). VEGFR-3 is involved in the lymphoangiogenic process and is 
homologous with the neurophilin-1 receptor (Ferrara 2000, Yancopoulos, Davis et 
al. 2000). Study of knock-out animals demonstrated that not only VEGF, but also its 
receptors 1 and 2 are fundamental in the development of the fetal vasculature. As it 
appeared from the knock-out animal’s phenotype, these two receptors mediate 
different responses: Flk-1 null mutant mice showed an impaired endothelial and 
hematopoietic cell development (Shalaby, Rossant et al. 1995) and Flt1 knock-out 
resulted in an overgrowth of ECs and disorganization of blood vessels (Fong, 




1.3.1.1 ROLE OF VEGF IN EC DIFFERENTIATION  
VEGF is a potent stimulus, able to drive endothelial differentiation in a large number 
of progenitor cell populations, leading to the creation of a reservoir of cells that 
could be therapeutically used to repair the endothelial monolayer and to improve 
vascular function following injury [reviewed in (Zampetaki, Kirton et al. 2008)].  
Indeed VEGF has been shown so far to be one of the most potent growth factors able 
to stimulate progenitor cell differentiation into ECs. In particular, treatment of Flk1
+
 
cells derived from ESCs with VEGF was able to induce EC differentiation 
(Yamashita, Itoh et al. 2000). Moreover, ESC-derived Flk1
+
 cells could differentiate 
into both endothelial and mural cells, after stimulation with VEGF and platelet-
derived growth factor BB (PDGF-BB) respectively, and reproduce the vascular 
organization process. To confirm this concept, Yamashita and his co-workers 
engineered mouse Flk1
+
 cells to express LacZ, and injected them into the developing 
hearts of stage 16–17 chick embryos. The -gal+ mouse cells populated blood 
vessels in the chicks' head, yolk sac, heart, and regions between the somites, showing 
differentiation towards ECs and mural cell lineages (Yamashita, Itoh et al. 2000). 
Indeed, Flk1
+
 cells can act as “vascular progenitor cells” in the formation of mature 





Figure 11 The two types of blood-vessel cells arise from a common progenitor 
Blood vessels are generally composed of two cell types: while endothelial cells line the inside and 
form channels that conduct blood, smooth muscle cells cover the outside, protecting the channels 
from rupture and controlling blood flow. These two cell types have been considered to arise from 
separate precursors: endothelial cells from the angioblasts or haemangioblasts in the embryo, or from 
circulating endothelial progenitors in the adult (not shown) and smooth muscle cells and pericytes 
from a variety of progenitors. However recently it has been shown that the two types of cells that 
make up blood vessels, endothelial cells and smooth muscle cells, can develop from common vascular 
progenitors upon stimulation with vascular endothelial growth factor (VEGF) or platelet-derived 
growth factor BB (PDGF-BB) respectively  (Carmeliet 2000). 
  
 
Several years later, Flk1
+
 cells isolated from human embryonic stem cells (hESCs) 
were used to differentiate into ECs and SMCs, which not only expressed phenotypic 
makers, but were also able to contract when treated with retinoic acid and/or 
dibutyryl-cydic adenosine monophosphate (db-cAMP) (Drab, Haller et al. 1997, 
Huang, Zhao et al. 2006).  
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Moreover ECs generated from Flk1
+
 precursors were shown to organize into vessel-
like structures when grown in collagen gel suspensions or transplanted in vivo. 
Interestingly, immunofluorescence analysis showed that the tube-like structures 
obtained mimicked the organization of blood islands in the early embryo, being 
composed of endothelial (PECAM-1
+
) and mural (SMA
+





) (Yurugi-Kobayashi, Itoh et al. 2003). 
Additionally, in a study conducted in our group, stem cell antigen-1-positive (Sca1
+
) 
progenitor cells, isolated from predifferentiated ESCs were cultured in medium 
containing VEGF which led to their differentiation into a pure and functional 
population of ECs, via VEGF-induced activation of histone deacetylase 3 (HDAC3) 
(Xiao, Zeng et al. 2006). When cultured with VEGF for 21 days Sca1
+ 
progenitors 
displayed cobblestone morphology and the majority of the cells expressed high 
levels of endothelial markers (CD31, CD106, CD144, Flk1, Flt1 and vWF). These 
ESC-derived ECs were also shown to form vascular structures when mixed with 
Matrigel and subcutaneously injected in mice (Xiao, Zeng et al. 2006). Moreover, 
when Sca1
+
 cells were injected in a mouse model of femoral artery denudation 
injury, the progenitor-derived ECs were able to decrease the process of neointimal 
formation (Xiao, Zeng et al. 2006).  
In another work, hESCs isolated from 10 to 15 day old human embryoid bodies were 
dissociated and labeled with anti-human CD34 antibodies. CD34
+
 cells were then 
isolated from the cell mixture using magnetic-activated cell separation and cultured 
in endothelial growth medium supplemented with VEGF. These specific 
differentiation conditions gave rise to an homogenous endothelial-like population 
(Levenberg, Ferreira et al. 2010). Similarly, undifferentiated ESCs were cultured on 
collagen IV-coated dishes, in a medium containing fetal calf serum but no LIF. This 
induced the generation of cells of the mesodermal lineage, including Flk1
+
 cells that 
were then purified by flow cytometry sorting. When these cells were cultured with 
medium containing VEGF, sheets of ECs expressing typical markers, such as 
PECAM-1, arose (Hirashima, Kataoka et al. 1999, Yamashita, Itoh et al. 2000). 
The growing number of publications showing the centrality of the role of VEGF in 
the process of endothelial differentiation of progenitor cells prompted us to apply it 
to our differentiation system. 
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1.3.2 SHEAR STRESS  
Apart from VEGF, another potent stimulus used to induce EC differentiation is the 
mechanical force of shear stress. 
Endothelial shear stress is the tangential stress derived from the friction of the 
flowing blood on the endothelial surface of the arterial wall and is expressed in units 
of force/unit area (N/m
2




 =1 Pa = 10 dyne/cm
2
). 
Endothelial shear stress is proportional to the product of the blood viscosity (µ) and 
the spatial gradient of blood velocity at the wall (endothelial shear stress= µxdv/dy).  
Abnormal responses of ECs to shear stress lead to impaired vascular functions and 
contribute to many vascular diseases, such as hypertension, thrombosis, and 
atherosclerosis. Previous studies showed that shear stress could lead to 
morphological changes of ECs via cytoskeleton reorganization with actin filaments 
becoming rearranged into stress fibers aligned in the direction of the shear stress 
(Ando and Yamamoto 2009).  
Laminar shear stress occurs naturally in vivo in straight regions of the vasculature 
but becomes turbulent in areas of disturbed flow, such as the inside wall of curved 
regions and lateral branching points, where a higher incidence of atherosclerosis is 
observed (Ku, Giddens et al. 1985). In healthy regions of the human vasculature 
where the laminar blood flow is unidirectional and pulsatile, the shear stress sensed 
by the endothelium is between 15 and 70 dynes/cm
2
. High shear stress induces an 
atheroprotective and anticoagulant endothelial phenotype (Boon and Horrevoets 
2009). On the other hand, regions of the vasculature predisposed to atherosclerotic 
lesion formation still sense pulsatile flow, though this is highly turbulent and 
bidirectional. The oscillatory shear stress sensed by the endothelium in these regions 
is between 0 and 10 dynes/cm
2
. Application of turbulent shear stress  through use of 
an in vivo cuff model determines a higher probability of development of 
atherosclerotic lesions (VanderLaan, Reardon et al. 2004).  
Moreover, occluded sections of atherosclerotic lesions which are subjected to 
elevated laminar shear stress showed an 85% decrease in EC apoptosis (Tricot, 
Mallat et al. 2000). Furthermore, it has been shown that ECs exposed to 24h of 
steady laminar shear flow at 12 dyn/cm
2
, which reproduces approximately the 
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hemodynamic force in straight parts of arteries, undergo anti-inflammatory (Wang, 
Miao et al. 2006) and anti-proliferative (Lin, Hsu et al. 2000) modifications. In 
contrast, exposure of ECs to disturbed flow, which mimics the hemodynamic force at 
branch points, leads to opposite responses (Hsiai, Cho et al. 2003) 
Cyclin-dependent-kinase (CDK) inhibitors (e.g., p21cip, p27kip) and tumour 
suppressor p53 expression and retinoblastoma (Rb) hypophosphorylation have been 
found to be involved in laminar shear-induced EC growth arrest (Akimoto, 
Mitsumata et al. 2000, Lin, Hsu et al. 2000). 
Different types of flow, such as steady, pulsatile, low and oscillatory, can initiate 
signalling cascades, leading to up or downregulation of a variety of genes and to 
cytoskeleton organization. Steady laminar shear stress activates mechanosensitve, 
atheroprotective signalling pathways, limiting oxidative stress, inflammation and 
apoptosis and maintaining EC integrity (Chatzizisis, Coskun et al. 2007). In contrast, 
in regions exposed to low shear stress, or high oscillatory (disturbed) flow, nitric 
oxide, reactive oxygen species (ROS) scavengers and prostacyclin production is 
attenuated with a consequent reduction of the vasodilatory, atheroprotective role of 
these molecules. Disturbed flow is also probably involved in neovascularisation, 
calcification and thrombogenecity of the atherosclerotic plaque, enhancing 
inflammation and leading to excessive expansive remodelling. All these factors can 
transform an early fibroatheroma into a high-risk plaque (Chatzizisis, Coskun et al. 
2007). 
 
1.3.2.1 ROLE OF SHEAR STRESS IN EC DIFFERENTIATION 
Beside the action of chemokines and growth factors, such as VEGF, endothelial 
differentiation can also be induced by mechanical stimuli. In particular shear stress 
has been studied in both in vitro and in vivo settings. 
Many studies have demonstrated that shear stress plays a critical role in promoting 
the differentiation of ESC-derived progenitor cells into ECs. 
In particular, Yamamoto et al. showed that when Flk1
+
 progenitors are exposed to 
shear stress (1.5 to 10 dynes/cm
2
), EC marker expression, such as Flk1, Flt1, 
PECAM-1 and VE-cadherin, is significantly increased at both protein and mRNA 
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levels as it is increased their tube formation capacity (Yamamoto, Sokabe et al. 
2005).  
In 2005 Wang et al. demonstrated for the first time that mesenchymal progenitors 
differentiate into ECs after exposure to shear stress (Wang, Riha et al. 2005). One 
year later the same investigators showed that shear stress may promote EC 
transdifferentiation from SMCs (Wang, Yan et al. 2006). 
Additionally, it has been demonstrated that murine ESC derived-ECs, when exposed 
to laminar flow, undergo cytoskeletal rearrangements and show increased 
vasculogenic and angiogenic potential in vitro, as compared to cells cultured in static 
conditions (McCloskey, Smith et al. 2006). Also hESC-derived ECs are capable of 
functionally responding to changes in fluid shear stress by modulating cell 
morphology and gene expression (Metallo, Vodyanik et al. 2008) 
Furthermore, data from our group showed that exposing Sca1
+
 progenitor cells to 
laminar shear stress (12 dynes/cm
2
) increased their proliferation and differentiation. 
Sheared Sca1
+ 
cells displayed increased expression levels of Flk1, eNOS and 
VCAM-1 and showed improved tube-like structure formation on Matrigel (Xiao, 
Zeng et al. 2006). 





cells, when exposed to short-term shear stress using an orbital shaker, showed an 
increased EC marker expression (in revision, Campagnolo et al.).  
Shear stress has been also shown to induce differentiation of EPCs towards arterial 
ECs by increasing the expression of ephrinB2 in the progenitor cells through specific 
protein 1 (Sp1) activation (Obi, Yamamoto et al. 2009). 
In another study, two days application of fluid-based shear stress at levels 
comparable to physiological during the first stages of mouse ESC differentiation 
induced an increase in cell proliferation and in the expression of the endothelial 
markers Flk1, VE-cadherin and CD31. Shear stress also induced the number of Flk1
+
 
cells from 1% to 40%, inducing the ability of the cells to form vessel-like structures 
in vitro (Ahsan T, Nerem RM. 2010). 
Finally, in a work published this year laminar shear stress has been applied to ESCs 
using a 2D adherent parallel plate configuration to study in a systematic way the 
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effects of mechanical parameters involved. Shear stress in the range of 1.5 to 15 
dyne/cm
2 
promoted endothelial and hematopoietic differentiation of cells seeded on 
collagen, fibronectin or laminin substrates. Prolonged duration of the treatment 
consistently induced an endothelial response, while application of shear at later 
stages of differentiation impaired hematopoietic differentiation (Wolfe and Ahsan 
2013).  
Thus, shear stress may be used to direct differentiation of ESCs and EPCs toward an 
endothelial-like phenotype, helping to find new cell sources in tissue engineering and 
cardiovascular regenerative medicine. 
 
1.3.3 MicroRNA (miRNA) 
Amongst the factors able to drive EC differentiation and to modify their 
proliferation/migration pathway are microRNAs (miRNAs), which have been 
recently discovered and are now the topic of cutting edge research. 
MiRNAs are single-stranded, noncoding molecules of RNA, 20-25 nucleotides long, 
able to regulate a wide range of cellular processes by binding to non-coding regions 
of messenger RNA (mRNA) (Daubman 2010). The first miRNAs, lin-4 and let-7, 
were discovered in Caenorhabditis elegans in 1993 (Lee, Feinbaum et al. 1993, 
Wightman, Ha et al. 1993, Reinhart, Slack et al. 2000).  Extensive research has 
shown that miRNAs are expressed by most eukaryotic cells and regulate several cell 
functions (Ambros 2008). The exact mechanism of this regulation remains unclear, 
however miRNAs seem to bind to 3’ untranslated regions (3’ UTRs) of target 
mRNAs by traditional base-pairing; in this way miRNA can promote mRNA 
degradation or modify its translational levels, therefore regulating the corresponding 
protein expression (Lee, Feinbaum et al. 1993, Wightman, Ha et al. 1993, Reinhart, 
Slack et al. 2000); (Lewis, Burge et al. 2005).  
MiRNA genes are mostly transcribed by RNA polymerase II (Pol II), resulting in a 
primary miRNA (pri-miRNA) which can be spliced (Lee, Jeon et al. 2002, Bracht 
2004, Cai, Hagedorn et al. 2004). Pri-miRNA are processed in the nucleus by the 
RNase III Drosha to produce a ~70-nt precursor miRNA (pre-miRNA) (Lee, Ahn et 
al. 2003) that is then transported in the cytoplasm by Exportin-5 (Bohnsack, 
59 
 
Czaplinski et al. 2004). In the cytoplasm, another Rnase III, Dicer, cleaves the pre-
miRNA in a ~22-nt miRNA duplex (Bernstein, Caudy et al. 2001, Chendrimada, 
Gregory et al. 2005). At this point, the strand of miRNA duplex with lower stability 
of base-pairing at its 5’ is incorporated into the RNA induced silencing complex 
(RISC), whereas the other strand is degraded. RISC is a trimeric complex composed 
of Dicer and the Argonaute protein Ago, which is recruited by the TAR RNA 
binding protein (TRBP) in human cells (Gregory, Chendrimada et al. 2005, 
Maniataki and Mourelatos 2005) (Figure 12). MiRNAs included in the RISC can 
target the mRNAs by base-pairing. If the base-pairing interaction is complementary, 
mRNAs are cleaved and actively degraded (Hutvágner and Zamore 2002, Martinez 
and Tuschl 2004). 
Theoretically, each miRNA should be able to regulate more than 100 mRNAs, 
potentially controlling the activity of 30% of all genes at the post-transcriptional 
level (Xie, Lu et al. 2005, Filipowicz, Bhattacharyya et al. 2008, Cordes, Sheehy et 
al. 2009) 
In the human genome, more than 1000 miRNAs have been identified and there is 
strong evidence that these small molecules are involved in a wide range of 
physiological and pathological processes such as cell proliferation and 
differentiation, angiogenesis and oncogenesis (Lu, Getz et al. 2005, Suarez and Sessa 
2009). Recent studies showed that miRNAs play an important role in vascular 
development and homeostasis (Suárez, Fernández-Hernando et al. 2008, Bonauer, 






Figure 12 miRNA production in cells 
RNA polymerase II (Pol II) transcribes miRNA genes and originates the primary miRNA (pri-
miRNA). In the nucleus the pri-miRNA is cleaved by the RNase III endonuclease Drosha and the 
double-stranded RNA binding domain (dsRBD) protein DGCR8/Pasha, originating a ~70-nt precursor 
miRNA (pre-miRNA). The pre-miRNA is transported from the nucleus to the cytoplasm by the 
protein Exportin-5. In the cytoplasm the pre-miRNA is cleaved by Dicer, another RNase III 
endonuclease, together with the TAR RNA binding protein (TRBP) /Loquacious, in a ~22-nt miRNA 
duplex*. The RNA induced silencing complex (RISC), a trimeric complex also composed by Dicer 
and the Argonaute protein Ago, incorporates the miRNA strand, whereas the miRNA* strand is 
degraded. Adapted from (Bushati and Cohen 2007). 
 
 
MiRNA expression is generally tissue specific and dysregulation can cause a cellular 
dysfunction, thus leading to development of diseases such as cancer (Iorio and Croce 
2012), metabolic diseases (Fernández-Hernando, Ramírez et al. 2013) or 




1.3.3.1 ROLE OF miRNAs IN ANGIOGENESIS AND EC 
DIFFERENTIATION AND FUNCTION 
Several miRNAs have been shown to be involved in regulating function, 
proliferation and growth of vascular ECs (Jakob and Landmesser 2012). The first 
evidence of a possible involvement of miRNAs in ESC differentiation was found in 
experiments conducted on Dicer or Drosha deficient ESCs, which are not able to 
produce mature miRNAs and therefore lack differentiation capacity (Murchison, 
Partridge et al. 2005, Wang, Medvid et al. 2007). 
Recent studies focused on angiogenesis-associated miRNAs which are involved in 
ESC differentiation towards ECs (Wu, Yang et al. 2009). In particular, miRNA-126 
has been shown to act as a key regulator of vascular integrity and angiogenesis in 
mouse and zebrafish. Indeed, miRNA-126 is enriched in human ECs and in 
developing mouse embryos and has been found to regulate vascular development, 
regeneration, and integrity (Fish, Santoro et al. 2008, Van Solingen, Seghers et al. 
2009). Knockdown of miRNA-126 in zebrafish caused hemorrhaging and loss of 
vascular integrity in the embryo (Fish, Santoro et al. 2008).  In a similar way, 
endothelial specific deletion of miR-126 in mouse embryos is lethal in ~40% of 
cases and in the surviving miR-126 null mice, lack of tight cell-cell interactions 
between ECs cause loss of vascular integrity (Wang, Aurora et al. 2008). 
Importantly, predicted targets of miRNA-126 include negative regulators of the 
VEGF pathway, such as Sprouty-related protein (SPRED1) and phosphoinositol-3 
kinase regulatory subunit 2 (PIK3R2/p85-beta). These results were confirmed by 
showing that overexpression of SPRED1 and inhibition of the VEGF pathway in 
zebrafish, led to results similar to those observed after miRNA-126 knockdown 
(Fish, Santoro et al. 2008). Finally, overexpression of miRNA-126 in pluripotent 
stem cells induced differentiation to endothelial lineage, corroborating its leading 
role in angiogenesis (Fish, Santoro et al. 2008). MiR-126 also regulates the 
expression of VCAM-1, a critical adhesion molecule, which promotes adherence 
between ECs and leukocytes (Harris, Yamakuchi et al. 2008). 
The family of pro-angiogenic miRNAs includes the miRNA-17-92 cluster, which is 
expressed in ECs and plays a role in tumour vascularization (Otsuka, Zheng et al. 
2008), the miRNA-92a, which has been shown to control angiogenesis in vivo and in 
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vitro and to induce functional recovery of mice ischemic tissues (Bonauer, Carmona 
et al. 2009), and the miRNAs Let-7b and f, which regulate sprout formation 
(Kuehbacher, Urbich et al. 2007). Moreover, the miRNA-130a controls the 
angiogenic phenotype of ECs and is considered to promote angiogenesis in ECs by 
inhibiting the expression of GAX, a homeodomain gene, an  angiogenesis inhibitor 
in vascular ECs (Chen and Gorski 2008). The miRNA-210 is involved in EC 
migration and capillary-like structure formation (Fasanaro, D'Alessandra et al. 
2008), the miRNA-378 promotes tumour angiogenesis (Lee, Deng et al. 2007) and 
the miRNA-296 regulates EC migration and tube formation, and tumour 
angiogenesis in vivo and it has been shown to target hepatocyte growth factor-
regulated tyrosine kinase substrate (HGS), thus leading to a reduction of HGS-
mediated degradation of VEGFR2 and PDGFRβ (Würdinger, Tannous et al. 2008). 
Finally miR-10 promotes the VEGFR2-mediated signalling to control EC 
proliferation, adhesion and migration (Hassel, Cheng et al. 2012). Therefore all the 
above mentioned pro-angiogenic miRNAs can be used as new therapeutic targets in 
the selective modulation of angiogenesis, for the treatment of cardiovascular diseases 
or tumours. 
On the other hand, the group of the anti-angiogenic miRNAs comprises for instance 
the miRNA-221 and 222 which inhibit EC migration and proliferation and have been 
shown to target the angiogenic ability of c-kit, the receptor for stem cell factor 
(SCF), thus modulating the capacity of ECs to form new capillaries (Poliseno, 
Tuccoli et al. 2006, Suarez, Fernandez-Hernando et al. 2007). Moreover, the 
miRNA-328 reduces formation of capillary structure (Wang, Lee et al. 2008), the 
miRNA-15b and 16 induce cell apoptosis (Guo, Pan et al. 2009) and together with 
the miRNA-20a and 20b, have been found to be downregulated in hypoxic 
conditions and to directly decrease VEGF expression in carcinoma cell lines (Hua, 
Lv et al. 2006). miR-92a inhibition has been shown to induce proliferation and 
migration in rat aortic ECs in vitro and to promote re-endothelialisation in injured rat 
carotid arteries in vivo (Poliseno, Tuccoli et al. 2006). Finally, the miRNA-100 
shows an anti-angiogenic function and represses mammalian target of rapamycin 
(mTOR) signalling in endothelial and vascular smooth muscle cells (Grundmann, 
Hans et al. 2011). 
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Study of miRNA expression in feeder and serum-free directed EC differentiation 
protocol in hESCs showed upregulation of angiogenesis-related miRNA let7b, 7f, 
miRNA-126, 130a, 133a and b, 210 and 296 (Wu, Yang et al. 2009) and 
downregulation of anti-angiogenic miRNA-20a, 20b, 221, and 222 (Wu, Yang et al. 
2009), concomitant with an increase in angiogenesis-associated proteins (Kane, 
Meloni et al. 2010).  
Additionally, in a recent work, Kane et al. demonstrated that miR-99b, 181a, and 
181b take part in the endothelial-miRNA signature and are able to enhance EC 
differentiation from pluripotent hESCs and to improve hESC-EC-induced 
therapeutic neovascularization in vivo (Kane, Howard et al. 2012).  
Finally, even though the miR-17-92 cluster plays a role in regulating vascular 
integrity and angiogenesis and EC function (Bonauer and Dimmeler 2009), it has 
been reported that knockdown of the miRNAs in this cluster using antagomirs had 
no effect on ESC differentiation into ECs (Tréguer 2012). 
Further investigations are required to explore miRNA involvement in the early 
development of the vascular system and EC fate commitment. In particular, analysis 
and confirmation of miRNA targets will help to elucidate the complicated network of 
proteins involved and the mechanisms underlying. A better understanding of miRNA 
regulation of cell commitment to vascular endothelial lineages, and the elucidation of 
their role in mature endothelial cells, may help in developing new vascular 
regeneration strategies, to repair damaged tissues after ischemic injury. 
 
1.3.3.2 ROLE OF MiRNA-21 IN ANGIOGENESIS AND ECs 
MiR-21 is one of the most well characterized miRNAs and it is overexpressed in 
many solid tumours (Volinia, Calin et al. 2006). Recent studies suggested that miR-
21 plays an important role in tumour growth and metastasis, showing that miR-21 
targets several tumour suppressors such as phosphatase and tensin homolog (PTEN) 
in human hepatocellular cancer (Meng, Henson et al. 2007), programmed cell death 
4 (PDCD4) in breast cancer cells (Frankel, Christoffersen et al. 2008), tumour 
suppressor gene tropomyosin (Zhu, Si et al. 2007) and matrix metalloproteinases 
inhibitors RECK and TIMP3 in promoting glioma invasion (Gabriely, Wurdinger et 
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al. 2008). Moreover, miR-21 inhibitor has been shown to suppress cell growth of 
breast cancer in vitro and tumour growth in a xenograft mouse model (Si, Zhu et al. 
2006). The role of miR-21 in tumour growth and metastasis led to the hypothesis that 
it might be involved in the development of tumour angiogenesis. 
Indeed, it has been reported that miR-21 overexpression in human prostate cancer 
cells increased hypoxia-inducible factor-1alpha (HIF-1α) and VEGF expression, 
thereby inducing tumour angiogenesis. The molecular mechanism involved AKT and 
ERK 1/2 activation by miR-21. On the other hand, miR-21 inhibition using the 
antagomir blocked this process. MiR-21 directly targeted PTEN, whose inhibition 
activated AKT and ERK and increased HIF-1 and VEGF expression, thus inducing 
tumour angiogenesis. Moreover, miR-21-induced tumour angiogenesis was 
abolished after inhibiting AKT and ERK using the inhibitors LY294002 and U0126 
respectively. The same effect was observed by HIF-1α inhibition, underlying the 
importance of HIF-1α in this process (Liu, Li et al. 2011). 
In another work conducted in primary bovine retinal microvascular endothelial cells, 
which represent a well-characterized in vitro system to study angiogenesis, RNA 
extracted from the cells was used to create RNA library for deep sequencing. 
Amongst the 250 known microRNAs mapped, the most highly expressed was miR-
21. Inhibition of miR-21 using a LNA inhibitor was found to decrease proliferation, 
migration and tube-formation ability of RMECs, suggesting that miR-21 is involved 
in the regulation of angiogenesis in the retinal microvasculature (Guduric-Fuchs, 
O'Connor et al. 2012). 
However, miR-21 has been also reported to exhibit anti-angiogenic functions. For 
instance, in a study conducted in human umbilical vein endothelial cells (HUVECs), 
miR-21 expression has been confirmed to be negatively regulated by the pro-
angiogenic factors serum and bFGF. Furthermore, in vitro angiogenic assays showed 
that miR-21 overexpression led to decreased proliferation, migration and tube 
formation capacity of ECs, whereas miR-21 inhibition with LNA-21 exerted the 
opposite action. The decrease in cell migration can probably be explained with a 
reduction in the organization of actin filaments into stress fibers by miR-21. In this 
process miR-21 targeted Ras homolog gene family, member B (RhoB), whose 
inhibition impaired EC migration and tubulogenesis; indeed the mechanism of miR-
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21 inhibition of angiogenesis is probably mediated by RhoB repression (Sabatel, 
Malvaux et al. 2011). Finally, in a mouse model of choroidal neovascularisation, 
miR-21 has been shown to act as a potential therapeutic inhibitor of angiogenesis 
(Sabatel, Malvaux et al. 2011).  
MiR-21 has also been implicated in shear stress-mediated endothelial differentiation. 
Mechanical forces associated with blood flow play in fact a relevant role in the 
regulation of vascular signalling and gene expression in ECs. In the work of Weber 
et al. the miRNA expression profile in human ECs subjected to unidirectional shear 
stress has been determined and the role of miR-21 in shear stress-induced changes in 
EC function has been elucidated. In HUVECs exposed to prolonged unidirectional 
shear stress (24h, 15 dynes/cm
2
) the miRNA that showed the greatest change was 
miR-21, which showed an upregulation of 5.2-fold, as compared to untreated cells. 
Protein expression of PTEN was also downregulated in HUVECs exposed to 
unidirectional shear stress or transfected with pre-miR-21. Interestingly, 
overexpression of miR-21 in HUVECs led to reduced apoptosis and increased eNOS 
phosphorylation and NO production. In conclusion, this study demonstrated that 
miR-21 expression is regulated by shear stress forces in ECs and these mechanisms 
are involved in the control of vascular homeostasis (Weber, Baker et al. 2010). 
While unidirectional shear stress is a known differentiation stimulus for endothelial 
differentiation, oscillatory shear stress is typically associated with the vascular 
inflammation processes leading to atherosclerosis. Oscillatory shear stress has been 
shown to induce transcription factor activator protein-1 (AP-1)-dependent miR-21 
expression in HUVECs. Moreover, miR-21 directly targeted PPARα, thus inducing 
the expression of VCAM-1 and monocyte chemotactic protein-1 (MCP-1) and the 
consequential adhesion of monocytes to ECs. In conclusion, the induction of miR-21 
by oscillatory shear stress contributes to proinflammatory responses of vascular 
endothelium (Zhou, Wang et al. 2011). 
MiRNAs have been shown to regulate many different biological processes, and miR-
21 has been reported to play a role not only in EC, but also in EPC function. In 
particular, a recent study described the miR-21 regulation of EPC scenescence, 
although the mechanisms underlying this process in EPCs are still unknown. In 
particular, microRNA profiling and microarray analysis have been performed in 
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lineage-negative bone marrow cells from young and aged wild-type and 
apolipoprotein E-deficient mice, in order to map the microRNA/gene expression 
signatures of EPC senescence. From this analysis, miR-10A and miR-21, together 
with their common target gene Hmga2 have been identified as critical regulators of 
EPC senescence. Overexpression of miR-10A and miR-21 in young EPCs led to 
upregulation of senescence-associated β-galactosidase, decreased self-renewal 
potential, increased p16(Ink4a)/p19(Arf) expression and impaired EPC angiogenesis 
in vitro and in vivo, causing EPC senescence. On the other hand, inhibition of miR-
10A* and miR-21 in aged EPCs, decreased senescence-associated β-galactosidase 
expression, increased self-renewal potential, decreased p16(Ink4a)/p19(Arf) 
expression and improved EPC angiogenesis in vitro and in vivo, thereby rejuvenating 
EPCs. In conclusion, miR-10A and miR-21 have been reported to regulate EPC 
senescence via inhibiting Hmga2 expression. Importantly, modulation of senescence-
associated microRNAs may offer new therapeutic applications to improve EPC-
mediated angiogenesis and vascular repair (Zhu, Deng et al. 2013). 
In summary, from the above reported studies, a contradictory role for miR-21 in 
angiogenesis is emerging and the molecular mechanisms involved in this regulation 
remain to be clarified. Furthermore, no studies have demonstrated a link between 
miR-21 and endothelial differentiation from stem cells. Indeed, in the experiments 
conducted in this thesis, we will try to investigate the role of miR-21 in promoting 
iPSC differentiation into functional ECs, also elucidating the underlying molecular 
mechanisms. 
 
1.3.4 TRANSFORMING GROWTH FACTOR BETA (TGF-β) 
FAMILY 
The transforming growth factor β (TGF-β) family is a superfamily of growth factors, 
which includes 2 families: the TGF-β/activin/Nodal family and the bone 
morphogenetic proteins (BMPs)/growth and differentiation factor (GDF)/Mullerian 
inhibiting substance (MIS) family.  
The TGF-β family regulates many different biological processes, such as 
differentiation, angiogenesis, cell growth, apoptosis, migration, extracellular matrix 
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production, tumour metastasis and invasion and embryonic development (Rahimi 
and Leof 2007, Zhang 2009).  
TGF-β is the most potent inducer of endothelial-to-mesenchymal transition (EndMT) 
and one of the best promoters of fibrosis in many organs (Hartsough and Mulder 
1995, Yu, Hebert et al. 2002).  
Epithelial-to-mesenchymal transition (EMT) is an essential process occurring during 
development, when epithelial cells lose their epithelial markers and start to express 
fibroblast markers, such as fibroblast-specific protein-1 (FSP-1). EMT occurs in 
many situations during normal development and also in pathologic conditions such 
as the progression of malignant epithelial tumours (Engel, McDonnell et al. 1999) 
and organ fibrosis (Wilkes, Mitchell et al. 2005). In a similar way, EndMT 
participates to fibroblast formation in fibrotic diseases of the heart (Lee, Hempel et 
al. 2010), lung
 
 (Kurpinski, Lam et al. 2010), kidney (Chen and Lechleider 2004), 
liver (Kennard, Liu et al. 2008) and carcinoma-associated fibrosis (Pardali and Ten 
Dijke 2009). 
 
In a recent study it has been shown that miR-21, which is highly expressed in 
fibroblasts and rapidly inducible by TGF-β, plays an important role in partially 
mediating EndMT via targeting the PTEN/AKT pathway (Mythreye and Blobe 
2009). 
Five distinct isoforms of TGF-β have been so far described, each approximately 65–
85% homologous, and arising after proteolytic cleavage of longer precursors. The 
mammalian TGF-β isoforms (TGF-β-1, -2 and -3) are secreted as latent precursors 
and mediate signal transduction through binding to multiple cell surface receptors 
(Clark and Coker 1998). The biological activities of the mature isoforms are not 
species-specific. The various TGF-β isotypes share many biological activities and 
their action on cells are qualitatively similar in most cases, apart from few examples 
of distinct functions. The biggest differences in the TGF-β isoforms are related to the 
spatial and temporal expression of their mRNAs and proteins in developing, 
regenerating and pathologic tissues (Roberts 1992).  
The TGF-β family exerts its action on the cells via binding of TGF-β1, 2 and 3 
ligands to specific type I and type II serine/threonine kinase receptors and 
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intracellular SMAD transcription factors. The human and mouse genomes encode for 
eight SMAD proteins, which are classified into three groups. The first group, 
receptor-regulated SMAD (R-SMAD), comprises SMAD1, SMAD5, and SMAD8 
which are activated by the BMP-specific type I receptors, and SMAD2 and SMAD3 
which are activated by the TGF-β-specific type I receptors; the second group is 
represented by a common mediator SMAD (Co-SMAD), such as SMAD4; the third 
SMAD group involves inhibitory SMADs (I- SMADs), such as SMAD6 and 
SMAD7 (Massagué, Seoane et al. 2005). Activated R-SMADs form complexes with 
the Co-SMAD, which translocate into the nucleus, where they regulate transcription 
of target genes (Song, Estrada et al. 2009). It is well-known that TGF-β exerts 
multiple biological effects via SMAD (Massagué, Seoane et al. 2005, Moustakas and 
Heldin 2005) and non-SMAD (Moustakas and Heldin 2005) pathways. In the SMAD 
pathway, two type I and two type II receptors (TβR-I and II) form a tetrameric 
complex through ligand binding to type II receptors on the cell surface. Both TGF-
β1 and TGF-β3 show a high affinity for TGF-βRII. In contrast, TGF-β2 has a low 
affinity for TGF-βRII and requires an accessory receptor, TGF-βRIII (also known as 
β-glycan), for high-affinity interaction with the heteromeric-signalling complex. 
After ligand binding to the complex, the type II receptor kinase activates the type I 
receptor kinase, which then trasduces the signal through phosphorylation of receptor-
activated SMADs (R- SMADs) (Goumans, Liu et al. 2009). In addition to the 
signalling via the canonical SMAD pathway described above, TGF-β can also 
activate other signalling molecules such as mitogen-activated protein kinases 
(MAPKs) in a cell-type dependent manner (Mu, Gudey et al. 2012). Examples of 
such MAPKs are ERK (Hartsough and Mulder 1995), c-Jun N-terminal kinase 
(JNK) (Engel, McDonnell et al. 1999), p38 kinase (Yu, Hebert et al. 2002), 
phosphatidylinositol-3-kinase (PI3K)/AKT (Wilkes, Mitchell et al. 2005), or Rho-




Figure 13 Mechanisms of TGF-β signalling 
TGF-β signalling is initiated by assembling receptor complexes that activate SMAD transcription 
factors. Firstly, TGF-β1, -β2, or -β3 isoform binds to the TGF-β type II receptor (TβRII), which 
becomes phosphorylated and activated. While TGF-β1 and TGF-β3 show a high affinity for TGF-
βRII, TGF-β2 has a low affinity for TGF-βRII and TGF-βRIII is required for its binding. Secondly, 
TGF-βRII-mediated phosphorylation recruits TGF-βRI into the complex and activates it.  Activated 
TGF-ΒRI recruits into the complex and phosphorylates the receptor-associated SMADs (R-SMAD), 
SMAD2 and SMAD3. This phosphorylation event causes R-SMAD dissociation from the activated 
receptor complex, association with the SMAD4, translocation into the nucleus and subsequent 
transcriptional activation or repression. In some physiological and pathological conditions TGF-β can 
also activate SMAD-independent signalling cascades, including the ERK, JNK, and p38 MAPK 






1.3.4.1 ROLE OF TGF-β IN ANGIOGENESIS, VASCULOGENESIS AND EC 
DIFFERENTIATION AND FUNCTION  
The role of TGF-β signalling in the vascular development has been studied mainly in 
the context of SMC differentiation. The role of TGF-β in EC differentiation has not 
been investigated in detail and in particular the specific role of the different isoforms 
is still in need of clarification, since limited research has been done to date to 
distinguish the function of the main isoforms in the different biological situations.  
The essential roles of TGF-β in angiogenesis have been clarified by genetic studies 
in human and mouse models. Deletions of many members of the TGF-β family, such 
as TGF-β1, TGF-βRII, activin receptor-like kinase 1(ALK1) and TGF-βRI (ALK5), 
endoglin, SMAD1, 4 and 5, cause vascular remodelling defects and absence of mural 
cell formation, thus leading to embryonic lethality (Pardali and Ten Dijke 2009). For 
instance, deletion of TGF-β1 in the mouse results in embryonic lethality because of 
defective yolk sac vasculogenesis and EC deletion of TGF-βRI and II results in 
embryonic lethality at embryonic day 10.5 due to vascular defects. However, TGF-
β1 deletion leads to vascular abnormalities only in a specific genetic background, 
suggesting that other factors may be involved in the development of vascular 
abnormalities caused by defects in TGF-β signalling (Pardali, Goumans et al. 2010). 
Moreover, mutations in the components of the TGF-β signalling pathways, such as 
endoglin, ALK1 and SMAD4 are responsible for the most clinical cases of 
Hereditary Hemorrhagic Telangiectasia (Pardali and Ten Dijke 2009). 
TGF-β plays a critical role in stem cells differentiation into SMCs by modulating and 
interacting with other pathways such as the Notch signalling pathway. In a recent 
work conducted on human mesenchymal stem cells, it has been shown that TGF-β 
induced the expression of Notch ligand Jagged 1 (JAG1) and SMC markers, 
including smooth muscle alpha-actin (ACTA2), calponin 1 (CNN1), and myocardin 
(MYOCD), via SMAD3 and Rho kinase-dependent activation. Furthermore, Notch 
signalling mediated TGF-β regulation of MSC differentiation and induced the 
differentiation of mesenchymal stem cells and hESCs into SMCs (Kurpinski, Lam et 
al. 2010). In another study, it was demonstrated that TGF-β-activated SMAD2 and 
SMAD3 were necessary for the induction of the SMC marker α-SMA, and that 
SMAD2 and SMAD3 may cooperate to induce a smooth muscle phenotype in neural 
crest stem cell line Monc-1 (Chen and Lechleider 2004).  
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In endothelial cells, TGF-β has been shown to bind to and signal through two distinct 
types of receptors: TGF-βR1 (ALK5) and ACVRL1 (ALK1); this results in 
activation of SMAD2/3 and SMAD1/5/8, respectively (Goumans, Valdimarsdottir et 
al. 2002, Goumans, Valdimarsdottir et al. 2003). The role of TGF signalling in ECs 
is still unclear and studies have led to opposite conclusions.  
TGF-β/ALK1 signalling has been reported to promote proliferation and migration of 
ECs whereas TGF-β/ALK5 has been shown to do the opposite (Figure 3.4) 
(Goumans, Valdimarsdottir et al. 2002, Goumans, Valdimarsdottir et al. 2003). 
Indeed, the balance between TGF-β/ALK1 and TGF-β/ALK5 signalling may 
determine the pro- or the anti-angiogenic effects of TGF-β.  
Furthermore, TGF-β1 negatively impacts on hESC-derived EC proliferation and 
commitment, through the inhibition of inhibitor of DNA binding protein-1 (Id1) 
expression (James, Nam et al. 2010). It has been also demonstrated that shear stress 
can induce endothelial differentiation from mouse embryonic mesenchymal 
progenitor cells, by suppressing TGF-β1 functions through down-regulation of TGF-
β1, TGF-βR1, TGF-βR2, SMAD2, SMAD3 and SMAD4 and up-regulation of 
SMAD7 (Wang, Li et al. 2008) 
Additionally, different effects of TGF-β on angiogenesis are usually dose- and 
cellular context- dependent; for instance the role of TGF-β1 in tumour angiogenesis 
is context-dependent, since it has been shown that TGF-β1 prevents tumour growth 
and angiogenesis in early phases of tumour development, whereas it promotes it in 
late-stages of tumour progression (Goumans, Valdimarsdottir et al. 2002, Serratì, 
Margheri et al. 2009, Pardali, Goumans et al. 2010). Moreover, low concentrations 
of TGF-β were shown to promote EC proliferation and migration and to enhance the 
angiogenic effects of bFGF or VEGF in a 3D fibrin or collagen assay, while high 
concentrations led to the opposite effect (Pepper 1997, Pardali and Ten Dijke 2009).  
In another study, it has been reported that treating bovine capillary endothelial 
(BCE) cells with TGF-β initially leads to apoptosis by inducing VEGF expression 
through conversion of VEGF/VEGFR2-activated p38 (MAPK) into a pro-apoptotic 
signal by TGF-β signalling (Ferrari, Pintucci et al. 2006). Prolonged TGF-β 
treatment resulted instead in EC remodelling and formation of cord-like structures 
(Ferrari, Cook et al. 2009).  
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In addition, the role of the different receptors TGF-β type I and II receptors on EC 
function is still unclear because of the remarkable diversity and context-dependent 
effects of TGF-β family members on the complex process of blood vessel formation. 
Recent studies suggested that the effects of TGF-βRII or TGF-βRI loss on 
angiogenesis are caused by defects in SMC function and not by their role on ECs 
(Harris, Yamakuchi et al. 2008).  
Some studies also remarked on a crosstalk between VEGF and ALK1/endoglin 
signalling in angiogenesis, even though the exact underlying molecular mechanisms 
remain to be elucidated. In particular, inhibition of ALK1/endoglin signalling using 
the soluble chimeric proteins ALK1-fragment crystallizable region (Fc) and 
endoglin-Fc impaired VEGF-induced EC sprouting in vitro. Moreover, ALK1-Fc has 
been shown to inhibit VEGF/bFGF-induced angiogenesis in an in vivo matrigel plug 
assay (Cunha, Pardali et al. 2010). In addition, treatment with ALK5 kinase inhibitor 
enhanced VEGF/bFGF-induced angiogenesis in a matrigel-plug assay in vivo (Liu, 
Kobayashi et al. 2009). 
The regulation of angiogenesis by TGF-β is further complicated by the role of 
several other key factors, such as SMAD and BMP, as well as the co-receptor 
endoglin. The activation of different classes of SMADs by the same ligand, such as 
TGF-β, may activate the formation of diverse receptor complexes, thus inducing 
opposite effects. The exact role of BMP9-induced SMAD1 or SMAD2 
phosphorylation in angiogenesisis is still not fully clear. Although BMP9 and 
BMP10 were considered to have an anti-angiogenic action, BMP9 in combination 
with TGF-β was shown to enhance VEGF-induced proliferation of ECs in vitro and 
VEGF/bFGF-induced angiogenesis in vivo (Cunha, Pardali et al. 2010). 
In conclusion, TGF-β and BMP signalling appears to play crucial roles in EC 
function and angiogenesis; however the molecular mechanisms by which these 
molecules regulate vascular system still remain to be elucidated. TGF-β signalling 
exerts apparently contradictory actions during the different stages of angiogenesis 
which are dependent on the distinct cellular context, local concentration of the 
ligands, receptors, coreceptors, antagonists and their interactions. Although there 
have been new insights into the role of TGF-β signalling in vascular development 
and function, the exact mechanisms remain to be elucidated. A better understanding 
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of the molecular mechanisms underlying the different effects of TGF-β signalling on 
angiogenesis will help in developing new therapeutic solutions to pathological 
vascular malformations and tumour growth and angiogenesis (Pardali, Goumans et 
al. 2010). 
 
1.3.5 SIGNALLING PATHWAYS INVOLVED IN EC 
DIFFERENTIATION AND ANGIOGENESIS 
 
1.3.5.1 VEGF AND SHEAR STRESS SIGNALLING INTERACTION 
External and environmental stimuli such as VEGF and shear stress have been 
demonstrated to play a pivotal role in the induction of endothelial differentiation. 
Both the binding of VEGF to its receptors and the stimulation of mechanoreceptors 
by shear stress activate a signal cascade inside the cells, which results in the 
promotion of endothelial-specific proteins. Interestingly, some of these pathways are 
common to multiple stimuli. The mechanisms of EC differentiation induced by 
VEGF have been thoroughly investigated. The effect of VEGF in ECs and their 
precursors is strongly dependent on its biding to VEGFR-2. For instance, it is well 
known that VEGFR-2 is fundamental in the recruitment and differentiation of 
endothelial precursors from mouse ESCs (Yamashita, Itoh et al. 2000, Schmidt, 
Brixius et al. 2007). Lack of this gene (Flk1-/-) in a mouse model arrests vascular 
and haematopoietic development; the reintroduction of VEGFR-2 through lentiviral 
transduction of ESC cultures differentiating in vitro as embryoid bodies is sufficient 
to rescue the phenotype (Li, Edholm et al. 2007).  
The action of VEGF, through its binding to VEGFR-2, is mediated by the activation 
of phospholipase C (PLC)/calcium and phosphokinase C (PKC), PI3K/AKT, focal 
adhesion kinase (FAK) and the RAS/RAF/MEK/ERK pathways (Figure 14) (Giles 
2001, Gélinas, Bernatchez et al. 2002, Zeng, Xiao et al. 2006, McCubrey, Steelman 





Figure 14 VEGF activates different signalling pathways leading to angiogenesis 
When vascular endothelial growth factor (VEGF) binds to Flk1/KDR, this tyrosine kinase receptor is 
activated by phosphorylation and activates different signalling cascades, which all together lead to 
angiogenesis. The activation of phospholipase C gamma (PLCγ) leads to cell proliferation and 
vasopermeability via the inositol triphosphate and calcium (IP3/Ca
++
) or diacylglycerol and 
phosphokinase C (DAG/PKC) pathways. VEGF induces immediate synthesis of nitric oxide (NO), 
also involved in promoting angiogenesis, through the PLC/Ca
++
 pathway. Activation of 
phosphoinositide 3-kinase (PI3K) promotes cell survival via the phosphokinase B (PKB) pathway. 
When SHC, an intermediate in the activation of the rat sarcoma (Ras) pathway, is phosphorylated by 
VEGF receptor, it activates the Ras/mitogen-activated protein kinase (MAPK) pathway, which 
promotes gene expression and cell proliferation. Finally, cytoskeletal rearrangement and cell 
migration are also involved in angiogenesis through the signalling cascade of focal adhesion kinase 
(FAK) and paxillin, two focal adhesion-associated proteins. Adapted from (Giles 2001). 
 
 
Recent evidence has revealed shear stress as an important key regulator for EPC 
differentiation. However, the specific mechanisms of mechanotransduction that 
contribute to the shear stress-induced EPC differentiation have still to be elucidated. 
Recently, in EPCs isolated from rat bone marrow and stimulated by shear stress, an 
increased expression of the EC markers vWF and CD31 was observed, which was 
found to be related to the levels of integrin β1 and β3. These integrins have indeed 
been demonstrated to play important roles in regulating the shear stress-induced 
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endothelial cell marker expression in late EPCs. Further study of these integrins may 
provide novel insights into the mechanisms of mechanotransduction in late EPC 
differentiation mediated by shear stress (Cui, Zhang et al. 2012). 
In addition the mechanosensor heparan sulphate proteoglycan has been found to 
mediate shear stress-induced expression of vWF, VE-cadherin, tight junction protein 
gene ZO-1 and vasodilatatory genes eNOS and COX-2 in ESC-derived ECs 
(Nikmanesh, Shi et al. 2012). 
VEGF signalling is also deeply involved in the effect of shear stress on endothelial 
differentiation. In particular, in Flk1
+
 progenitor cells derived from mouse ESCs 
exposed to shear stress, the mRNA levels of venous endothelial marker Eprhin B4 
decreased, whereas mRNA of the arterial EC marker Ephrin B2 levels increased 
dose-dependently. The increased Ephrin B2 expression after exposure to shear stress 
is mediated by VEGF-Notch signalling pathway, in which VEGF receptor 
phosphorylation leads to the activation of Notch (Masumura, Yamamoto et al. 2009). 
In a very recent study showing that endothelial and hematopoietic differentiation are 
both stimulated by shear stress application to ESCs, inhibition of Flk1 neutralized 
this effect. This result indicates that the membrane protein is a critical mediator of 
both endothelial and hematopoietic differentiation by applied shear stress to ESCs 
(Wolfe and Ahsan 2013).  
Moreover VEGF-R2 and the PI3K/AKT/mTOR signal pathway have been shown to 
be activated by shear stress and to induce differentiation, migration, adhesion, 
proliferation, prevent apoptosis and ultimately to increase the vasculogenesis 
potential of circulating EPCs (Obi, Masuda et al. 2012)  
Furthermore, in the study by Ye et al., activation of AKT has been shown to be 
essential in the shear stress-induced differentiation of EPCs. Both shear stress and 
VSMCs co-culture were shown to induce the differentiation of EPCs, increasing the 
expression of the endothelial markers CD31 and simultaneously decreasing the 
progenitor markers CD133 and CD34. This effect was blunted by the presence of 
AKT inhibitor, indicating the essential role of AKT activation in shear stress and/or 
VSMC-induced EPC differentiation, which provide a new insight to clinical 
application on the regeneration of the vascular endothelium (Ye, Bai et al. 2008).   
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Lee et al. studied the role of HDACs in EC differentiation, showing that ESCs 
undergo gene-specific and chromatin remodelling which results in the inhibition of 
HDACs and prevents differentiation (Lee, Hart et al. 2004). In particular, data from 
our group demonstrated that the Flk1–PI3K–AKT–HDAC3–p53–p21 pathway is 
crucial in the shear stress-induced endothelial differentiation of progenitor cells 
(Sca1
+
) derived from ESCs, and also that VEGF induces EC differentiation through 
a similar pathway. Specifically, it has been shown that that laminar shear stress (12 
dyne/cm
2
) is able to activate HDAC3 through activation of Flk1 and its downstream 
PI3K-AKT cascade. Activated HDAC3 in turn deacetylates p53 and activates p21, 
resulting in EC differentiation and survival (Xiao, Zeng et al. 2006). 
 
1.3.5.2 miRNA-21 INTERACTION WITH THE VEGF AND SHEAR STRESS 
SIGNALLING  
MiR-21 function in angiogenesis is still unclear, since some studies show that it 
promotes the angiogenic process, while others show the opposite. 
Its role in tumour angiogenesis and the mechanisms involved in this process were 
described in a work by Liu et al. miR-21 was found to induce tumour angiogenesis 
in human prostate cancer by targeting PTEN, leading to the activation of AKT and 
ERK1/2 signalling pathways, which enhanced HIF-1α and VEGF downstream 
expression. On the other hand, overexpression of PTEN inhibited tumour 
angiogenesis by partially inactivating AKT and ERK and decreasing the expression 
of HIF-1 and VEGF. Moreover, using AKT and ERK inhibitors, HIF-1α and VEGF 
expression and angiogenesis were suppressed. Finally, inhibition of HIF-1α 
abolished miR-21-inducing tumour angiogenesis, indicating that this gene is a key 
downstream target of miR-21 in the regulation of tumour angiogenesis (Liu, Li et al. 
2011).  
Moreover, in human pancreatic cells miR-21 expression has been found to be 
increased by hypoxia, together with VEGF and IL6 expression, leading to increase in 
cancer stem cell marker expression, cell migration/invasion and angiogenesis (Bao, 
Ali et al. 2012). 
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In contrast, miR-21 has been shown to negatively regulate angiogenesis in 
HUVECS, where its expression is negatively regulated by serum and bFGF, two pro-
angiogenic factors. In in vitro angiogenic assays, miR-21 overexpression reduced 
endothelial cell proliferation, migration and the ability of the cells to form tube-like 
structures, whereas miR-21 inhibition led to opposite results. After miR-21 
overexpression, the organization of actin into stress fibers was also reduced, 
explaining the decrease in cell migration. This negative regulation of angiogenesis 
by miR-21 occurs through directly targeting RhoB expression (Sabatel, Malvaux et 
al. 2011). 
In a recently published study, the drug rapamycin, which is eluted by some coronary 
artery stents, was found to suppress endothelial proliferation and migration in 
HUVECs, through overexpression of miR-21. RhoB is directly targeted by miR-21 
in this rapamycin-mediated mechanism. Accordingly, miR-21 inhibition abolished 
the negative effects of rapamycin on endothelial cell growth and mobility (Jin, Zhao 
et al. 2013).  
Furthermore it has been shown that shear stress can regulate the expression of some 
miRNAs. In particular, in a study conducted by Weber et al. in 2010 in HUVECs 
subjected to prolonged unidirectional shear stress (24h, 15 dynes/cm
2
), the 
expression of miR-21 was increased approximately 5 fold, as compared to static 
control cells. Overexpression of miR-21 in the cells influenced endothelial biology 
by decreasing apoptosis and activating the NO pathway. This demonstrates that the 
positive effect of shear stress is at least partially mediated by miR-21 (Weber, Baker 
et al. 2010). 
 
1.3.5.3 TGF-β INTERACTION WITH THE VEGF AND SHEAR STRESS 
SIGNALLING  
Both VEGF and TGF-β1 have been shown to induce angiogenesis, but with opposite 
effects on ECs. In fact, in ECs VEGF promotes survival, while TGF-β1 induces 
apoptosis through a VEGF/Flk1 mediated signalling. Genetic deficiency of VEGF 
abolishes TGF-β1 induction of EC differentiation and formation of vascular 
structures in embryoid bodies. Furthermore, inhibition of VEGF blocks TGF-β1 
induction of both apoptosis and angiogenesis. TGF-β1 induces endothelial cell 
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apoptosis via up-regulation of VEGF expression and activation of VEGF/Flk1 
signalling, which is a rapid and transient process required for TGF-β1-induced 
angiogenesis. In conclusion, in this study a new role of VEGF in mediating EC 
apoptosis has been elucidated, which might represent a target to control TGF-β1-
induced-angiogenic process (Ferrari, Cook et al. 2009). 
VEGF induction of cell survival also occurs via activation of PI3K/AKT pathway 
through the formation of a multi-protein complex that involves Flk1 and the 
adherens junction proteins VE-cadherin and beta-catenin. In another work conducted 
by Cook and Ferrari on the TGF-β1-VEGF interaction in ECs, it has been reported 
that TGF-β1 induces changes in the adherens junction structure by separating Flk1 
from VE-cadherin and promoting association of beta-catenin with Flk1 and VE-
cadherin. These rearrangements are mediated by VEGF/Flk1 signalling. In 
conclusion, the adherens junction plays an important role in the TGF-β1-VEGF 
interaction in ECs. (Cook, Ferrari et al. 2008) 
Finally, in mouse embryonic mesenchymal progenitor cells, fluid shear stress has 
been shown to promote EC differentiation. Shear stress application also abolished 
TGF-β function through inhibition of TGF-β1, TGF-R1 and 2 and positive signalling 
molecules SMAD2, SMAD3 and SMAD4 and induction of negative signalling 
molecule SMAD7. In conclusion, this study suggests that shear stress-induced EC 
differentiation in mesenchymal progenitor cells might involve a negative regulation 
of TGF-1 (Wang, Li et al. 2008). 
In synthesis, in this paragraph we have clustered the most important mechanisms and 
signalling pathways involved in EC differentiation and angiogenesis. In particular, 
we focused on the interactions amongst the pathways activated by VEGF, shear 
stress, miR-21 and TGF-β stimuli. Indeed, in this work, the mechanisms involving 






1.4 USE OF STEM CELLS IN 
CARDIOVASCULAR THERAPY 
 
The study of the differentiation potential of stem cells and the associated 
mechanisms presents the opportunity of a new and exciting prospect of therapy for 
many illnesses, including cardiovascular diseases. The possibility of using cell-based 
therapies to improve endothelial and cardiac function after injury is causing a great 
interest and has prompted a large number of studies. In the recent years, a wide 
variety of cell types have been considered as candidates for therapeutic delivery in 
patients with cardiovascular problems, in particular in the context of myocardial 
infarction (Figure 15) (Segers and Lee 2008). Although the ideal cell type has not 
been found yet, many studies have been carried out to compare the efficacy of 
different stem cell populations (Wollert and Drexler 2005). 
 
 
Figure 15 Potential cell types and mechanism involved in cardiac therapy 
Many types of stem or progenitor cell populations can be isolated from different autologous or 
allogeneic organs or tissues: stem cells from blastula or induced from skin fibroblasts, cardiac stem 
cells from the heart, endothelial progenitor cells from blood and bone marrow and mesenchymal stem 
cells from bone marrow or adipose tissue. Most of those cells are able to differentiate into 
cardiomyocytes, endothelial cells, smooth muscle cells and/or to release pro-angiogenic and pro-
mitotic paracrine factors, potentially leading to remodelling, angiogenesis or activation of exogenous 




Ever since the first therapeutic bone marrow transplantation was performed in dogs 
in the early fifties by E. Donnall Thomas, the possibility of using adult stem cells in 
autologous or heterologous cell therapy has been deeply exploited. Adult stem cells 
are therapeutically attractive because they can potentially be derived from the patient 
in need of transplantation and therefore they do not present immunological or ethical 
issues. Furthermore, they possess limited proliferation capacity and differentiation 
potential, reducing the risk of tumourigenesis.  
On the other hand, adult stem cells use is hampered by their limited availability and 
accessibility and their low ex-vivo proliferation, which reduce their application. More 
importantly, while proof of efficient differentiation of adult stem cells in in vivo 
settings is still debated (Hombach-Klonisch, Panigrahi et al. 2008), clinical trials 
involving the use of autologous stem cells have shown limited improvement in the 
functional outcome (Dill, Schächinger et al. 2009, Zhang, Sun et al. 2009, Perez 
Simon, Lopez-Villar et al. 2011). The prospective of stimulation of resident stem 
cells within the organs through the use of specific drugs or by the delivery of pro-
angiogenic and pro-survival progenitor cells is of major interest, although it is not 
yet clear if the resident stem cell number would be sufficient after a severe injury 
(Chavakis, Koyanagi et al. 2010). Additionally, it has recently been shown that an 
epicardial progenitor population is able to give rise to de novo cardiomyocytes in the 
case of myocardial infarction through stimulation by peptide thymosin β4; this 
suggests a regenerative mechanism within the mammalian adult heart (Smart, Bollini 
et al. 2011).  
The use of allogenic cells for transplantation presents the same immunological 
problems associated with any other tissue or organ transplantation. Within all the cell 
types studied, ESCs have the advantage of an immunoprivileged phenotype, as 
shown in pre-clinical studies (Deb and Sarda 2008). This, together with their 
reported high proliferation and differentiation capacity, made ESCs the focus of 
numerous in vivo studies aiming to investigate their clinical potential. During the 
past few years, ESCs have become a major focus of translational medicine, 
regenerative medicine (Ehnert, Glanemann et al. 2009) and functional tissue 
engineering (Guilak, Butler et al. 2001), due to their potential  clinical applications in 
the treatment of degenerative diseases such as  metabolic diseases, brain and myelin 




Figure 16 Isolation, culture and differentiation of embryonic stem cells 
Embryonic stem cells (ESCs) are isolated from the inner cell mass of the blastocyst and then cultured 
and differentiated in vitro towards different cell types using established differentiation protocols. 
http://www.csa.com/discoveryguides/stemcell/overview.php.              
 
Recent reports showed that ESCs delivered into a mouse infarcted myocardium were 
able to originate cardiomyocytes, which integrated in the host tissue. Treatment 
resulted in a stable and beneficial outcome observed over 12 weeks of follow-up and 
normalization of the ventricular architecture, decrease of the entity of scars and of 
myocardial necrosis (Hodgson, Behfar et al. 2004). ESC transplantation also reduced 
cardiac fibrosis, cardiomyocyte hypertrophy and apoptosis resulting in the inhibition 
of adverse cardiac remodelling (Singla, Lyons et al. 2007).  
Beside their ability to give rise to functional cardiomyocytes, ESCs were also shown 
to be able to release pro-angiogenic and pro-survival factors contributing to their 
therapeutic effect. A recent study investigated the effect of embryonic and adult stem 
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cells treatments in a mouse model of myocardial infarction. ESC-treated hearts 
showed a greater post-ischemic recovery in function, increased cardioprotection and 
levels of VEGF and IL-10, relative to adult bone marrow cells (BMC)-treated hearts 
or medium-injected controls. A marked decrease of pro-inflammatory cytokines was 
also observed after ESC treatment (Crisostomo, Abarbanell et al. 2008).  
Before therapeutic applications can be fully realized it has to be taken into 
consideration that ESC-based therapy has raised many important problems. Firstly 
ethical issues arise from the derivation of human ESCs from in vitro fertilized 
blastocysts and the isolation of human ESCs requires the destruction of the embryo. 
Furthermore there are technical issues in the directed differentiation into somatic cell 
populations, which is still inefficient and generates heterogeneous cell populations. 
Moreover transplanted ESCs might form teratoma, which is caused by the 
accumulation of undifferentiated cells in a non-cancerous tumour, and could be 
rejected immunologically due to the different genetic makeup between the patient 
and donor. Therefore the use of anti-rejection drugs with serious side effects would 
be required to avoid immune rejection problems. The risk of tumour formation is due 
to the innate pluripotency and high proliferative capacity of ESCs (Laflamme and 
Murry 2005, Swijnenburg, Sheikh et al. 2007).  
To reduce this possibility, recent research has focused on the implantation of 
predifferentiated ESC-derived endothelial or cardiomyocytes (Laflamme, Chen et al. 
2007, Tomescot, Leschik et al. 2007). For instance, ESCs pre-differentiation into 
cardiomyocytes can be promoted with the addition of tumour necrosis factor-alpha 
(TNF-α). Differentiated ESCs can be implanted in the infarcted myocardium in 
presence of a “cocktail” of prosurvival factors such as Matrigel, cyclosporine A, 
insulin-like growth factor-1 (IGF-1) and the caspase inhibitor ZVAD-fmk. 
Downstream analysis demonstrated the survival of the transplanted cells and their 
ability to improve myocardial function and recovery (Laflamme, Chen et al. 2007). 
In another work, ESCs-derived ECs transplanted in a mouse model of myocardial 
infarction, were shown to improve ventricular function and to promote 
neoangiogenesis without inducing teratoma formation, as reported in the control 
animals treated with ESCs (Li, Wu et al. 2007).  
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When ESC-derived ECs were injected intramuscularly into ischemic mouse limbs, 
increased limb salvage and blood perfusion were observed (Cho, Moon et al. 2007). 
Similarly, implantation of hESC-ECs in a hindlimb ischemia model of 
immunodeficient mice has demonstrated a therapeutic improvement of blood 
perfusion and limb salvage: transplanted hESC-derived ECs were successfully 
incorporated into the host circulation and significantly accelerated improvement of 
local blood flow (Sone, Itoh et al. 2007). 
Additionally, in a recent study, hESCs have been directly differentiated into ECs 
using a feeder- and serum-free protocol. Differentiated cells showed rapid loss of 
pluripotency markers and progressive induction of vascular markers, such as CD31 
and VE-cadherin and angiogenic growth factors, like VEGF; the cells also showed 
an increased expression of angiogenesis-associated microRNAs, including miR-126 
and miR-210, and EC morphology. In vitro, differentiated cells were able to produce 
NO, to migrate across a wound and to form tubular structures in presence or absence 
of Matrigel. In vivo, implantation of the cells previously differentiated for 10 days 
induced therapeutic neovascularisation, and hESC-derived ECs were incorporated 
into the blood-perfused vasculature of recipient mice (Kane, Meloni et al. 2010). 
Furthermore, mouse ESCs pretreated with retinoic acid to promote neuronal 
differentiation, were transplanted into an ischemic brain of an adult rat. After 1-8 
weeks, transplanted ESCs originated cells able to fill the lesion cavity and to express 
markers typical of neurons, oligodendrocytes, astrocytes and ECs. ESC-transplanted 
animals showed an increased recovery in neuronal function and behaviour as 
compared with the controls rats injected with adult mouse cortical cells or vehicle 
(Wei, Cui et al. 2005).   
Although the tumourigenesis and immunological issues connected with the use of 
ESCs have been partially addressed, the ethical debate associated with the use of 
human embryos is still ongoing. Furthermore, the number of available human ESC 
lines may also be insufficient for their therapeutic potential (Wobus and Boheler 
2005).  
In order to find a solution to all the issues involving the use of ESCs, scientists are 
searching for alternative sources of pluripotent cells, such as the generation of iPSCs. 
The ethical and immunological problems associated with the use of ESCs are 
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bypassed using iPSCs as they can be derived from somatic cell population isolated 
from the patient. 
iPSCs are able to differentiate into many cell types and, like ESCs, are considered a 
powerful cell source for regenerative medicine, such as vascular tissue engineering. 
These cells also show a huge potential for drug screening and for the construction of 
disease models by obtaining somatic cells from patients with specific diseases. 
 
Figure 17 iPSC technology for regenerative medicine and drug screening 
iPSCs generated from patient adult cells can differentiate into many different somatic cell types, 
which could be used for regenerative medicine applications, to screen new and safe drugs and to 
construct models of disease (Yamanaka 2009). 
 
Some research groups have already shown applications of iPSCs to treat disease 
states. For instance, it has been demonstrated that iPSCs can treat sickle cell anemia 
in vivo in mice. iPSCs reprogrammed from fibroblasts of mice affected by sickle cell 
anemia, have been differentiated into hematopoietic progenitor cells, after correction 
of the human sickle hemoglobin allele by gene-specific targeting. Mice can be 
rescued after transplantation with hematopoietic progenitors obtained in vitro from 
autologous iPS cells. These results prove that genetically modified iPSCs can be 
applied to treat diseases in mice.  
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In addition, skin fibroblasts from an 82 year-old woman with a familial form of 
amyotrophic lateral sclerosis, have been reprogrammed to iPSCs and differentiated 
into motor neurons, the cells affected by the disease (Dimos, Rodolfa et al. 2008).  
Similarly to what has been found for ESCs, iPSCs can be predifferentiated and 
transplanted into a mice model of hind-limb ischemia promoting vascular and
 
muscle 
regeneration via direct de novo differentiation and via paracrine mechanisms. 
Furthermore, their effect was stronger than that obtained with the control population, 
adult bone marrow mesenchymal stem cells (Lian, Zhang et al. 2010). In another 
study, iPSC-derived Flk1
+ 
cells were transplanted in a mouse model of hind limb 
ischemia and were shown to improve recovery and angiogenesis (Suzuki, Shibata et 
al. 2010). Furthermore, iPSCs directly injected into damaged areas after induction of 
ischemic stroke in the rat cortex were able to reduce infarct size, improve the motor 
function and attenuate the inflammation response (Chen, Chang et al. 2010). 
The use of patient specific iPSCs derived from adult tissues has opened the 
possibility of autologous regenerative medicine, but there are many limitations to the 
iPSC application in the clinical setting. These limitations are mainly due to the 
delivery of reprogramming factors that introduces risks of permanent transgene 
integration into the genome and to the oncogenicity of the reprogramming factors. 
Reprogramming factors such as the known oncogene c-Myc, although mostly 
silenced in iPSCs, can be reactivated and lead to tumourigenesis (Okita, Ichisaka et 
al. 2007).  Teratoma formation is indeed one of the most severe and common issues 
concerning the use of iPSCs and even small numbers of undifferentiated cells can 
originate teratomas (Yamanaka 2009). Moreover, most of the protocols used so far 
showed reprogramming efficiencies as low as 0.01% suggesting that the methods 
used to generate iPSCs need to be improved and new strategies will have to be 
developed (Hochedlinger and Plath 2009). 
However, new methods have been developed to reduce the risk of stable integration 
of the reprogramming factors in the genome of iPSCs during the reprogramming 
procedure [reviewed in (Muller, Daley et al. 2009)].  
Reprogramming can in fact be obtained using plasmids containing the four factors or 
by direct delivery of reprogramming proteins (Okita, Nakagawa et al. 2008, Kim, 
Kim et al. 2009), avoiding the risk of using retroviruses and lentiviruses which can 
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be integrated into the host genome disrupting the normal gene expression. A number 
of studies are also focusing on enhancing the efficiency of the process, in particular 
by using specific chemicals, such as the TGF-β inhibitor Alk5i, which increases 
reprogramming in the absence of c-Myc (Lin, Ambasudhan et al. 2009), or small 
molecules that promote reprogramming (Xu, Shi et al. 2008). Further research into 
this field could thus produce a highly efficient method of reprogramming that does 
not involve genetic modification of the initial somatic cell.  
Another recently raised issue concerning the therapeutic application of iPSCs is 
about their immunogenicity. Although iPSCs might not show alloreactivity, if the 
iPSC harbors a genetic abnormality which is corrected before transplantation into the 
iPSC donor, then an immune response can occur (Fairchild 2010). It has been, in 
fact, demonstrated that abnormal expression in some cells derived from iPSCs can 
induce T-cell-dependent immune response in syngenic recipients (Zhao, Zhang et al. 
2011). Indeed the immunogenicity of the patient-specific iPSCs should be seriously 
evaluated before their clinical application. 
There is also a big concern about the consistency of the current methods used to 
assess pluripotency of the iPSCs lines. In a recent study it has been shown that 
amongst 122 published iPSC lines, only 21% of the researchers used the teratoma 
formation assay, one of the most important tests for pluripotency, to characterize 
these cell lines (Smith, Luong et al. 2009).  Furthermore, recent microarray analyses 
showed that there are still differences in the gene expression profiles of iPSC and 
ESCs. 
In conclusion, the recent innovative approaches in generating iPSCs have 
significantly advanced stem cell research. However, several technical issues still 
remain to be addressed, in order to exploit the full potential of iPSCs. 
However, despite success in pre-clinical settings, iPSC technology is not yet ready 
for transplanting cells into patients, because iPSCs, like ESCs, tend to form 
teratomas, and the current differentiation protocols are not designed to efficiently 
eliminate residual undifferentiated cells (Wernig, Zhao et al. 2008). 
Furthermore, the potential therapeutic use of iPSCs is also limited by the relatively 
little knowledge of their molecular and functional equivalence to ESCs. Indeed a 
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careful analysis of the genomic and epigenomic integrity of iPSCs as well the 
development of optimized differentiation protocols will be required to evaluate the 





1.5 HYPOTHESIS AND AIMS OF THE STUDY 
 
The hypothesis in this work is that the VEGF-induced iPSC differentiation into an 
endothelial lineage is regulated by miRNAs and their specific signalling pathways. 
This project aimed to identify the mechanisms regulating iPSC differentiation into 
ECs, with a particular focus on miRNAs and their targets. 
Initially, we aimed to optimise a protocol to provide an efficient differentiation of 
iPSCs towards an EC lineage, through the use of collagen IV, VEGF and shear stress 
in different combinations. 
After establishing the optimal differentiation protocol, microRNA array technique 
was performed in collaboration with Dr. Anna Zampetaki, to identify changes in 
miRNA expression during the initial days of differentiation; this allowed us to 
investigate the crucial early changes in miRNA expression that drive the downstream 
differentiation process. In particular, we aimed to study the function of miRNAs 
selected from the array, able to drive the iPSC specific differentiation towards ECs, 
via activation of downstream targets.  
Next, we intended to elucidate the molecular targets involved in this process and the 
regulating mechanisms occurring between those, in order to clarify the miRNA-
regulated EC differentiation process. In an effort to find the miRNA targets, we 
performed bioinformatic in silico analysis and we then confirmed the results by 
evaluating target gene expression after miRNA overexpression or anti-miRNA-
mediated silencing. Furthermore, we aimed to study the direct effect of miRNA on 
specific 3’-UTR of its target using a luciferase reporter assay. Finally, our 
understanding of the miRNA-targets networks was furthered through modification of 
their expression during the iPSC differentiation process. 
Ultimately, iPSCs might represent an ethically and technically suitable source of 
cells for transplantation. iPSC derived-ECs could become useful for the treatment of 
cardiovascular diseases such as myocardial infarction, ischemia and atherosclerosis, 
in which EC death and dysfunction represent a critical initiation process.  
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Furthermore, an understanding of the molecular mechanisms that involve miRNA 
regulation during differentiation may accelerate the translation of this basic science 
to a clinical setting. The identification of molecular targets might translate into new 
treatments for patients affected by cardiovascular diseases; it might also offer 
potential applications for stem cell therapy, e.g. tissue engineering and endothelial 










Cell culture media, serum and cell culture supplements were purchased from ATCC, 
Millipore, Gibco and PAA. Mouse recombinant VEGF165 and human recombinant 
TGF-β2 were purchased from Peprotech, aliquoted into stock solutions of 0.1mg/ml 
in BSA and stored at -20
oC. Human TGFβ-2 quantikine ELISA kit was purchased 
from R&D systems. Mouse VEGF ELISA kit was purchased from Invitrogen. 
Mouse VEGF164 and TGFβ-2 neutralizing antibodies were purchased from R&D 
systems, aliquoted into stock solutions of 0.2mg/ml and 1mg/ml respectively in 
sterile PBS and stored at -20
o
C (normal IgG was used as control). SMAD3 inhibitor 
SIS3 was purchased from Calbiochem, aliquoted into stock solutions of 25mM in 
DMSO and stored at -20
o
C. PTEN inhibitor PTP bpV (phen) was purchased from 
Enzo Life Sciences, aliquoted into stock solutions of 25mM in DMSO and stored at -
20
o
C. Total RNAs were extracted with the RNeasy and miRNeasy kits purchased 
from Qiagen. Taqman microRNA Reverse Transcription kit, rodent Taqman 
microRNA assay stem loop primers and rodent preamplification primers were 
purchased from Applied Biosystems. Resulting cDNAs were used for quantitative 
real-time PCR using Taqman microRNA assay and Taqman universal PCR master 
mix reagents from Applied Biosystems. Rodent Taqman miRNA Arrays A and B 
were purchased from Applied Biosystems. MiR-20b and miR-21 precursors (Pre-20b 
and Pre-21) and the precursor control (Pre-Ctrl) 5nmol were purchased from Ambion 
AB and resuspended in 100µl sterile water to have a stock concentration of 50µM. 
1:10 dilution was applied to Pre-20b, Pre-21 and Pre-Ctrl for the transfection 
experiments. MiR-20b and miR-21 inhibitors (LNA-20b and LNA-21) and the 
inhibitor control (LNA-Ctrl) 5 nmol were purchased from Exiqon and resuspended 
in 100µl sterile water to have a stock concentration of 50µM. Lipofectamine™ 
RNAiMAX for miRNA transfection was purchased from Invitrogen.  The Luciferase 
Assay System and Renilla were purchased from Promega. DNA & siRNA 
cotrasfection reagent jetPRIME® was purchased from Polyplus-trasfection SA. 
Mission
®
 Sh-RNA for PTEN was purchased from SIGMA-ALDRICH. Polybrene 
for lentiviral infection was purchased from Millipore. Reporter plasmids pGL3-
control-PTEN-3’UTR-wild type and -mutant were created by Joshua Mendell 
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laboratory and distributed by Addgene (Addgene plasmid 21326 and 21327 
respectively). Matrigel for the in vitro angiogenesis assay was purchased from BD 
Biosciences. Purchased antibodies used for immunoblotting and their recommended 
dilutions are shown in Table 8. Primary antibodies used for immunoblotting were 
diluted in PBS containing 5% milk, 0.05 Tween
®
 20 (Sigma-Aldrich, Cat No P2287) 
and 0.02% sodium azide and stored at -20
o
C. Buffers made for the methods herein 




2.2.1 CELL CULTURE OF mESC AND iPSCs 
mESCs (ES-D3, from ATCC) and iPSCs were cultured on gelatine-coated flasks 
(PBS containing 0.04% of gelatine from bovine skin, Sigma) in DMEM (ATCC) 
supplemented with 10% Fetal Bovine Serum ES cell qualified (Embriomax, 
Millipore), 100IU/ml penicillin and 100μg/ml streptomycin (Gibco), non essential 
aminoacids (NEAA) 100X (Gibco) (for mESC culture only), 10ng/ml recombinant 
human leukemia inhibitory factor (LIF, Millipore) and 0.1mM 2-mercaptoethanol 
(Gibco) in a humidified incubator supplemented with 5% CO2. The cells were 
passaged every 2 days at a ratio of 1:4 to 1:6.  
 
2.2.2 GENERATION OF MOUSE iPSCs 
iPSCs were generated in our laboratory starting from MEF isolated as stated in 
(Takahashi, Okita et al. 2007), using a similar method stated in (Kaji, Norrby et al. 
2009). Briefly, 2 x10
6
 MEF were nucleofected with 2µg of linerised 
pCAG2LMKOSimO (Addgene) using the MEF Nucleofector® Kit 2 and nuclefector 
programme T-020 (Amaxa) and re-plated on gelatine-coated tissue culture plastic 
with standard MEF media. The media was then changed to ESC media on day 1. 
Cells were then re-nucleofected on day 4 and maintained in ESC media. iPS-like 
colonies were picked between day 18-22 and expanded as described before 
(Takahashi, Okita et al. 2007). Colonies were expanded, characterised for ESC 
markers and mOrange expression, indicating exogenous gene expression. iPSC 
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colonies were tranfected using Fugene with pCre-GFP (Addgene) according to the 
manufactures instructions, in order to excise the remaining transgene plasmid. Two 
days post transfection, GFP positive cells were selected using a cell sorter and 
clonally re-seeded and expanded. Successful Cre-excision of exogenous DNA was 
confirmed by genomic DNA PCR, as previously demonstrated in (Kaji, Norrby et al. 
2009), and immunoflorescence to show lack of mOrange expression.  
 
2.2.3 DIFFERENTIATION 




) on type IV mouse collagen (5µg/ml, VWR 
International) coated flasks and maintained for four days in differentiation medium 
(DM) containing alpha MEM (Gibco) supplemented with 10% FBS (Gibco), 0.2mM 
2-mercaptoethanol and 100u/ml penicillin and 100μg/ml streptomycin. 
Subsequently, c-kit
+
 progenitor cells were isolated with magnetic-activated cell 
separation magnetic beads as described below, and seeded on collagen IV coated 
wells and maintained in differentiation medium as mentioned before. After 3 days of 
differentiation, shear stress was applied using an orbital shaking platform (P0S-330 
Grant-Bio), at an orbital speed of 120 rpm which correspond to 8 dynes/cm
2
 as 
previously described (Dardik, Chen et al. 2005), for 24h and 48h in presence or 
absence in the media of 50ng/ml vascular endothelial growth factor (VEGF, 
Peprotech). The cells in the central area of the plate, which are subjected to 
oscillatory stress as compared to the directional and laminar flow in the periphery, 
were removed by scraping before proceeding to further analysis (Chakraborty, 
Chakraborty et al. 2012). Differentiation of iPSCs was obtained by seeding them on 
type IV mouse collagen (5µg/ml) coated dishes in differentiation medium (DM) that 
contains alpha-MEM supplemented with 10% FBS (Gibco), 0.05mM 2-
mercaptoethanol and 100u/ml penicillin and 100μg/ml streptomycin. The medium 
was supplemented with 50ng/ml VEGF and the cells were maintained under these 
conditions for 3, 5 and 7 days when samples were harvested. The number of iPSCs 













(d7). Shear stress studies were performed on iPSCs differentiated 
for three days, shear stress was applied for 48h in presence or absence in the media 




2.2.4 CELL SORTING 
Pre-differentiated mESCs were trypsinized and centrifuged at 1000rpm for 5min. 
The cell pellet was resuspended in 60µl of magnetic-activated cell separation buffer 
(2mM EDTA, 0.5% bovine serum albumin, BSA) to which 40µl of CD117 
MicroBeads (Miltenyi) were added. Cell suspension was incubated for 15min at 4-
8
o
C and then washed in 2.5ml of buffer and centrifuged at 1000rpm for 5min. 
Meanwhile, a MS magnetic-activated cell separation column (Miltenyi) was placed 
in the magnetic field of a magnetic-activated cell separator and washed with 500µl of 
buffer. The cell pellet was resuspended in 500µl of buffer and applied onto the 
column. The unlabeled cells that do not bind to the column pass through and are 
discarded. The column was washed further three times by adding 500µl of buffer 
each time. The column was then removed from the separator and placed in a suitable 
collection tube. Finally, 1ml of buffer was pipetted onto the column and the 
magnetically labelled cells were flushed out by pushing the plunger into the column. 
 
2.2.5 HARVESTING CELLS 
The supernatant medium was removed or collected from the flasks or dishes and 
cells were washed with cold PBS (4
o
C). An additional volume (5-10ml) of cold PBS 
was added and cells were scraped off, decanted into 15ml tubes and centrifuged at 
1000rpm for 5min. Supernatant PBS was discarded and cells were resuspended in 
1ml of which 750μl and 250μl were transferred to micro centrifuge tubes and 
centrifuged shortly at 4
o
C (high speed) for protein and RNA extraction, respectively. 
 
2.2.6 RNA EXTRACTION  
RNA extraction was performed using RNeasy Mini Kit for isolation of total RNA 
from animal cells (Qiagen), according to the manufacturer’s protocol at room 
temperature with a centrifugal force of 8000 g unless otherwise stated. The cell pellet 
was resuspended in 350μl of RLT lysis buffer that disrupt the cell membrane and 
organelles to release total RNA contained in the sample. The lysate was then 
transferred into a QIAshredder spin column and centrifuged for 2min to create a 
homogenous lysate by shearing high-molecular-weight genomic DNA and other 
cellular components. An equal volume of 70% ethanol was added to the 
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homogenized lysate to provide appropriate conditions for the RNA to bind to the 
RNeasy spin column membrane. At this point the mixture was applied to the RNeasy 
mini column placed in a 2ml collection tube and centrifuged for 30s and the flow 
though obtained was discarded. 350μl of RW1 washing buffer were added to the 
column followed by centrifugation for 15s, and the flow through was once again 
discarded. On-column DNase digestion was then performed mixing gently 10μl of 
DNase I stock solution to 70μl of buffer RDD and adding the DNase I incubation 
mix directly to the RNase spin column membrane (RNase-Free DNase Set, Qiagen). 
After placing the reaction for 15min at room temperature, 350μl of RW1 washing 
buffer were added to the column followed by centrifugation for 15s. The flow 
through was discarded and 2 more washes were carried out with 500μl of RPE 
buffer. The washing buffers are applied to remove all contaminants. The flow 
through was discarded and an additional centrifugation of 1min took place to remove 
all remaining solution that could reduce the purity of the RNA extract. To elute the 
RNA, the RNeasy column was transferred to a clean 1.5ml autoclaved micro 
centrifuge collection tube and 30μl of RNase-free water was added to the RNeasy 
column membrane followed by spinning for 1min. The RNA concentration was 
measured using a Nanodrop Spectrophotometer. 
 
2.2.7 REVERSE TRANSCRIPTION  
cDNA was synthesised from 1μg total RNA. Reverse transcription was performed 
using the Improm-II reverse transcription system (Promega) in a 25μl reaction as 
outlined below. Mix A was heated at 70
o
C for 5min to allow denaturation of cDNA. 
After adding Mix B, the samples were kept at 4
o
C for 5min and 25
o
C for further 
5min and then at 42
o
C for 90min for the extension step to take place. Finally a 
temperature of 72
o
C was applied for 5min in order to deactivate the enzyme (Table 
1). The cDNA obtained was diluted with 75μl of DEPC-treated water to obtain a 








Table 1 Reverse Transcription reaction 
























 40IU/μl  RNasin ribonuclease inhibitor 










2.2.8 POLYMERASE CHAIN REACTION 
50ng of cDNA was used to perform polymerase chain reaction using 2x PCR Master 
Mix (containing 50units/ml Taq DNA polymerase, 400μM each: dATP, dGTP, 
dCTP, dTTP, and 3mM MgCl2) from Promega. The reaction mix for 25µl reaction 
volume and primer parameters are given in the table below (Table 2 and 3). 
 
Table 2 PCR reaction 
Component Volume (μl) Final concentration 
cDNA 
PCR Master Mix, 2X 
20μM Forward Primer 













Primers specific to the PCR template were designed from human mRNA sequences 
using the Primer-BLAST tool (www.ncbi.nlm.gov.uk/tools/primer-blast). All 
primers were ordered from Sigma-Aldrich, resuspended in DEPC water and the 
stocks (100mM) were stored at -80 
o






Table 3 Primer parameters and their sequence 
Gene 
Target 















































































55 35 198 
 
The PCR protocols were optimized: Initial denaturation, 95
o
C for 5min; 30-35 cycles 
of 94 
o
C for 30s, 58 
o
C for 30s and 72
 o
C for 1min; Final extension 72 
o







2.2.9 QUANTITATIVE REAL TIME POLYMERASE CHAIN 
REACTION (Q-PCR) 
Total RNA was isolated as previously described. Relative gene expression was 
detected by Q-PCR using the Eppendorf Mastercycler® ep realplex. Each real-time 
PCR reaction was performed in duplicate. Each real-time reaction contained 20ng 
cDNA, 6.5μl DEPC-treated water and 0.75μl of each 20mΜ forward and reverse 
primers and 10μl of sybr green reaction mix (Applied Biosystems). The reaction 
mixture was placed in each well of a 96-well plate (Eppendorf, twin.tec real-time 
PCR plates) and placed into a sequence detection system 7000 (Eppendorf). The Q-
PCR conditions were 5min at 95
o
C and then 40 cycles of 95
o
C for 15s and 60
o
C for 
30s followed by 10min of 95
o
C to establish the melting curve of the primers. The 
threshold cycle (Ct) values were automatically obtained in excel format and the 18s 
RNA Ct values served as the internal endogenous control. For every sample, Q-PCR 
was performed in duplicate. The primers used for Q-PCR were designed using a 
software provided by DNA Integrated Technologies 
























Table 4 Real Time PCR primer sequences 
Gene symbol Gene name Sequence (5ˈ3ˈ) 









vWF Von Willebrand Factor 
GGCTGTGCGGTGATTTTAACAT 
CGTTTACACCGCTGTTCCTCA 





18s ribosomal RNA 
CCCAGTAAGTGCGGGTCATAA 
CCGAGGGCCTCACTAAACC 
SMA Smooth Muscle Actin 
TCCTGACGCTGAAGTATCCGAT 
GGCCACACGAAGCTCGTTATAG 











GATA4 GATA Binding Protein 4 
TCCAGTGCTGTCTGCTCTAAGC 
TGGCCTGCGATGTCTGAGT 
MEF2C Myocyte Enhancer Factor 2C 
AAGCCAAATCTCCTCCCCCTAT 
TGATTCACTGATGGCATCGTGT 






TUBB3 Tubulin beta3 
TCCGTTCGCTCAGGTCCTT 
CCCAGACTGACCGAAAACGA 








































Integration Syte 1 
GGTTTCTACTACGTTGCTACTGG 
GGAATCCGTCAACAGGTTCGT 
RhoB Ras Homolog Family Member B 
GTGCCTGCTGATCGTGTTCA 
CCGAGAAGCACATAAGGATGAC 
Spry1 Sprouty Homolog 1 
ATGGATTCCCCAAGTCAGCAT 
CCTGTCATAGTCTAACCTCTGCC 














PTEN Phosphatase and Tensin Homolog 
ACAATTCCCAGTCAGAGGCG 
ACTGAGGATTGCAAGTTCCG 
REGFX1 Regulatory Factor X1 
GGCAGCCAGAAGCAGTATGT 
GCACCTTCCGATACGGTGA 







Bone Morphogenetic Protein 





Pax3 Paired Box 3 
TTTCACCTCAGGTAATGGGACT 
GAACGTCCAAGGCTTACTTTGT 








ID2 Inhibitor of DNA Binding2 
GGACCTGCAGATCGCCCTGG 
TGGACGCCTGGTTCTGTCCA 
TCF1 HNF1 Homeobox 1 
TGGCCCCTCCTCGATGTCCC 
GGAGGCACCATCCAACGGGC 




















2.2.10 AGAROSE GEL ELECTROPHORESIS 
A 1.5% Agarose (Sigma) gel, was made with Tris-Acetate EDTA buffer and 0.01 % 
safeview (NBS), and placed in the electrophoresis apparatus immersed in 1x Tris-
Acetate EDTA buffer. Samples were loaded after the addition of 6x DNA Loading 
dye (30% glycerol, 0.3% bromophenol blue). The electrophoresis was performed at 




2.2.11 MiRNA EXTRACTION  
Extraction of total RNA including miRNA was performed using miRNeasy Mini Kit 
(Qiagen). It was performed according to the manufacturer’s protocol at room 
temperature with a centrifugal force of 8000 x g unless otherwise stated. After 
harvesting the cells as described above, the cell pellet was disrupted by adding 700μl 
of QIAazol Lysis Reagent to up to 2x10
6
 cells and pipetting to mix well. Disruption 
of plasma membranes of cells and organelles is required to release all the RNA 
contained in the sample. The tube containing the homogenate was then placed on the 
benchtop for 5min. 140μl of chloroform were added to the tube shaking it vigorously 
for 15s and the tube was left at room temperature for further 2-3min. At this point 
the homogenate was centrifugated for 15min at 12000 x g at 4°C. After 
centrifugation the sample separated in three phases: an upper, colorless, aqueous 
phase containing RNA; a white interphase; and a lower, red, organic phase. The 
volume of the aqueous phase, approximately 350μl, was then transferred to a new 
collection tube and 1.5 volumes (usually 525μl) of 100% ethanol were added mixing 
thoroughly by pipetting several times. Up to 700μl of the sample were pipetted into 
an RNeasy mini spin column in a 2ml collection tube and the sample was centrifuged 
at 8000 x g for 15s and the flow though obtained was discarded. 700μl of RWT 
washing buffer provided by the kit were then added to the column and another 
centrifugation at 8000 x g for 15s was performed; the flow through was once again 
discarded. Two more washes were carried out with 500μl of RPE buffer. The 
washing buffers are applied to remove all contaminants. The flow through was 
discarded and an additional centrifugation of 1min took place to remove all 
remaining solution that could reduce the purity of the RNA extract. To elute the 
RNA, the RNeasy column was transferred to a clean 1.5ml autoclaved micro 
centrifuge collection tube and 30μl of RNase-free water was added to the RNeasy 
column membrane followed by spinning for 1min. The RNA concentration was 
measured using a Nanodrop Spectrophotometer.  
 
2.2.12 REVERSE TRANSCRIPTION AND PREAMPLIFICATION 
A fixed volume of 2μl of RNA solution from the 30μl eluate was used as input in 
each reverse transcription reaction. miRNAs were reverse transcribed using the 
Megaplex reverse transcription Primers which is a set of two predefined pools 
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(Rodent Pools A and B v3.0) from Applied Biosystem. Reverse transcription 
reaction was performed according to the company’s recommendations combining 
2μl of RNA with 0.8μl of Pooled Primers 0.2μl of 100mmol/L dNTPs with dTTP, 
0.8μl of 10x Reverse-Transcription Buffer, 0.9μl of MgCl2 (25mmol/L), 1.5μl of 
Multiscribe Reverse-Transcriptase, 0.1μl of RNAsin (20U/μl) to a final volume of 
7.5μl. The reverse transcription-PCR reaction was set as follows: 16°C for 2min, 
42°C for 1min and 50°C for 1s for 40 cycles and then incubation at 85°C for 5min 
using a Veriti thermocycler (Applied Biosystems). The reverse transcription reaction 
products were further amplified using the Megaplex PreAmp Primers (Rodent 
Primers A and B v3.0). The PreAmp Primers significantly enhance the ability to 
detect low-expression miRNAs, enabling the generation of a comprehensive 
expression profile using as little as 1ng of input total RNA. A 1μl aliquot of the 
reverse transcription product was combined with 5μl of Pre-amplification Mastermix 
(2x), 1μl of Megaplex PreAmp Primers (10x) to a final volume of 10μl. The pre-
amplification reaction was performed by heating the samples at 95°C for 10min, 
followed by 12 cycles of 95°C for 15s and 60°C for 4min. Finally, samples were 
heated at 95°C for 10min to ensure enzyme inactivation. Pre-amplification reaction 
products were diluted to a final volume of 40μl and stored at -20°C.  
 
2.2.13 TAQMAN miRNA ARRAY 
The expression profile of miRNAs in the samples was determined using the Rodent 
Taqman miRNA Arrays A and B (Applied Biosystems), which is a set of two 384-
well microfluidic cards (Array A and Array B v3.0). The arrays enable quantification 
of gene expression levels of 375 miRNAs per pool and are specific to human, mouse 
or rat. Five endogenous controls and a negative control were included in each array 
for data normalization. PCR reactions were performed using 450μl of the Taqman 
Universal PCR Master Mix No AmpErase UNG (2x) and 9μl of the diluted pre-
amplification product to a final volume of 900μl. 100μl of the PCR mix were loaded 
to each port of the Taqman miRNA Array. The fluidic card was then centrifuged and 
mechanically sealed. Real-Time PCR was carried out on an Applied Biosystems 




2.2.14 TAQMAN qPCR ASSAY 
Taqman miRNA assays were used to assess the expression of individual miRNAs. 
0.5μl of the diluted pre-amplification product were combined with 0.25μl of Taqman 
miRNA Assay (20x) (Applied Biosystems) and 2.5μl of the Taqman Universal PCR 
Master Mix No AmpErase UNG (2x) to a final volume of 5μl. QPCR was performed 
on an Applied Biosystems 7900HT thermocycler at 95°C for 10min, followed by 40 
cycles of 95°C for 15s and 60°C for 1min. All samples were run in duplicates and 
standardized to miR-202, 135 and RNU6b using SDS2.2 (Applied Biosystems) 
software. 
 
2.2.15 MiRNA TRANSIENT TRANSFECTION 
To alter miR-20b and miR-21 levels in iPSCs differentiated in presence of VEGF for 
3 days, cells were cultured to 60–70% confluence, and transfected with the pre-20b 
and pre-21, the negative control precursor miRNA (Ambion), miR-20b and miR-21 
inhibitor, and the negative control of miRNA inhibitor (Exiqon) using 
Lipofectamine™ RNAiMAX in serum-free alpha MEM medium. The final 
concentration of the oligomers was 50µM for LNA-20b, LNA-21 and the LNA-Ctrl 
and 5µM (1:10 diluition) for pre-20b, pre-21 and the pre-Ctrl. Briefly, for each petri 
dish we removed complete DM and we added 5ml of serum-free alpha MEM 
medium. In sterile tubes we prepared mastermix A containing 394µl of serum-free 
alpha MEM and 6µl of precursors/inhibitors/controls; then we prepared mastermix B 
containing 400µl of serum-free alpha MEM and 25µl of Lipofectamine™ 
RNAiMAX. We indeed combined mastemix A and B mixing gently and incubating 
for 10min at room temperature. Next, we added the precursor/inhibitor/controls –
Lipofectamine complexes to each petri dish, mixing gently. After 5h, an equal 
volume of fresh alpha MEM containing 20% FBS, but without GP, was added to the 
transfection medium. 24h after transfection, the media was refreshed with complete 
DM until the next day, when cells were harvested and RNA and protein expression 
was analyzed by Q-PCR and Western blot, respectively. The above mentioned 




2.2.16 PROTEIN EXTRACTION 
The cell pellet was resuspended in 30-50μl of a protein lysis buffer (50mM Tris-Cl 
pH 7.5, 150mM NaCl, 1mM EDTA pH 8.0). The lysate was then sonicated with the 
Branson Sonifier 150 at the lowest setting for 12s at 4
o
C and incubated on ice for at 
least 20min. The lysate was then centrifuged at full speed for 2min at 4
o
C. The 
supernatant was transferred to a new tube and the protein level was detected using a 
Biorad Protein Assay. Briefly, 2μl of the protein lysate was mixed with 998μl of the 
Bio-Rad Reagent (diluted 1:5 in water) and incubated at room temperature for 5min. 
Duplicates were measured using the Bio-Rad Spectrophotometer 3000. Lysis buffer 
was used as the blank measurement. 
 
2.2.17 WESTERN BLOT 
30-50μg of protein was mixed with 1X SDS loading buffer and heated at 94oC for 
10min before loading onto NuPage®, 6-8% Bis-Tris gel immersed in NuPage® 
MOPS SDS running buffer in a XCell SureLock™ Mini-Cell (Life technologies 
(Novex®). Protein ladder (Precision Plus Protein Ladder, Bio-Rad) was loaded 
simultaneously and the samples were run at 160V. The gel was then transferred onto 
a PVDF membrane (Amersham, hypond-P) with the XCell™ Blot Module 
(Invitrogen) at 30V for 2h immersed in transfer buffer. The membrane was then 
blocked with 5% milk in PBS-Tween and then incubated overnight at 4
o
C in the 















Table 5 Primary antibodies used in Western Blotting 
Primary Antibody 
Dilution (in 5% milk in 
PBS-Tween) 
Company of origin 
Rabbit anti-VE-cad 1:1000 Abcam 
Rabbit anti-CD31 1:750 ABBiotec 
Goat anti-vWF 1:1000 Santa Cruz 
Rabbit anti-Flk1 1:1000 Abcam 
Rabbit anti-eNOS 1:1000 Abcam 
Goat anti-Akt 1/2 1:200 Santa Cruz 
Rabbit anti-PSer473 
AKT  
1 :200 Santa Cruz 
Rabbit anti-PTEN  1:1000 New England Biolabs 
Mouse anti-GAPDH 1:5000 Abcam 
 
 
The membranes were incubated in the primary antibody (diluted in PBS-Tween 
containing 5% milk) overnight at 4
o
C. Secondary antibodies diluted in 5% milk 
PBS-Tween (1:3000) were incubated in room temperature for 1h after washing with 
PBS-Tween (10min x3). Further washing was then carried out before addition of 
ECL detection solutions (GE healthcare, 5min). Exposure of films (Amersham, 
Kodak) was carried out using the Compact X4 (Xograph Imaging System). 
 
2.2.18 INDIRECT IMMUNOFLUORESCENCE ASSAY  




 cells (for 3 
or 5 days of differentiation respectively) were seeded on each well of an 8-chamber 
slide coated with gelatine (for undifferentiated iPSCs that were used as negative 
control) or collagen IV (for iPSCs cultured in DM with VEGF). Three to five days 
after seeding, medium was discarded and cells were washed twice with warm PBS. 
The cells were then fixed with 4% paraformaldehyde in PBS for 20min in room 
temperature. They were then washed x3 with PBS and permeabilised with 0.1% 
Triton-X-100 in PBS for 10min in room temperature. An additional wash with PBS 
took place at room temperature for 5min.  
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Frozen sections of in vivo matrigel plaque were instead fixed in 100% acetone for 
10min and then washed x3 with PBS. All samples were then blocked with 5% 
normal swine serum in PBS and incubated for 30min at room temperature. The 
primary antibodies used and the dilutions in which they were used are shown in 
Table 6 and the incubation was carried out overnight at 4
o
C. The samples were once 
again washed with PBS (10min x3) and secondary antibodies were applied in the 
concentrations shown in Table 10, for 30min at 37
o
C. Samples were washed 3 x 
5min before counterstaining with DAPI (1:1000 in PBS) for 2min at room 
temperature. They were then mounted with fluorescent mounting media (Dako) and 
images were taken with the Axio Imager M2 microscope and AxioVision Digital 
Imaging System (Carl Zeiss Ltd) or SP5 confocal microscopy. 
 
Table 6 Primary and secondary antibodies used in immunofluorescence staining 
Primary 
Antibody 



















1:50 Santa Cruz 





1:50 Santa Cruz 











2.2.19 IN VITRO AND IN VIVO TUBE FORMATION ASSAY 
iPSCs were differentiated in presence of VEGF for 4 days and then transfected with 
Pre-21, Pre-ctrl, LNA-21 and LNA-ctrl. In vitro and in vivo angiogenesis assays 
were performed after further 48h. For the in vitro assay, 100μl of complete Matrigel 
(BD) was layered in each well of an 8 well chamber slide and let to solidify. Cells 
were detached and counted and 4x10
4
 cells were plated in each well; quadruplicates 
were performed for each condition. Representative images were acquired 7-8h later 
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with Axioplan 2 imaging and total tube length was quantified with ImageJ image 
processing program.  
In vivo angiogenesis was performed by mixing 5x10
5
 cells with 200μl Matrigel and 
injecting it subcutaneously in mice (C57BL/6), where it rapidly solidifies, forming a 
plug; triplicates were performed per each condition. After 7 days, mice were 
euthanized, and the skin of the mouse was pulled back to expose the Matrigel. Plugs 
were then removed and fixed in liquid nitrogen and cryosections were prepared. 
Some of the cryosections were stained with hematoxylin, which colours nuclei of 
cells blue and eosin, which colours other structures in various shades of red. Some of 
the cryosections were stained with CD31 and VE-cadherin antibodies. 
Immunostaining was assesed by confocal imaging and capillary density was 
calculated as the number of capillary number per mm
2
. 
In vitro angiogenesis assay was performed using the protocol described above also 
after 7 days of differentiation in presence of VEGF or TGF-β2 treatment. 
 
2.2.20 BACTERIA CULTURE FROM STAB AND PLASMID 
PURIFICATION  
Using a sterile pipette tip the bacteria was touched within the punctured area of the 
stab culture and streaked on Ampicilin LB Agar sterile plates (50μg/ml) and 
incubated overnight at 37
o
C. Single colonies were picked and amplified in LB 
containing Ampicilin (100μg/ml) overnight. Plasmid purification was then 
performed using a QIAprep Spin Miniprep kit (Qiagen) as instructed by the 
manufacturer.   
Verification of plasmid size was performed by running the plasmidic DNA on a 1% 
agarose gel. 
 
2.2.21 LENTIVIRAL PARTICLE PRODUCTION  
Lentiviral particles were produced by transfecting HEK 293T with shPTEN pLKO.1 
plasmid (Sigma Mission) together with the packaging plasmids. Non-targeting 
pLKO.1 plasmid was used to obtain non-targeting lentiviral particles. Cells were 
plated at 60% confluency, the next day cells were transfected using a mix of Fugene 
(Promega) and 4.5μg shRNA-PTEN (or NT), 3.6μg pCMV-dR8.2 packaging 
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plasmid and 0.9μg pCMV-VSV-G envelope plasmid (Addgene) at a ratio of 3:1 (μl 
of Fugene:μg of plasmids). During the overnight transfection period, cells were kept 
in DMEM containing 2% FBS without antibiotics. The media was changed the next 
morning to complete medium and the supernatants containing the lentivirus particles 
were harvested 48h and 96h after transfection, pooled and then filtered through a 
0.45 μm filter. The transduction unit (TU) was calculated as previously described 
(Margariti, Zampetaki et al. 2010). 
 
2.2.22 shRNA LENTIVIRAL INFECTION 
Knockdown of PTEN was achieved by infecting iPSCs differentiated for 3 days in 
DM containing VEGF 50ng/ml with lentiviruses expressing with short hairpin RNA 
(shRNA). Lentiviruses were generated as described before from plasmids encoding 
for shRNA specific for PTEN or non-coding control. Cells were infected with 
shPTEN or the non targeting control (10
7
TU/ml) complete growth medium 
supplemented with 10μg/ml of polybrene for 16-24h. The viruses were then removed 
and the cells were transfected with LNA-21 and LNA-Ctrl, as described before. Cells 
were harvested for further analysis after 48h. 
  
2.2.23 LUCIFERASE REPORTER ASSAY  
For the Luciferase Reporter Assays, 3x10
4
 iPSCs cells were seeded in each collagen-
coated well of a12-well plate in DM VEGF. 72h later, cells were transfected with the 
plasmid expressing Luciferase under the control of the PTEN 3’UTR (pGL3-control-
PTEN-3’UTR-wild type) and the miR-21 inhibitor and its control. As a control the 
same experiment was performed with a plasmid expressing luciferase under the 
control of a mutated and inactive PTEN 3’UTR. Briefly, 0.33μg/well of the reporter 
plasmids (AddGene, Joshua Mendell laboratory (O'Donnell, Wentzel et al. 2005)) 
were cotransfected with the miR-21 precursor and inhibitor and their negative 
controls, (5µM and 50µM respectively) using jetPRIME® (2μl/well) (Polyplus-
trasfection SA), according to the protocol provided. pGL3-Luc-Renilla (0.1μg/well) 
(AddGene) was also included in all transfections as a control of the transfection 
efficiency. Cells were lysated 48h later using Reporter lysis 5x buffer (Promega). 
The Luciferase (Luciferase Assay System, Promega) and Renilla (Coelenterazine, 
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Promega) enzymatic activities were detected 48h after transfection using the Lumat 
LB 9507 illuminometer. Relative luciferase unit was defined as the ratio of luciferase 




Table 7 Map of the pGL3-Luciferase Basic vector. 




2.2.24 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)  
Supernatant was collected from the cells, aliquoted and stored at-80
o
C until used. 
The concentration of the VEGF and TGF-β2 released glycoprotein in the supernatant 
was detected by a VEGF and TGF-β2 ELISA kit (Invitrogen and R&D respectively). 
For the TGF-β2 ELISA kit, before starting the assay, latent TGF-β2 had to be 
activated to the immunoreactive form according to the manufacturer’s protocol. A 
monoclonal antibody specific for TGF-β2 was pre-coated onto a 96-well microplate. 
100μl of Assay Diluent was added to each well. The microplate was subsequently 
coated with 100μl per well of the standards, control or activated sample and then 
sealed and incubated for 2h at room temperature (Standards comprised human 
recombinant TGF-β2 in 7 2-fold serial dilutions with 250pg/mL peak and were used 
for the generation of a standard curve). The solution was then removed and the wells 
were washed three times with Wash Buffer (0.05% Tween® 20 in PBS). Each well 
was then incubated with 200μl of TGF-β2 conjugated (polyclonal antibody against 
TGF-β2 conjugated to horseradish peroxidise) and the plate was sealed and 
maintained in room temperature for a further 2h. The wells were once again washed 
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three times with Wash Buffer. 200μl of the Substrate Solution were added per well 
(1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbenzidine)). The plate was incubated at room temperature for 25min 
avoiding direct exposure to light. Finally, the reaction was stopped using 50μl of 
Stop Solution (2N H2SO4). The optical density of each well was determined 
immediately using a Teecan microplate reader set to 450nm. Wavelength correction 
was set to 540nm and was used for normalisation of the readings. A standard curve 
was generated and the concentration of released TGF-β2 of each sample was 
calculated in pg/ml. 
Before starting the ELISA to detect VEGF secretion, cells were serum-deprived 
overnight. The supernatants were then harvested from an equal cell number (4x10
5
 
cells) and were 7.7-fold concentrated after centrifuging for 1h with centrifugal filter 
units (ultracel YM-3, Millipore). A purified antibody specific for VEGF was pre-
coated onto a 96-well microplate. The microplate was subsequently coated with 
100μl per well of the standards, standard diluent buffer to the blank standard wells or 
sample of concentrated supernatants and then sealed and incubated for 1h at room 
temperature (Standards comprised mouse recombinant VEGF in 7 2-fold serial 
dilutions with 250pg/mL peak and were used for the generation of a standard curve). 
The solution was then removed and the wells were washed three times with Wash 
Buffer (0.05% Tween® 20 in PBS). Each well was then incubated with 100μl of 
biotinylated mouse VEGF biotin conjugate solution into each well without the 
chromogen blank and the plate was sealed and maintained in room temperature for 
further 1h. The wells were once again washed three times with Wash Buffer. 100μl 
of streptavidin-HRP working solution (1X) were added per well without the 
chromogen blank. The plate was incubated at room temperature for 30min. After 
washing once again, the plate was incubated with 100μl of stabilized chromogen for 
25min at room temperature in the dark. Finally, the reaction was stopped using 100μl 
of Stop Solution (2N H2SO4) to each well. The optical density of each well was 
determined immediately using a Tecan microplate reader set to 450nm. Wavelength 
correction was set to 540nm and was used for normalisation of the readings. A 
standard curve was generated and the concentration of released VEGF of each 




2.2.25 PHARMACOLOGICAL INHIBITION OF SIGNALLING 
PATHWAYS 
To chemically inhibit PTEN iPSCs cells were seeded on Collagen IV, in DM 
containing VEGF 50ng/ml up to day 5 when the medium was removed and refreshed 
with serum free alpha MEM for 4h. Then it was replaced with fresh serum free alpha 
MEM containing 5µM PTEN inhibitor PTP bpV (phen) (Enzo Life Sciences) for 
24h, 2h and 30min, when the cells were harvested. DMSO was added to the cells for 
2h as a control. Protein expression of P-AKT, tot AKT and PTEN was analyzed.  
For SMAD3 inhibition iPSCs cells were cultured from day 1 in DM containing 5μM 
SMAD3 inhibitor SIS3 (Calbiochem) or DMSO as a control, in presence or absence 
of TGF-β2. At day seven the cells were harvested and EC marker epression was 
analyzed at protein and RNA level.  
In order to neutralize TGFβ-2 secretion, iPSCs were transfected with Pre-21 and Pre-
Ctrl as described before. 5h after transfection to the medium was added fresh alpha 
MEM containing FBS serum and either 1µg/ml TGFβ-2 neutralizing antibody 
antibody or IgG control (R&D System). 24h after transfection the media was 
refreshed with complete DM containing TGFβ-2 neutralizing antibody antibody or 
IgG control for further 24h. The gene expression of the EC markers was analyzed 
with Q-PCR.  
In order to neutralize VEGF secretion, iPSCs were seeded on collagen IV, in DM 
containing TGF-β2 for seven days. From day 1 the cells were treated with either 
0.1µg/ml VEGF neutralizing antibody or IgG as a control (R&D System). The 
protein expression of the EC markers was analyzed with Western Blot.  
 
2.2.26 STATISTICAL ANALYSIS OF DATA 
Statistical analysis of data was performed using ABI Graphpad Prism 5 software.  
Data were analyzed using a student’s unpaired T-test to compare two data sets for 
statistical differences and 1way ANOVA for multiple comparisons. A value of 





Table 8 Buffers and their composition 
Buffer Composition 
5X SDS Loading 
Buffer 
10% sodium dodecyl sulphate, 50% glycerol, 0.05% 
bromophenol blue, 
10mM β-mercaptoethanol in 500mM Tris-
hydrochloride (pH 6.8) 
6x DNA Loading 
Buffer 
30% glycerol, 0.3% bromophenol blue in distilled water 
Phosphate Buffered 
Saline 
137 mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4 • 2 H2O, 
1.76mM 
KH2PO4 to pH 7.4 
Protein Lysis Buffer 1mM EDTA, 50mM tris-hydochloride (pH7.4), 150mM 
NaCl, 1% Triton 
X, cocktail of protease inhibitors (Roche;1 tablet in 
50ml) 




















3.1 ROLE OF VEGF AND SHEAR STRESS IN 
STEM CELL DIFFERENTIATION INTO ECs 
Previous work from our laboratory identified a protocol for ESC differentiation 
towards ECs involving the use of collagen IV, VEGF and shear stress (Zeng, Xiao et 
al. 2006). In order to adapt this protocol to the differentiation of mouse iPSCs, 
several protocols involving different VEGF concentrations, and time points were 
tested. A protocol combining VEGF and shear stress was also tested, firstly on ESCs 
and then on iPSCs. 
 
3.1.1 VEGF induces functional differentiation of iPSC towards EC 
lineage 
Firstly, in order to identify the optimal concentration of VEGF able to induce the 
strongest level of endothelial cell differentiation in iPSCs, cells were cultured in 
differentiation medium (DM) containing 0, 10, 20, 50 and 100ng/ml of VEGF for 5 
days. Quantitative gene expression analysis showed a consistent upregulation of the 
endothelial markers VE-cadherin, Flk1 and vWF, in particular when the cells were 
stimulated with 20 and 50ng/ml of VEGF, as compared to untreated cells cultured in 
differentiation (Figure 18). 
 
 
Figure 18 Dose-dependent response of iPSCs to VEGF 
iPSCs were differentiated for 5 days on collagen IV and in the presence of differentiation medium 
containing different concentrations of VEGF (0, 10, 20, 50 and 100 ng/ml). Gene expression level 
was assessed by real-time PCR for the endothelial markers VE-cadherin (VE-cad, A), Flk1 (B), and 
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vWF (C). Statistical analysis performed is 1-way ANOVA for multiple comparisons. Data are shown 
as mean ±SEM and are representative of 4 individual experiments. *P < 0.05, **P < 0.01 and ***P < 
0.001 vs. 0ng/ml. Controls (0ng/ml) represent iPSCs cultured in differentiation medium containing 
0ng/mL of VEGF. 
 
On the basis of results obtained from the VEGF concentration curve, the next series 
of experiments were designed to elucidate the timing of the progression towards 
endothelial differentiation. The concentrations of 20 and 50ng/ml of VEGF were 
chosen because they induced the greatest upregulation of endothelial marker 
expression. The effects of these two conditions were tested after 3, 5 and 7 days of 
stimulation.  
Cells cultured in the presence of 20ng/ml of VEGF showed an increase in 
endothelial marker expression starting at day 5. Strong and significant upregulation 
of VE-cadherin, Flk1 and vWF was observed at day 7 (Figure 19). 
 
Figure 19 Time course study of EC markers expression in iPSCs differentiated with 20ng/ml 
VEGF 
iPSCs were seeded on collagen IV and cultured in differentiation medium with 20ng/ml VEGF. Gene 
expression analysis was performed by real-time PCR after 3, 5, and 7 days of differentiation. Results 
are shown for VE-cadherin (VE-cad, A), Flk1 (B) and vWF (C). The statistical analysis used is 1-way 
ANOVA for multiple comparisons. Data are shown as mean ±SEM and are representative of 4 
individual experiments. *P < 0.05 and **P < 0.01 vs. d0 (d0 represents iPSCs seeded on gelatin and 
cultured in undifferentiated conditions). 
 
Since the concentration curve analysis showed that the addition of 50ng/ml of VEGF 
was able to induce a stronger endothelial differentiation than 20ng/ml, we tested the 
progression of differentiation over a 7 days period adding 50ng/ml of VEGF to the 
medium. Results showed a strong upregulation of the endothelial marker expression 
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at day 7 (Figure 20). As compared to the results obtained with 20ng/ml of VEGF, the 
higher dose of the growth factor induced a stronger expression of some 
differentiation markers, in particular VE-cadherin and an earlier upregulation of the 
mature endothelial cell marker vWF, starting from day 3. 
 
 
Figure 20 Time course study of EC marker expression in iPSCs differentiated with 50ng/ml 
VEGF 
iPSCs were cultured on collagen IV and in differentiation medium supplemented with 50ng/ml 
VEGF. Real-time PCR was performed after 3, 5, and 7 days of differentiation to analyze the gene 
expression of VE-cadherin (Ve-cad, A), Flk1 (B) and vWF (C). The statistical analysis used is 1way 
ANOVA for multiple comparisons Data are shown as mean ±SEM and are representative of 4 
individual experiments. **P < 0.01 and ***P < 0.001 vs. d0 (d0 represents iPSCs seeded on gelatin 
and cultured in undifferentiated conditions). 
 
 
To confirm the expression of the differentiation markers, Western blot analysis was 
performed on cell lysate derived from iPSCs differentiated at different time points. 
Protein analysis confirmed the differentiation pattern observed at gene expression 
level. In particular, cells showed an increased level of the endothelial cell markers 
CD31 and Flk1 starting at day 3, further increasing at day 5 and day 7. A similar 
pattern was observed for the late endothelial cell marker VE-cadherin, which was 







Figure 21 EC marker protein expression in iPSCs differentiated with 50ng/ml VEGF at 
different time points 
iPSCs were seeded on collagen IV, in differentiation medium containing 50ng/ml VEGF and the 
samples were harvested after 3, 5 and 7 days of differentiation. Protein expression level was assessed 
by Western Blot analysis of early endothelial markers CD31 (A) and Flk1 (B), and the late marker 
VE-cadherin (VE-cad, C). As a control iPSCs were seeded on gelatin and cultured in undifferentiating 
conditions. GAPDH (D) was used as loading control. 
 
We also observed a different morphology of the cells cultured on collagen IV, in DM 
containing VEGF 50ng/ml, as compared to the undifferentiated cells in gelatin. 
While the undifferentiated iPSCs appeared clustered in round three-dimensional 
colonies, the differentiated cells assumed a flat adherent phenotype, becoming 










Figure 22 Morpholgy of iPSC-derived ECs and undifferentiated iPSCs 
iPSCs were differentiated for 5 days on collagen IV and cultured in differentiation medium containing 
50ng/ml VEGF (B) or cultured in undifferentiated conditions on gelatin (A). Light microscopy 
images were taken with the Nikon Eclipse TS100 and are representative of at least 3 experiments. 
Scale bar, 25 μm. 
Furthermore, immunofluorescence analysis of the endothelial cell markers VE-
cadherin, eNOS and vWF was performed to confirm expression and assess the 
correct localization of the proteins in the cells. Cells were seeded on collagen in the 
presence of 50ng/ml of VEGF for 5 days. Confocal imaging showed a clear 
expression pattern of VE-cadherin at cell junction level, and of eNOS and vWF on 








Figure 23 Staining of iPSC-derived ECs treated with 50ng/ml VEGF 
iPSCs were differentiated on collagen IV and in differentiation medium containing 50ng/ml VEGF 
for 5 days. Leica SP5 inverted Confocal microscope images showed positivity for the endothelial cell 
markers VE-cadherin (VE-cad, A) and eNOS (B), and vWF (C). Negative controls consisted of cells 
incubated with IgG followed by secondary antibody (D). Scale bar, 50 μm. 
In addition, expression of VE-cadherin after 7 days was confirmed by 
immunocytochemistry. Cells cultured for 7 days on collagen IV in DM containing 
50ng/ml VEGF, showed a clear pattern of VE-cadherin expression at the cell-cell 
junctions (Figure 24). Comparison with the results of the previous experiment 
(performed after five days with 50ng/ml VEGF) demonstrated that an increased 






Figure 24 Staining of iPSC-derived ECs treated with 50ng/ml VEGF 
iPSCs were differentiated for 7 days on collagen IV and cultured in differentiation medium containing 
50ng/ml VEGF. Leica SP5 inverted confocal imaging showed a strong positivity of the cells for the 
endothelial cell marker VE-cadherin (VE-cad, A). Negative controls consisted of cells incubated with 
IgG followed by secondary antibody (Neg C, B). Scale bar, 50 μm.  
Finally, to test the functionality of iPSCs after VEGF treatment we performed an in 
vitro angiogenesis assay. Cells treated for 7 days with VEGF (Figure 25, B) showed 
an increased tube formation ability, as compared to the cells grown in absence of 
VEGF (Figure 25, A). The results of the assay were confirmed by total tube length 
quantification, which showed a 4-fold increase in tube-like structure formation 
capacity in cells differentiated with VEGF (Figure 25, C). These findings showed 
that the endothelial lineage differentiation of iPSCs has given rise to functional, 







Figure 25 In vitro angiogenesis assay in iPSCs differentiated with VEGF 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) with or without 
VEGF. After 7 days, cells were seeded on Matrigel and incubated for 7-8h to test their angiogenesis 
potential. Representative images show tube formation in the cells treated with VEGF (B) and 
untreated in DM (A). Total tube length was measured to quantify the effect of differentiation on tube-
like formation capacity (C). The statistical analysis used is Student’s unpaired T-test. Data are shown 
as mean ±SEM and are representative of 3 individual experiments. ***P < 0.01 vs. DM (DM 








3.1.2 Role of shear stress in stem cell differentiation 
Previous studies conducted in our group revealed the importance of shear stress in 
the differentiation of stem and progenitor cells. In particular, application of shear 
stress on Sca1
+
 progenitor cells increased their proliferation and induced EC marker 
upregulation and this effect is mediated by the VEGF pathway (Xiao, Zeng et al. 
2006). 
In order to further improve the differentiation protocol described in the first part of 
the work, we included a set of experiments performed on ESCs and then replicated 
with iPSCs, combining VEGF and shear stress. In particular, we chose to study a 
ckit
+
 population that is being characterized in our laboratory and has been 
demonstrated to represent a novel vascular progenitor cell population. 
ESCs were seeded on collagen IV and cultured in differentiation medium for 4 days. 
Subsequently, ckit
+
 progenitor cells were isolated using immunomagnetic beads and 
seeded on collagen IV coated wells in the presence of differentiation medium. After 
three days of culture, shear stress was applied for either 24h or 48h and then cells 
were collected and analyzed for their expression of endothelial markers. Quantitative 
gene expression analysis on cells subjected to 24h of shear stress showed some 
degree of upregulation of the endothelial markers CD31 and VE-cadherin, although 
consistent results were obtained only for CD31 after 24h. Flk1 and eNOS were 
upregulated approximately 2-fold, as compared to cells cultured in static conditions. 
Treatment of the cells with shear stress for 48h did not induce a relevant increase in 




Figure 26 Effect of shear stress on ESC differentiation 
ckit
+
 progenitor cells isolated from mESCs pre-differentiated for 4 days on collagen IV and in 
differentiation medium,  were cultured in the same differentiation conditions for a further three days 
and subjected to shear stress for 24h and 48h. Real time PCR shows the effect on endothelial cell 
marker expression of the addition of shear stress (SS) to the static differentiation conditions (st). 
Results are shown for VE-cadherin (VE-cad, A), CD31 (B), Flk1 (C) and eNOS (D). The statistical 
analysis used is 1way ANOVA for multiple comparisons. Data are presented as mean ±SEM of 3 
individual experiments.*P < 0.05 vs. iPSCs differentiated for 24h in static conditions. The shear stress 
results were normalized to the relative time points. 
 
3.1.3 Synergistic action of shear stress and VEGF in ESC 
differentiation into ECs  
Previous results in this chapter showed that shear stress is able to induce some 
upregulation of the endothelial cell markers in mESC. Therefore, in order to increase 
the response we decided to combine the mechanical force of shear stress to the 
biochemical action of VEGF. 
ESC-derived ckit
+
 progenitor cells were obtained as described previously 
(Campagnolo et al., submitted to Circulation) and differentiated for three days in 
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collagen IV before stimulation with 50ng/ml VEGF for 24 and 48h, with or without 
the application of shear stress. Quantitative gene expression analysis of the 
endothelial markers CD31, Flk1 and eNOS showed upregulation of approximately 2 
fold in the cells treated for 24h with a combination of shear stress and VEGF, 
relative to the cells treated with VEGF alone. eNOS and the late EC marker VE-
cadherin showed an increase of 2 and 2.5 fold respectively after 48h of combined 
treatment with VEGF and shear stress, compared to static cells (Figure 27).  
 
 




 progenitor cells were differentiated for a further three days in DM on collagen and then 
stimulated with VEGF 50ng/ml for 24h and 48h, in presence or absence of shear stress stimulation. 
Real time PCR shows the synergistic effect on the endothelial marker expression of the combination 
of shear stress (SS) and VEGF (V). Results are reported for VE-cadherin (VE-cad, A), CD31 (B), 
Flk1 (C) and eNOS (D). The statistical analysis used is 1way ANOVA for multiple comparisons. Data 
are shown as mean ±SEM and are representative of 3 individual experiments. *P < 0.05 vs. iPSCs 
cultured in VEGF only (V). Results of shear stress and VEGF combined treatment were normalized to 





 cells the combined action of shear stress and VEGF was shown to induce 
the expression of EC markers to a greater level, as compared to each stimulus 
applied alone, the logical next step was application of this protocol to iPSCs. 
 
3.1.4 Synergistic action of shear stress and VEGF in iPSC 
differentiation into ECs 
Once we had established the protocol in ESC-derived ckit
+
 progenitors, we 
proceeded to apply it to iPSCs. 
We used a mixed population of iPSCs and pre-differentiated them for three days. 
These cells were then treated with shear stress, VEGF or a combination of the two 
for 48h. After combined application of VEGF and shear stress, results showed a 
significant and stronger EC marker expression, as compared to each stimulus applied 
alone (Figure 28). 
 
Figure 28 Combined application of shear stress and VEGF improves EC differentiation in 
iPSCs 
iPSCs were differentiated for three days on collagen IV and in differentiation medium and then 
treated with shear stress, VEGF or a combination of the two stimuli for 48h. Real time PCR shows a 
synergistic effect on endothelial marker expression after addition of shear stress (SS) and VEGF (V) 
to the differentiation conditions, as compared to either stimulus alone. Results are shown for VE-
cadherin (VE-cad, A), Flk1 (B) and vWF (C). The statistical analysis used is 1way ANOVA for 
multiple comparisons. Data are presented as mean ±SEM of 3 individual experiments.*P < 0.05 vs. 




3.1.5 Conclusions  
In conclusion, in this first part of the work we described the optimization of the 
differentiation protocols for ESCs and iPSCs.  
Firstly, we tested several conditions and established that a greater level of 
endothelial differentiation could be obtained by culturing iPSCs with differentiation 
medium containing 50ng/ml VEGF for up to 7 days, as shown by EC marker 
expression results and in vitro angiogenesis assay. 
Additionally, using ESCs as a model, we further optimized the previous protocol 
through the addition of shear stress. 
We finally applied the combination of shear stress, a mechanical force, and VEGF, a 
chemical stimulation, to iPSCs. VEGF and shear stress together were able to increase 
the EC differentiation of the cells, as compared to each stimulus applied alone. 
However, a limitation of this protocol is represented by the poor reproducibility of 
the experiments performed in presence of shear stress, which will be explained in 












3.2 CHARACTERIZATION OF miRNA PROFILE 
DURING VEGF- AND SHEAR STRESS- INDUCED 
iPSC DIFFERENTIATION: MiRNA-21 
REGULATES VEGF-INDUCED iPSC 
DIFFERENTIATION INTO ECs 
 
The optimization of the protocol described in the previous section (3.1) led to the 
design of a method to differentiate iPSCs into ECs, involving the use of DM with 
50ng/ml of VEGF or a combination of VEGF and shear stress treatment. Using these 
protocols we now aimed to characterize the miRNA signature of the differentiating 
iPSCs in order to study the involvement of miRNAs in the relevant signalling 
pathways and to elucidate the underlying molecular mechanism. 
 
3.2.1 MiRNA array analysis on iPSCs differentiated with VEGF and 
undifferentiated  
Our results showed that the treatment of iPSCs with 50ng/ml of VEGF induced 
endothelial differentiation, starting at day 5, with a peak at day 7. Minor changes in 
marker expression were detected also at day 3, but were not consistent in all the 
markers. 
Using the protocol described in Chapter 3 we then aimed to study the molecular 
mechanisms underlying iPSC differentiation.  
For this purpose, we performed a miRNA array to study the miRNA involvement in 
the differentiation process. The array was performed in order to compare the 
expression of miRNAs in iPSCs undifferentiated and differentiated for three days in 
the presence of 50ng/ml VEGF. 
The choice of such an early time point was made in order to investigate the initial 




Each experiment was performed in quadruplicates, and 2 controls (undifferentiated 
iPSCs) and 2 treated samples (3 days VEGF 50ng/ml) were loaded on two 
microfluidic cards each (pool A and B). 
The two microfluidic cards used in the experiment contained probes for 750 target 
miRNAs. Card A focuses on more highly characterized miRNAs, while Card B 
contains many of the more recently discovered miRNAs along with the miR* 
sequences or passenger strands. Indeed, before assembling the active RNA induced 
silencing complex (RISC) to perform gene silencing, the double-stranded duplex is 
separated into the guide strand, functional and complementary to the mRNA target, 
and the passenger strand, which is subsequently degraded (Narazaki, Uosaki et al. 
2008). The function of these passenger strands is still unclear, but well-conserved 
miRNA* strands may contribute to the regulation network (Park, Afrikanova et al. 
2004). 
Data obtained from the miRNA array were normalized to 3 different control 
miRNAs, differential expression was then considered for those miRNAs that 
obtained similar results in all three normalizations. Out of the 750 probes present in 
the cards, 123 in pool A and 88 in  pool B reported expression of the relative miRNA 
in our system and therefore could be detected under the threshold of 30 cycles. 
Amongst the detected miRNAs, differential expression was observed in 25 (pool A) 
and 15 (pool B) miRNAs; only miRNAs consistently up or down regulated in both 
the experiments analyzed were considered. Finally, miRNAs which showed a 
consistent differential expression of at least 2 fold were picked. The final number of 
miRNAs selected was 24 for pool A (20 upregulated and 4 downregulated, Table 9) 
and 11 for pool B (8 upregulated and 3 downregulated, Table 10). 
Some of the miRNAs identified in the array analysis are already known to be 
involved in stem cells maintenance, such as the miRNA-302-367 cluster (Taniyama 
and Griendling 2003), angiogenesis, such as the miRNA-20b and 21 (Cascio, 
D'Andrea et al. 2010, Sabatel, Malvaux et al. 2011), and smooth muscle cell 





Target name snoRNA202 snoRNA135 MammU6 
mmu-let-7c  6.7 ± 3.4  4.9  ± 3.2  6.8 ± 1.9  
mmu-miR-129-3p  33.9 ± 15  22.6 ± 6.2  39.1 ± 25.9  
mmu-miR-133a  7.2 ± 4.4   5.3 ± 3.9  7.2 ± 2.8  
mmu-miR-139-5p  3.6 ± 2.5  2.3 ± 1.3   4.2 ± 3.7  
mmu-miR-188-5p  3.3 ± 0.5  2.3 ± 0.7  3.5 ± 0.4  
mmu-miR-20b  3.1 ± 1.6  2.1 ± 0.7  3.6 ± 2.6  
mmu-miR-21  22.7 ± 27.3  17.5 ± 21.8  21.0 ± 23.4  
mmu-miR-218  2.9 ± 0.5  2.1 ± 0.7  3.1 ± 0.3  
mmu-miR-224  126.5 ± 170.7  98.5 ± 134.3  114.3 ± 151.0  
mmu-miR-26b  23.0 ± 13.1  15.1 ± 6.3  26.9 ± 20.7  
mmu-miR-29b  145.9 ± 189.9  113.2 ± 150.1  132.7 ± 166.7  
mmu-miR-302a  88.1 ± 3.6  61.5 ± 13.4  95.7 ± 20.7  
mmu-miR-302b  4432 ± 4226 2820 ± 2391 5436 ± 5862 
mmu-miR-302c  27395 ± 34072 21156 ± 27080 25158 ± 29548 
mmu-miR-340-5p  7.8 ± 2.0   5.6 ± 2.4  8.3 ± 0.0  
mmu-miR-34b-3p  6.6 ± 1.1   4.7 ± 1.1   7.1 ± 0.6  
mmu-miR-367  65.9 ± 16.9  44.8 ± 3.6   74.4 ± 37.0  
mmu-miR-449a  19.8 ± 12.9  14.5 ± 11.4   19.8 ± 8.6  
mmu-miR-685  2.9 ± 0.2  2.0 ± 0.2  3.2 ± 1.1  
rno-miR-224  9.3 ± 5.1  6.1 ± 2.4  10.8 ± 8.2  
mmu-miR-145  0.3 ± 0.1  0.2 ± 0.1  0.3 ± 0.1  
mmu-miR-467e  0.5 ± 0.3  0.4 ± 0.3  0.5 ± 0.2  
mmu-miR-669a  0.5 ± 0.2  0.3 ± 0.2  0.5 ± 0.1  
mmu-miR-409-3p  0.3 ± 0.4  0.3 ± 0.3  0.3 ± 0.3  
 
Table 9 Pool A miRNAs target. The miRNA array for pool A was performed on iPSCs 
differentiated for three days on collagen IV and in differentiation medium containing 50ng/ml of 
VEGF; undifferentiated cells were used as control. The results represent an average of the differential 
expression between two independent experiments. In the table are shown 20 (green panel) and 4 (red 
panel) miRNAs, respectively up and down regulated at least two fold relative to the undifferentiated 
iPSCs. Results were obtained after normalization with three different endogenous controls (mouse 
snoRNA202 and 135, and mammalian MammU6). These miRNAs were initially characterized in 








Target name snoRNA135 snoRNA202 Mamm U6 
hsa-miR-200b 2.0 ± 0.6  2.0 ± 0.3  2.5 ± 0.6  
mmu-miR-212 4.4 ± 1.0  4.3 ± 0.5  5.6 ± 1.6  
mmu-miR-2138       6.5 ± 4.5  6.2 ± 3.8   7.1 ± 1.8  
mmu-miR-302a# 108.1 ± 46.1  104.7 ± 34.8  129.4 ± 9.8  
mmu-miR-34c# 7.0 ± 2.5   6.8 ± 1.7  8.5 ± 1.3  
mmu-miR-374-5p 8.9 ± 7.1  8.4 ± 6.1  9.5 ± 3.6  
mmu-miR-449b 370.8 ± 512.4  341.1 ± 469.7  326.7 ± 440.3  
mmu-miR-92a# 4.1 ± 2.1  3.9 ± 1.7  4.7 ± 0.1  
mmu-miR-467a 0.3 ± 0.1  0.3 ± 0.1  0.4 ± 0.0  
mmu-miR-690 0.4 ± 0.1  0.3 ± 0.1  0.4 ± 0.0  
mmu-miR-706 0.4 ± 0.2  0.4 ± 0.2  0.4 ± 0.0  
Table 10 Pool B miRNAs target. miRNA array for pool B on iPSCs undifferentiated used as control, 
and differentiated for three days on collagen IV and in differentiation medium containing 50ng/ml of 
VEGF. The results represent an average of the differential expression between two independent 
experiments. In the table are shown 8 (green panel) and 3 (red panel) miRNAs, respectively up and 
down regulated at least two times relative to the control. MiR-302a#, 34c# and 92a# represent miR* 
passenger strands. Results were normalized with three different endogenous controls (mouse 
snoRNA202 and 135, and mammalian MammU6). These miRNAs were initially characterized in 
human or mouse (hsa= homo sapiens; mmu= mus musculus). 
 
3.2.2 Real time PCR validation of selected miRNAs 
In order to choose some relevant candidates and to study their involvement in the 
mechanisms of iPSC differentiation toward an endothelial lineage, we decided to 
validate some of the most consistently upregulated or downregulated miRNAs in the 
array and some of those previously shown to contribute to angiogenesis.  
We chose to analyze the expression of five of the selected miRNAs in the cells 







Figure 29 Analysis of the expression of selected miRNAs in iPSCs differentiated with 50ng/ml 
VEGF for up to 7 days 
Five of the most consistently upregulated miRNAs were selected from the miRNA array and validated 
by real time PCR. Results show the expression levels of miRNAs 21 (A), 218 (B), miRNA 20b (C), 
133a (D) and 29b (E) after 3, 5 and 7 days of VEGF treatment, as compared to the undifferentiated 
cells. The statistical analysis used is 1way ANOVA for multiple comparisons. Data are presented as 
mean ±SEM of 4 individual experiments.*P < 0.05 and **P < 0.01 vs. d0 (d0 represents iPSCs 
seeded on gelatin and cultured in undifferentiated conditions). 
 
3.2.3 MiRNA array analysis on iPSCs treated with shear stress for 
48h and static 
 
In section 3.1 we described a differentiation protocol for ESCs and iPSCs involving 
the application of shear stress and VEGF. In order to investigate possible common 
mechanisms in the iPSC differentiation process induced by the two stimuli, we 
aimed to investigate the miRNA signature of the cells treated with shear stress and 
untreated. For this purpose we performed a second miRNA array to compare the 
miRNA expression in iPSCs differentiated for three days on collagen IV, in DM and 
iPSCs differentiated in the same conditions and with 48h of shear stress treatment.  
133 
 
Each experiment was performed in quadruplicates, and 2 controls (3 days collagen 
IV and DM) and 2 treated samples (3 days collagen IV and DM, 48h of shear stress) 
were loaded on two microfluidic cards each (pool A and B).  
As explained before, data obtained from the miRNA array were normalized to 3 
different control miRNAs, differential expression was then considered for those 
miRNAs that obtained similar results in all three normalizations. Out of the 750 
probes present in the cards, 138 in pool A and 94 in pool B reported expression of 
the relative miRNA in our system and therefore could be detected under the 
threshold of 30 cycles. Only differentially expressed miRNAs consistently up or 
down regulated of at least 2 fold in both the experiments analyzed were considered. 
The final number of miRNAs selected was 6 for pool A (4 upregulated and 2 
downregulated, Table 11) and 8 for pool B (3 upregulated and 5 downregulated, 
Table 12). 
 
Target name snoRNA202 snoRNA135 MammU6 
mmu-miR-218 1.9 ± 0.0  4.1 ± 4.2  2.3 ± 0.6  
mmu-miR-369-5p 37.8 ± 49.1  42.0 ± 43.2  39.2 ± 49.1  
mmu-miR-425 2.4 ± 0.3  5.6 ± 6.0  3.0 ± 1.1  
mmu-let-7e 14.6 ± 8.9  21.6 ± 13.1  16.6 ± 6.6  
mmu-miR-328 0.2 ± 0.0  0.3 ± 0.3  0.2 ± 0.0  
mmu-miR-302b 0.4 ± 0.0  0.7 ± 0.7  0.4 ± 0.1  
Table 11 Pool A miRNAs target. The miRNA array for pool A was performed on iPSCs 
differentiated for three days on collagen VI and in differentiation medium (DM), under shear stress 
stimuli for 48h. Differentiated cells on collagen IV and in DM were used as controls. The results 
represent an average of the differential expression between two independent experiments. In the table 
are shown 4 (green panel) and 2 (red panel) miRNAs, respectively up and down regulated at least two 
fold relative to the untreated iPSCs.  Results were obtained after normalization with three different 
endogenous controls (mouse snoRNA202 and 135, and mammalian MammU6). These miRNAs were 








Target name snoRNA202 snoRNA135 MammU6 
hsa-miR-200b 1.2 ± 0.0  1.5 ± 0.2  1.6 ± 0.4  
mmu-miR-31# 6.1 ± 2.9  7.2 ± 2.7  0.9 ± 0.3  
rno-miR-7a# 128.4 ± 36.4  152.6 ± 28.5  0.8 ± 0.2  
Y1  0.3 ± 0.1   0.4 ± 0.1  0.4 ± 0.0  
hsa-miR-15b# 0.5 ± 0.2   0.6 ± 0.3  0.6 ± 0.1  
hsa-miR-378  0.2 ± 0.1  0.2 ± 0.1  0.2 ± 0.2  
hsa-miR-99b# 0.4 ± 0.2  0.4 ± 0.2  0.5 ± 0.4  
mmu-miR-721  0.4 ± 0.1  0.5 ± 0.1  4.6 ± 3  
Table 12 Pool B miRNAs target. MiRNA array for pool B on iPSCs differentiated for three days on 
collagen IV and in differentiation medium (DM), under shear stress stimuli for 48h. Differentiated 
cells on collagen IV and in DM were used as controls. The results represent an average of the 
differential expression between two independent experiments. In the table are shown 3 (green panel) 
and 5 (red panel) miRNAs, respectively up and down regulated at least two times relative to the 
untreated control iPSCs. MiR-31#, 7a#, 15b# and 99b# represent miR* passenger strands. Results 
were normalized to three different endogenous controls (mouse snoRNA202 and 135, and mammalian 
MammU6). These miRNAs were initially characterized in human or mouse (hsa= homo sapiens; 
mmu= mus musculus). 
 
3.2.4 Analysis of differential expression of selected miRNAs in iPSCs 
treated with shear stress for 48h and untreated 
We then aimed to validate observed changes to some of the most consistently 
upregulated and downregulated miRNAs from the array performed in cells after 
shear stress treatment, in order to study their involvement in the mechanisms of iPSC 
differentiation toward an endothelial lineage. We analyzed the differential expression 
of six selected miRNAs in the cells treated with shear stress for 48h, compared to the 
untreated cells on collagen IV and DM.  
On analysis of the results of the Real time PCR we were unable to confirm any 
significant differential expression of the selected miRNAs in the cells treated with 





Figure 30 Analysis of the expression of miRNAs selected from the miRNA array performed in 
iPSCs treated with shear stress and static 
Four of the most consistently upregulated miRNAs, miR-218 (A), miR-425 5p (D), miR-LET 7E (E) 
and miR-302B (F), and two of the most consistently downregulated miRNAs, miR-378 (B) and miR-
202B (C), were selected from the array and validation experiments performed by real time PCR. 
Expression levels of these markers are shown in the static cells differentiated for 3 days on collagen 
IV, in differentiation medium (DM) and in cells differentiated in the same conditions plus 48h of 
shear stress treatment (DM SS). The statistical analysis used is 1way ANOVA for multiple 
comparisons. Data are presented as mean ±SEM of 4 individual experiments. No results were 
significant (*P < 0.05). 
 
A possible reason for these results is that, as mentioned in section 3.1, the 
experiments performed in the presence of shear stress showed a lot of variability, 
which does not allow the establishment of an efficient differentiation system. 
Explanation of this observed variability will be further explored in the discussion.  
 
 
3.2.5 Study of the role of miRNAs in endothelial differentiation 
Based on the data shown above, we decided to select one of the most suitable 
candidates amongst the validated miRNAs to investigate its role in iPSC 
differentiation towards an EC lineage. We decided to focus on miR-20b and 
miRNA-21, since their involvement in angiogenesis has already been documented. 
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3.2.5.1 MiR-20b expression does not affect iPSC endothelial differentiation 
MiR-20b is considered one of the potential anti-angiogenic miRNAs, through 
targeting VEGF expression (Wang and Olson 2009); miR-20b  has also been shown 
to be downregulated in hypoxic conditions and to directly decrease VEGF 
expression in carcinoma cell lines (Hua, Lv et al. 2006). Therefore, miR-20b appears 
to play a role in regulating angiogenesis, but its function in EC differentiation has 
not yet been clarified.  
Aiming to investigate a potential involvement of miR-20b in the VEGF-induced 
iPSC differentiation towards ECs, we first altered the levels of this miRNA in iPSCs 
differentiated with VEGF for three days. In order to do so, we overexpressed miR-
20b by transfecting iPSCs with the miR-20b precursor (Pre-20b). The mature 
miRNA expression was increased by approximately 300-fold in iPSCs transfected 
with Pre-20b, as compared to cells transfected with the precursor control (Pre-Ctrl) 
(Figure 4.3, A). We then inhibited miR-20b expression by transfecting iPSCs with an 
anti-miR LNA-20b, which is a chemically modified, single stranded nucleic acid 
designed to specifically bind to and inhibit endogenous miR-20b molecules. Results 
showed an approximately 13-fold decrease in the mature expression level of miR-
20b in iPSCs transfected with LNA-20b, as compared to cells transfected with the 







Figure 31 MiR-20b overexpression and inhibition in iPSCs differentiated with VEGF 
iPSCs were differentiated for three days on collagen IV and in differentiation medium containing  
50ng/ml VEGF. The levels of miR-20b were altered by transfecting the cells with precursor of miR-
20b (Pre-20b), negative control precursor (Pre-Ctrl), inhibitor of miR-20b (LNA-20b) and negative 
control of miRNA inhibitor (LNA-Ctrl). Real time PCR analysis was performed after 48h to assess 
the expression level of the mature miR-20b. Results are shown for miR-20b expression after 
transfection with Pre-20b compared to Pre-Ctrl (A) and with LNA-20b, compared to LNA-Ctrl (B). 
The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM of 3 
individual experiments. ***P < 0.001 vs. Pre-Ctrl and LNA-Ctrl. 
 
Next, we aimed to analyze the effect of miR-20b on the expression of the EC 
markers VE-cadherin and Flk1 in iPSCs differentiated in presence of VEGF. 
However, Q-PCR results showed that miR-20b overexpression (Figure 32 A and C) 






Figure 32 Analysis of EC marker expression in iPSCs differentiated with VEGF, after miR-20b 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-20b precursor (Pre-20b), inhibitor (LNA-20b) and the negative controls of the 
miR-20b precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis was performed 48h 
later. Results are shown for the EC markers VE-cadherin (VE-cad) (A and B) and Flk1 (C and D), 
after miR-20b overexpression and inhibition. The statistical analysis used is Student’s unpaired T-test. 
Data are presented as mean ±SEM of 3 individual experiments. No results were significant (*P < 
0.05). 
From the above shown results, we can indeed conclude that miR-20b does not 
regulate iPSC differentiation into ECs. 
 
3.2.5.2 MiR-21 specifically regulates iPSC differentiation into ECs 
MiR-21 has previously been shown to induce tumour angiogenesis through AKT and 
ERK pathway activation, increasing the expression of VEGF and HIF-1α (Liu, Li et 
al. 2011). However, the role of miR-21 in regulating endothelial differentiation 
remains to be elucidated. Therefore we decided to investigate its involvement in the 
VEGF-induced iPSC differentiation into ECs by altering the levels of miR-21 in 
iPSCs differentiated in the presence of VEGF for three days. 
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Firstly we overexpressed miR-21 by transfecting with the miR-21 precursor (Pre-
21). The level of miR-21 was increased by approximately 80 fold in the presence of 
the Pre-21, as compared to cells transfected with the precursor control (Pre-Ctrl) 
(Figure 33, A). We then inhibited miR-21 expression by transfecting iPSCs with an 
anti-miR LNA-21, which is a chemically modified, single stranded nucleic acid 
designed to specifically bind to and inhibit endogenous miR-21 molecules. Results 
showed an approximately 34-fold decrease in the mature miRNA expression after 
LNA-21 transfection, as compared to the cell transfected with the inhibitor negative 
control (LNA-Ctrl) (Figure 33, B). 
 
Figure 33 MiR-21 overexpression and inhibition in iPSCs differentiated with VEGF 
iPSCs were differentiated for three days on collagen IV and in differentiation medium containing  
50ng/ml VEGF. In order to alter the levels of miR-21, cells were transfected with precursor (Pre-21), 
negative control precursor (Pre-Ctrl), inhibitor of miR-21(LNA-21) and negative control of miRNA 
inhibitor (LNA-Ctrl). After 48h gene expression was assessed by Real time PCR analysis, results are 
shown for miR-21 expression after transfection with pre-21 compared to Pre-Ctrl (A) and with LNA-
21, compared to LNA-Ctrl (B). The statistical analysis used is Student’s unpaired T-test. Data are 
shown as mean ±SEM of 3 individual experiments. ***P < 0.001 vs. Pre-Ctrl and LNA-Ctrl. 
 
We then analyzed the EC marker expression in iPSCs differentiated with VEGF for 
three days and then transfected with miR-21 precursor and inhibitor.  
Transfection with Pre-21 led to an upregulation of approximately 5- and 2.5-fold in 
the expression of the EC markers VE-cadherin and Flk1, respectively (Figure 34, A 
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and C). Whereas, after transfecting the cells with LNA-21 we did not observe any 
significant change in the EC marker expression (Figure 34, B and D). 
 
 
Figure 34 Analysis of EC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis was performed 48h later. 
Results are shown for the EC markers VE-cadherin (VE-cad) (A and B) and Flk1 (C and D), after 
miR-21 overexpression and inhibition. The statistical analysis used is Student’s unpaired T-test (the 
mean ±SEM of 4 individual experiments is shown). *P < 0.05 and **P < 0.01 vs. Pre-Ctrl.  
 
In accordance with the Real time PCR results, protein expression analysis on iPSCs 
transfected with Pre-21 confirmed the increased expression of the EC markers VE-
cadherin and CD31, compared to Pre-Ctrl (Figure 35, A and C). Surprisingly, despite 
no detectable changes in gene expression, transfection with LNA-21 led to a 




Figure 35 Protein analysis of EC markers in iPSCs after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) or the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Protein expression was assessed after 48h by 
Western Blot analysis of VE-cadherin (VE-cad) (A and B) and CD31(C and D) after miR-21 
overexpression and inhibition. GAPDH was used as a loading control for cells transfected with Pre-
miR (E) and LNA (F).  
 
ECs, like SMCs which form the tunica media of all the blood vessels, and cardiac 
cells are derived from the embryonic mesoderm layer. Indeed, in order to exclude a 
non-specific effect of miR-21 on the differentiation of iPSCs towards the SMC or 
other mesoderm cell lineages, we investigated the expression of markers typical of 
these cell types after miR-21 overexpression and inhibition.  
Real time PCR was performed after transfecting VEGF-differentiated iPSCs with 
Pre-21 and showed some upregulation in the expression of the SMC markers 
calponin and smooth muscle actin (SMA), but no statistical significance was 
detected (Figure 36, A and C). There were no changes in the expression levels of the 





Figure 36 Analysis of SMC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis was performed after 48h. 
Results are shown for Calponin (A and B) and Smooth muscle actin (SMA, C and D). The data are 
representative of three independent experiments. The statistical analysis used is Student’s unpaired T-




Furthermore, we analyzed the expression of the cardiac markers GATA4 and 
MEF2C and could not detect any significant changes in their expression, even if a 




Figure 37 Analysis of SMC marker expression in iPSCs differentiated with VEGF, after miR-21 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis was performed after 48h. 
Results are shown for GATA4 (A and B) and MEF2C (C and D). The statistical analysis used is 
Student’s unpaired T-test. Data are shown as mean ±SEM of 3 individual experiments. No results 
were significant (*P < 0.05). 
 
After having excluded an effect of miR-21 on any other cell type of the mesodermal 
lineage, we proceeded to test its effect on the endoderm and ectoderm. 
After transfecting differentiated iPSCs with precursor or inhibitor of miR-21, no 
significant differences were observed in the expression levels of the pancreatic 
marker Nkx 6.1 (Figure 38, A and B) or the liver marker alpha-fetoprotein (AFP) 




Figure 38 Analysis of pancreatic and liver marker expression in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis performed after 48h; results 
are shown for Nkx 6.1 (A and B) and alpha-fetoprotein (AFP, C and D). The statistical analysis used 
is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 individual experiments. No 
results were significant (*P < 0.05). 
 
Similarly, results obtained from the analysis of the ectoderm markers, showed no 
significant changes in the expression of neuronal or epidermal markers. Results after 
miR-21 overexpression (Figure 39, A and C) and inhibition (Figure 39, B and D) are 





Figure 39 Analysis of neuronal and epidermal markers expression in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Real time PCR analysis was performed after 48h; 
results are reported for beta 3 tubulin (β3 tubul, A and B) and Krt 2-5 (C and D). The statistical 
analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM of 3 individual 
experiments. No results were significant (*P < 0.05). 
 
 
In conclusion, the expression levels of SMC, cardiac, endoderm and ectoderm 
markers were not affected by miR-21 overexpression and inhibition. We confirmed 
that miR-21 specifically regulates iPSC differentiation towards ECs and not towards 






3.2.5.3 MiR-21 regulates the functional differentiation of iPSCs into ECs in in 
vitro angiogenesis assay 
The next step to confirm the specific role of miR-21 in iPSC differentiation into ECs 
was to assess whether this miRNA is able to drive the functional differentiation of 
the cells, modulating the cell organization into tube-like structures.  
Therefore, we performed an in vitro angiogenesis assay on iPSCs differentiated with 
VEGF for four days and then transfected with Pre-21, Pre-Ctrl, LNA-21 or LNA-
Ctrl.  
Results showed that cells transfected with miR-21 were endowed with increased 
capacity for tube-like structure formation in Matrigel (Figure 40, B), as compared to 
the cells transfected with Pre-Ctrl (Figure 40, A). Results of the in vitro angiogenesis 
assay were then quantified measuring the total tube length; transfection with Pre-21 





Figure 40 In vitro angiogenesis assay in iPSCs transfected with miR-21 
iPSCs differentiated for four days on collagen IV in differentiation medium containing VEGF, were 
transfected with miR-21 precursor (Pre-21) or precursor negative control (Pre-Ctrl). After a further 
72h of differentiation, cells were seeded on Matrigel and incubated for 7-8h to test their angiogenesis 
potential. Representative images show the increased tube formation capacity in the cells transfected 
with Pre-21 (B), as compared to precursor negative control (A). Results were confirmed by total tube 
length quantification in the cells transfected with Pre-21 and Pre-Ctrl (C). The statistical analysis used 
is Student’s unpaired T-test. Data are shown as mean ±SEM of 3 individual experiments. *P < 0.05 
vs. Pre-Ctrl. Scale bar, 25 μm. 
 
On the other hand, inhibition of miR-21 in differentiating iPSCs seeded onto 
Matrigel in vitro decreased the capacity of the cells to form a tube network. Results 
showed that transfection with LNA-21 (Figure 41, B) impaired the ability of the cells 
to form tube-like structures, as compared to transfection with LNA-Ctrl (Figure 41, 
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A). Total tube length quantification showed that LNA-21 transfected iPSCs had total 
tube lengths decreased by approximately 50% (Figure 41, C).  
 
 
Figure 41 In vitro angiogenesis assay in iPSCs transfected with miR-21 inhibitor 
iPSCs differentiated for four days on collagen IV in differentiation medium containing VEGF, were 
transfected with miR-21 inhibitor (LNA-21) and inhibitor negative control (LNA-Ctrl). After a further 
72h of differentiation the cells were seeded on Matrigel and incubated for 7-8h to test their angiogenic 
potential. Representative images show tube formation capacity in the cells transfected with LNA-21 
(B), as compared to LNA-Ctrl (A). Results were confirmed by total tube length quantification (C). 
The statistical analysis used is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 




Indeed, we showed that miR21 is able to drive the functional differentiation of iPSCs 
as shown by their increased capacity for organisation into tube-like structures in an 
in vitro angiogenesis assay. Accordingly, in response to miR-21 inhibition we 
observed a reduction in tube formation, indicating a reduction in functional 
differentiation. 
 
3.2.5.4 MiR-21 regulates the functional differentiation of iPSCs into ECs in an 
in vivo angiogenesis assay  
The results obtained so far indicated that miR-21 is able to induce iPSCs to 
differentiate towards the endothelial lineage and to form tube-like structures in vitro. 
Next, we aimed at assessing the effect of miR-21 in an in vivo angiogenesis assay. 
iPSCs were differentiated in the presence of VEGF for 4 days and then transfected 
with Pre-21, Pre-ctrl, LNA-21 and LNA-ctrl and then mixed with Matrigel and 
injected subcutaneously into nude C57BL/6 mice. After the injections, the Matrigel 
rapidly formed a subcutaneous plug that was collected after 7 days for capillary 
quantification. After 7 days, plugs were removed and cryosections were prepared. 
We stained the sections in hematoxylin and eosin or we performed 
immunohistochemistry for CD31 and VE-cadherin to quantify capillary density. 
Immunohistochemical analysis of the Matrigel plugs showed a significant induction 
in the density of CD31+ capillaries in the plugs seeded with miR-21 transfected cells 
(Figure 42, B), as compared to the control cells (Figure 42, A). Results of the 
capillary density quantification showed a 2.7 fold induction in the number CD31-
positive capillaries per mm
2









Figure 42 miR-21 overexpression increases the number of CD31-positive capillaries in in vivo 
Matrigel plugs 
iPSCs differentiated for four days on collagen IV in differentiation medium containing VEGF, were 
transfected with miR-21 precursor (Pre-21) and precursor negative control (Pre-Ctrl). After further 
72h of differentiation the cells were mixed with Matrigel and subcutaneously injected into mice for 1 
week to test their angiogenic potential. Confocal microscopy images showed increased number of 
CD31
+
 capillaries in plugs containing the cells transfected with Pre-21 (B), as compared to Pre-Ctrl 
(A). Results were confirmed by capillary density quantification (C). The statistical analysis used is a 
Student’s unpaired T-test. Data are shown as mean ±SEM of 3 individual experiments. ***P < 0.001 
vs. Pre-Ctrl. Scale bar, 100 μm. 
 
Additionally, to confirm these results we quantified the number of VE-cadherin 
positive capillaries and found a similar trend, where the number of capillaries was 
induced by miR-21 overexpression (Figure 43, B), as compared to Pre-Ctrl (Figure 
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43, A). Quantification of VE-cadherin
+
 capillaries showed 2.3 folds of induction by 
miR-21(Figure 43, C). 
 
 
Figure 43 miR-21 overexpression induces the number of VE-cadherin-positive capillaries in 
matrigel plaques 
iPSCs differentiated for four days on collagen IV in differentiation medium containing VEGF, were 
transfected with miR-21 precursor (Pre-21) and precursor negative control (Pre-Ctrl). After a further 
72h of differentiation the cells were mixed with Matrigel and subcutaneously injected into the mice 
for 1 week to test the angiogenesis potential. Confocal microscopy imaging revealed a higher density 
of VE-cadherin (VE-cad)-positive capillaries in plugs seeded with Pre-21 transfected cells (B), as 
compared to Pre-Ctrl (A). Results were confirmed by capillary density quantification of the number of 
VE-cad
+
 capillaries per mm
2 (C). The statistical analysis used is Student’s unpaired T-test. Data are 




To confirm the results obtained with the cells transfected with Pre-21, we knocked 
down miR-21 expression by transfecting the cells with LNA-21 and used them in an 
in vivo Matrigel plug assay. Similarly to the results obtained in vitro, inhibition of 
miR-21 led to a decreased number of capillaries positive for the endothelial cell 
markers CD31 (Figure 44, B) and VE-cadherin (Figure 45, B), as compared to LNA-
Ctrl (Figure 44 A and 45 A, respectively). 
Quantification of capillary density indicated a significant reduction in the number of 






Figure 44 miR-21 inhibition decreases the number of CD31-positive capillaries in Matrigel 
plugs 
iPSCs differentiated for four days on collagen IV in differentiation medium containing VEGF, were 
transfected with miR-21 inhibitor (LNA-21) and inhibitor negative control (LNA-Ctrl). After a further 
72h of differentiation the cells were mixed with Matrigel and subcutaneously injected into the mice 
for 1 week to test their angiogenic potential. Confocal microscopy images of the Matrigel plugs show 
CD31-positive capillaries in the cells transfected with LNA-21 (B), as compared to LNA-Ctrl (A). 
Capillary density was calculated by quantification of the number of CD31-positive capillaries per unit 
of area
 (C). The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM 
of 3 individual experiments. ***P < 0.001 vs. LNA-Ctrl. Scale bar, 100 μm. 
 
 
Similar results were obtained when the Matrigel plugs were stained and quantified 
for VE-cadherin
+




Figure 45 miR-21 inhibition decreases the number of VE-cadherin-positive capillaries in 
Matrigel plugs 
iPSCs differentiated for four days on collagen IV and differentiation medium containing VEGF, were 
transfected with miR-21 inhibitor (LNA-21) and inhibitor negative control (LNA-Ctrl). After a further 
72h of differentiation the cells were mixed with Matrigel and subcutaneously injected into the mice 
for 1 week to test their angiogenic potential. Confocal microscopy showed a decreased number of VE-
cadherin (VE-cad)-positive capillaries in the cells transfected with LNA-21 (B), as compared to LNA-
Ctrl (A). Results were confirmed by capillary density quantification of the number of VE-cad-positive 
capillaries per mm
2 (C). The statistical analysis used is Student’s unpaired t-test. Data are presented as 




3.2.5.5 VEGF stimulation is required in miR-21-induced EC differentiation 
In the first part of this work we showed that VEGF is required for the differentiation 
of iPSCs into ECs. We also reported that iPSCs differentiated in the presence of 
VEGF display a specific miRNA profile and express more miR-21 than 
undifferentiated iPSCs. 
We showed that in iPSCs pre-differentiated with VEGF, miR-21 overexpression 
induces a functional differentiation of the cells into ECs.  In contrast, inhibition of 
miR-21 impairs iPSC differentiation into ECs and reduces capillary formation in 
vitro and in vivo.  
Next, we decided to examine the requirement for the VEGF stimulation in the 
process of miR-21-induced iPSC differentiation into ECs. 
In order to do so, we pre-differentiated iPSCs in DM without VEGF for 3 days and 
then we altered the expression levels of miR-21 in the cells. As described previously, 
cells were transfected with precursor (Pre-21), negative control precursor (Pre-Ctrl) 
or inhibitor of miR-21 (LNA-21) and negative control of miRNA inhibitor (LNA-
Ctrl) and then expression levels of mature miR-21 were assessed.  
The expression of miR-21 increased by approximately 60 fold after Pre-21 
transfection when compared to the negative control, indicating that transfection of 
Pre-21 increased mature miR-21 expression (Figure 46, A). We then overexpressed 
miR-21 inhibitor, and detected a 33-fold reduction in the mature miRNA expression 






Figure 46 miR-21 overexpression and inhibition in iPSCs differentiated in absence of VEGF 
iPSCs were seeded for three days on collagen IV and cultured in differentiation medium without 
VEGF. In order to alter the levels of miR-21, cells were transfected with precursor (Pre-21), negative 
control precursor (Pre-Ctrl), inhibitor of miR-21(LNA-21) and negative control of miRNA inhibitor 
(LNA-Ctrl), using lipofectamin RNAiMAX. After 48h gene expression was assessed by Real time 
PCR analysis. Results show miR-21 expression levels after transfection with Pre-21, compared to Pre-
Ctrl (A) and after transfection with LNA-21, compared to LNA-Ctrl (B). ). The statistical analysis 
used is Student’s unpaired t-test. Data are shown as mean ±SEM of 3 individual experiments. ***P < 
0.001 vs. Pre-Ctrl and LNA-Ctrl. 
 
Subsequently, we then analyzed the EC marker expression in iPSCs pre-
differentiated without VEGF, after miR-21 overexpression and inhibition. 
Transfection with Pre-21 did not alter the expression of VE-cadherin, as compared to 
cells transfected with Pre-Ctrl (Figure 47, A). Flk1 gene expression was increased by 
approximately two fold by Pre-21, but this result was not statistically significant 
(Figure 47, C).  
After transfecting the cells with LNA-21, we did not observe any significant 







Figure 47 Analysis of the EC marker expression in iPSCs differentiated in the absence of 
VEGF, after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium without VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Gene expression was analysed by Real time PCR in 
samples collected after 48h. Results are shown for VE-cadherin (VE-cad, A and B) and Flk1 (C and 
D) after miR-21 overexpression and inhibition. The statistical analysis used is Student’s unpaired T-
test. Data are shown as mean ±SEM of 3 individual experiments. No results were significant (*P < 
0.05). 
In conclusion, without adding VEGF to the iPSCs differentiation system, miR-21 
induction of the EC marker expression was abolished. These data indeed show that 







3.2.6 Conclusions  
In conclusion, in this second part of our study we characterized the miRNA signature 
typical of iPSC during their differentiation towards an EC lineage. 
We performed a miRNA array on iPSCs differentiated for 3 days in presence of 
VEGF and undifferentiated and we confirmed a differential expression of five 
miRNAs in the two groups of cells. 
We also performed a miRNA array on iPSCs differentiated for 3 days on collagen 
IV, in static condition and compared them to iPSCs cultured in the same way, but 
subjected to 48h of shear stress. However, due to the lack of reproducibility of the 
experiments performed with shear stress application, we could not confirm 
differential expression of any miRNAs in the two groups of cells. 
Amongst the five validated miRNAs obtained from the differentiated vs. 
undifferentiated array, we further investigated the role of miR-20b and of miR-21 in 
driving EC differentiation. Results showed no indication of EC differentiation in 
cells transfected with miR-20b, but significant upregulation of EC markers by miR-
21. 
Further studies, allowed us to establish that miR-21 was able to specifically induce 
EC marker expression exclusively in cells pre-differentiated in the presence of 
VEGF. 
Furthermore, in vitro and in vivo tube formation assays revealed that miR-21 also 
induced functional differentiation of iPSCs, promoting the organization of the cells 








3.3 IDENTIFICATION OF THE MOLECULAR 
TARGETS OF MiRNA-21: TGF-β2 PATHWAY IS 
A DOWNSTREAM TARGET OF MiR-21 AND 
DRIVES iPSC DIFFERENTIATION INTO ECs 
In the present study we so far optimized a differentiation protocol for iPSCs 
differentiation into ECs involving the use of VEGF. Based on this protocol we 
characterized a miRNA signature during the iPSC differentiation process and in 
particular we found that miR-21 plays a role in specifically inducing iPSC 
differentiation towards the EC lineage.  
At this point we aimed to elucidate the molecular mechanisms which occur during 
the miR-21 induced differentiation of iPSCs. Indeed, we started by identifying the 
molecular targets of miR-21 in order to elucidate the signalling pathways involved in 
the differentiation process. 
 
3.3.1 Screening for the potential target genes of miR-21 
The next important step in this work is the identification of the molecular targets of 
miR-21, using bioinformatic tools and in silico target screenings. 
As mentioned before, miRNAs induce mRNA degradation and post-transcriptional 
gene silencing by binding to conserved regions in the 3’ untranslated region (UTR) 
of target mRNAs (Pillai, Bhattacharyya et al. 2007). 
In order to identify putative target genes regulated by miR-21 and involved in the 
control of iPSC differentiation, we evaluated targets predicted by several of the 
available algorithms. In particular, we used a miRNA target database (miRGEN) 
based on the intersection of four prediction algorithms: DIANA-micro-T, miRanda, 
Pic Tar and TargetScanS. From the lists of in silico predicted targets, we focused on 
genes that may be involved in the angiogenic processes. Among those we analyzed 
genes regulating endothelial cell function and vessel growth, such as transforming 
growth factor receptor II (TGF-βRII), the regulator of ERK activation Sprouty 1 
(SPRY1), the RhoGTPase RhoB and Sox7. From the same list we also searched for 
genes encoding for regulators of cell migration such as vinculin (Vcl). 
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Together with the predicted targets, we also considered other pathways that were 
implicated with miR-21 in several published papers. For instance, miR-21 is known 
to be involved in the hypoxia-inducible factor 1-alpha (HIF1α) pathway, which 
induces tumor angiogenesis through stimulation of VEGF gene expression (Kong, 
Kong et al. 2012). Furthermore, we considered the Wnt signalling pathway, which 
has previously been found to be involved in EC proliferation and differentiation 
during development and healing and also in physiological and pathological 
angiogenesis (Logan and Nusse 2004, Dejana 2010). Furthermore the Wnt/β-catenin 
signalling pathway has been reported to play a role in cardiomyocyte differentiation 
from human pluripotent stem cells (Lian, Zhang et al. 2013). Moreover, wnt5a has 
been shown to drive the EC differentiation of ESCs, through both Wnt/β-catenin and 
Protein Kinase Cα and is implicated in vascular development in vivo (Yang, Yoon et 
al. 2009). 
Analysis of miR-21 regulation of the chosen genes from miRgen or part of the Wnt 
and the HIF1α/VEGF signalling pathways is reported in Figure 48 and 49. 
Interestingly, we found that transfection with miR-21 inhibitor was able to reduce 
VEGF gene expression. These results highlighted the possibility of a mutual 
regulation between miR-21 and VEGF during iPSC differentiation, by showing that 
not only VEGF regulates miR-21 expression, but also miR-21 is important in the 
regulation of VEGF, since cells lacking miR-21expressed reduced amount of VEGF 













































































































































Figure 48 Analysis of the expression of potential targets of miR-21 after overexpression 
iPSCs differentiated for 3 days on collagen IV and in DM containing VEGF were transfected with 
miR-21 precursor (Pre-21) or the negative control of the miR-21 precursor. Real time PCR analysis 
was performed after 48h. Results show the expression levels of some of the genes predicted by 
MiRgen database and some genes from the Wnt signalling pathway, after miR-21 overexpression. 
The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM of 3 
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Figure 49 Analysis of the expression of potential targets of miR-21, after its inhibition 
iPSCs differentiated for 3 days on collagen IV and in DM containing VEGF were transfected with 
miR-21 inhibitor (LNA-21) and the negative control of the miR-21 inhibitor. Real time PCR analysis 
was performed after 48h. Results show the expression levels of some of the genes predicted by the 
MiRgen database and some genes from the Wnt signalling pathway, after miR-21 inhibition. The 
statistical analysis used is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 
individual experiments. No results were significant (*P < 0.05), except for VEGFA expression (***P 
< 0.001 vs LNA-Ctrl).  
 
3.3.2 TGF-β2 is a downstream target of miR-21 
Despite the lack of variation in the other genes identified through miRGEN, we 
decided to expand our investigation starting from other two predicted targets, TGF-
βRII and transforming growth factor-beta-induced (TGF-βI), which are known 
components of the TGF-β signalling pathway. 
TGF-β is a multifunctional cytokine which regulates proliferation, migration, 
differentiation and survival of many different cell types (Munger, Harpel et al. 
1997); in mammals there are three known isoforms, TGF-β1, TGF-β2 and TGF-β3, 
with distinct and shared functions. Interestingly, knockout studies for the different 
components of the TGF-β signalling pathway have shown the pivotal role of TGF-β 
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signalling in angiogenesis. Deletions of many members of the TGF-β family, such as 
TGF-β1, TGF-βRII, TGF-βRI or ALK5, SMAD1, 4 and 5 cause vascular 
remodelling defects and the absence of mural cell formation, thus leading to 
embryonic lethality (Pardali and Ten Dijke 2009). Moreover, mutations in ALK1 
and the accessory TGF-β receptor endoglin led to hereditary hemorrhagic 
telangiectasia, a severe vascular disorder (Bertolino, Deckers et al. 2005, Lebrin, 
Deckers et al. 2005).   
Indeed, we decided to investigate the role of the TGF-β signalling pathway in miR-
21-dependent iPSCs differentiation. We firstly analyzed the effect of miR-21 on the 
expression of TGF-βRII and TGF-βI. However, Q-PCR results showed that miR-21 
overexpression (Figure 50, A and C) and inhibition (Figure 50, B and D) did not 







Figure 50 Analysis of TGF-βRII and TGF-βI expression after miR-21 overexpression and 
inhibition 
iPSCs differentiated for 3 days on collagen IV and in DM containing VEGF were transfected with 
miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-21 precursor 
(Pre-Ctrl) and inhibitor (LNA-Ctrl) and samples for Real time PCR were collected after 48h. Results 
show the expression levels of transforming growth factor-beta receptor II (TGF-βRII, A and B) and 
transforming growth factor-beta-induced (TGF-βI, C and D) after miR-21 overexpression and 
inhibition. The statistical analysis used is Student’s unpaired T-test. Data are presented as mean 
±SEM of 3 individual experiments. No results were significant (*P < 0.05). 
Additionally, we analysed the expression of other components of this pathway, such 
as TGF-βRI, TGF-β1 and TGF-β2. The analysis of the results showed that the 
expression of TGF-β1 and TGF-βRI was not affected by miR-21 overexpression 





Figure 51 Analysis of the TGF-β1 and TGF-βRI expression in iPSCs differentiated with VEGF 
after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium with VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl) and samples for Real time PCR were collected after 
48h. Results show the expression levels of transforming growth factor-beta1 (TGF-β1, A and B) and 
transforming growth factor-beta receptor I (TGF-βRI, C and D) after miR-21 overexpression and 
inhibition. The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM of 
3 individual experiments. No results were significant (*P < 0.05). 
 
Finally, analysis of TGF-β2 gene expression revealed approximately 2 fold induction 
upon miR-21 overexpression (Figure 52, A). On the other hand, after miR-21 
inhibition the gene expression of TGF-β2 was slightly, but not significantly 





Figure 52 Analysis of TGF-β2 expression in iPSCs pre-differentiated with VEGF, after miR-21 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in DM containing VEGF were transfected with 
miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-21 precursor 
(Pre-Ctrl) and inhibitor (LNA-Ctrl) and samples for Real time PCR were collected after 48h. Results 
show TGF-β2 expression levels after transfection with Pre-21, compared to Pre-Ctrl (A) and after 
transfection with LNA-21, compared to LNA-Ctrl (B). The statistical analysis used is Student’s 
unpaired T-test. Data are presented as mean ±SEM of 3 individual experiments. *P < 0.05 vs. Pre-
Ctrl.  
 
We performed ELISAs in order to confirm that the increase in TGF-β2 mRNA after 
miR-21 transfection corresponded to an increase in the secreted protein. An ELISA 
specific for TGF-β2 showed a 2-fold increase in the protein in the supernatants of 
cells transfected with Pre-21 (Figure 53, A). Interestingly, we also observed a 






Figure 53 Analysis of TFG-β2 secretion after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl) and supernatants were collected for ELISA analysis 
after 48h. Results show the secretion level of TGF-β2 after transfection with Pre-21 and Pre-Ctrl (A) 
and after transfection with LNA-21, as compared to LNA-Ctrl (B). The statistical analysis used is 
Student’s unpaired T-test. Data are shown as mean ±SEM of 3 individual experiments. *P < 0.05 vs. 
Pre-Ctrl and LNA-Ctrl.  
 
From the data showed above we could conclude that miR-21 induced the expression 
and the secretion of TGF-β2, which indeed can be considered a downstream target of 
the miRNA.   
 
3.3.3 TGF-β2 pathway is required in the miR-21-inducing iPSC 
differentiation into ECs 
To further determine whether TGF-β2 is an essential downstream molecule 
mediating miR-21-inducing EC differentiation, iPSCs were differentiated with 
VEGF for 3 days and then transfected with pre-21 and its control. After 5h from 
transfection, the cells were treated with 1µg/ml TGFβ-2 neutralizing antibody or IgG 
as a control. 48h after transfection the cells were harvested and the protein 
expression was analyzed.  
Real time PCR analysis showed that treating the cells with 1µg/ml TGFβ-2 
neutralizing antibody inhibited miR-21-induced VE-cad upregulation, as compared 




Figure 54 TGF-β2 is required in miR-21 induced iPSC differentiation into ECs 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21) and precursor control (Pre-Ctrl). After 5h from 
transfection, 1µg/ml TGF-β2 neutralizing antibody (TGF-β2 Ab) or IgG, as a control were added to 
the culture medium. Q-PCR performed 48h after transfection shows the expression levels of VE-
cadherin (VE-cad). The statistical analysis used is 1way ANOVA for multiple comparisons. Data are 
presented as mean ±SEM of 3 individual experiments. ***P < 0.001 vs. Pre-Ctrl IgG and vs. Pre-21 
IgG. 
 
Western Blot analysis for CD31 expression level confirmed that TGF-β2 is required 
in miR-21 induced iPSC differentiation into ECs. In particular, miR-21-induced 
CD31 upregulation observed in the cells treated with IgG as a control was abolished 






Figure 55 Analysis of CD-31 protein expression in iPSCs transfected with miR-21 precursor and 
treated with TGF-β2 antibody 
iPSCs were transfected with miR-21 precursor (Pre-21) and precursor control (Pre-Ctrl) after 3 days 
of differentiation on collagen IV and in differentiation medium containing VEGF. After 5h from 
transfection, 1µg/ml TGF-β2 neutralizing antibody (TGF-β2 Ab) or IgG, as a control, was added to 
the culture medium. Protein expression was assessed after 48h by Western Blot analysis of CD31 (A). 
GAPDH was used as a loading control (B).  
These data suggest that the induction of TGFβ-2 is necessary for miR-21 to drive 
iPSC differentiation into ECs.  
 
3.3.4 TGF-β2 pathway regulates iPSC differentiation into ECs 
At this point we decided to investigate the involvement of TGF-β2 miR-21-
dependent iPSC differentiation into ECs. In order to do so, we first analyzed its 
expression during VEGF-induced EC differentiation.   
 
3.3.4.1 TGF-β2 expression is increased during VEGF-induced iPSC 
differentiation 
Data collected so far demonstrated that TGF-β2 plays a role in the differentiation of 
iPSCs towards the endothelial lineage. We therefore analyzed its expression during 
the first 7 days of differentiation with VEGF. As results showed, TGF-β2 expression 
was increased 50 and 200-fold, after 5 and 7 days respectively (Figure 56, A). In 
contrast, TGF-β1 was increased by approximately 5 and 10 fold after 5 and 7 days, 




Figure 56 Analysis of TGF-β2 and TGF-β1 gene expression during VEGF induced iPSC 
differentiation 
iPSCs were seeded on collagen IV and cultured in differentiation medium with 50ng/ml VEGF. Gene 
expression analysis was performed by real-time PCR after 3, 5, and 7 days of differentiation. Results 
are shown for transforming growth factor-β2 (TGF-β2, A) and transforming growth factor-β1 (TGF-
β1, B). The statistical analysis used is 1way ANOVA for multiple comparisons. Data are presented as 
mean ±SEM of 3 individual experiments. ***P < 0.001 vs. d0 (d0 represents iPSCs seeded on gelatin 
and cultured in undifferentiated conditions). 
 
Next, we analyzed the expression of the receptors of TGF-β signalling during the 
VEGF-induced iPSC differentiation. Consistent with the expression of the ligands, 
we found a strong upregulation of TGF-βRII and III of approximately 20 and 200 
fold after 7 days (Figure 57, B and C). Although a trend was visible, the TGF-βRI 





Figure 57 Analysis of TGF-βRIII, II and I expression during VEGF induced iPSC 
differentiation 
iPSCs were seeded on collagen IV and cultured in differentiation medium with 50ng/ml VEGF. Gene 
expression analysis was performed by real-time PCR after 3, 5, and 7 days of differentiation. Results 
are shown for transforming growth factor-β receptor III (TGF-βRIII, A), transforming growth factor-β 
receptor II (TGF-βRII, B) and transforming growth factor-β receptor I (TGF-βRI, C). The statistical 
analysis used is 1way ANOVA for multiple comparisons. Data are shown as mean ±SEM of 3 
individual experiments. *P < 0.05 and **P < 0.01 vs. d0 (d0 represents iPSCs seeded on gelatin and 
cultured in undifferentiated conditions). 
 
We showed that the expression of TGF-β2 and its receptors TGF-βRIII and II is 
increased during the VEGF-induced iPSC differentiation after 5 and 7 days. On the 
other hand, the expression of TGF-β1 and its receptor TGF-βRI was not significantly 
induced during the differentiation of iPSCs in presence of VEGF.  
These data indicate that TGF-β2 has a specific role during the iPSC differentiation 
process induced by VEGF. 
 
3.3.4.2 TGF-β2 treatment induces iPSC differentiation specifically 
towards EC lineage 
At this point, in order to clarify the role of TGF-β2 in iPSC differentiation, we 
treated iPSCs for up to 7 days with TGF-β2 and analyzed the expression of the 
endothelial cell markers.  
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Accordingly, as with previous results, our findings showed an upregulation of the 
endothelial markers VE-cadherin (VE-cad, Figure 58, A) and Flk1 (Figure 58, B) 
after TGF-β2 treatment. 
 
Figure 58 Analysis of EC marker expression in iPSCs treated with TGF-β2 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) containing 3ng/ml 
TGF-β2. Gene expression analysis performed by real-time PCR after 7 days. Results show the 
expression levels of VE-cadherin (VE-cad) and Flk1 (B). The statistical analysis used is Student’s 
unpaired T-test. Data are presented as mean ±SEM of 3 individual experiments. *P < 0.05 and **P < 
0.01 vs. iPSCs differentiated for 7 days on collagen IV and in DM (DM). 
 
Protein analysis confirmed the upregulation of the EC markers observed at a gene 
expression level. Treatment of iPSCs with TGF-β2 for 7 days induced the expression 
of VE-cadherin (VE-cad, Figure 59, A) and CD31 (Figure 59, B), compared to 







Figure 59 Protein expression analysis of EC markers in iPSCs treated with TGF-β2 
iPSCs were seeded on collagen IV and cultured in differentiation medium containing 3ng/ml TGF-β2 
(DM TGF-β2) or normal differentiation medium (DM). Protein expression was assessed by Western 
blot analysis after 7 days. Results are shown for VE-cadherin (Ve-cad, A) and CD31 (B). GAPDH 
was used as loading control (C). 
 
In order to exclude any unspecific effect of TGF-β2 on iPSC differentiation towards 
other mesodermal lineages, we analyzed the expression of SMC markers after 7 days 
of TGF-β2 treatment. The expression of smooth muscle myosin heavy chain (SM-
MHC), smooth muscle 22 (SM22) and calponin was not affected by treatment with 








Figure 60 Analysis of SMC markers expression in iPSCs treated withTGF-β2 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) containing 3ng/ml 
TGF-β2. Gene expression analysis performed by real-time PCR after 7 days. Results are shown for 
smooth muscle myosin heavy chain (A, SM-MHC), smooth muscle 22 (B, SM22) and calponin (C). 
The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM of 3 
individual experiments. No results were significant (*P < 0.05).  
We could indeed confirm that TGF-β2 is able to drive iPSCs differentiation 
specifically towards the EC lineage. 
 
3.3.4.3 TGF-β2 promotes the functional differentiation of iPSCs  
To test the functionality of iPSCs after TGF-β2 treatment we performed in vitro 
angiogenesis assays. Cells treated for 7 days with TGF-β2 (Figure 61, B) showed 
increased tube formation ability, as compared to the untreated cells (Figure 61, A). 
The results of the assay were confirmed by total tube length quantification. TGF-β2 





Figure 61 In vitro angiogenesis assay in iPSCs differentiated with TGF-β2 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) containing 3ng/ml 
TGF-β2. After 7 days cells were seeded on Matrigel and incubated for 7-8h to test the angiogenesis 
potential. Representative images show tube formation capacity in the cells treated with TGF-β2 (B) 
and untreated cell in DM (A). Results were confirmed by total tube length quantification (C). The 
statistical analysis used is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 
individual experiments. ***P < 0.001 vs. DM (DM represents iPSCs seeded on collagen IV and 
cultured in differentiation medium). Scale bar, 25 μm. 
 
In vitro angiogenesis assays showed that TGF-β2 treatment promotes the functional 





3.3.4.4 Inhibition of SMAD3 abolishes TGF-β2 stimulation of VE-cadherin 
expression  
As already mentioned in the introduction section (1.3.4), the TGF-β family exerts its 
action on the cells via specific type I and type II serine/threonine kinase receptors 
and intracellular SMAD transcription factors. SMAD3, together with SMAD1, 
SMAD5, and SMAD8 and SMAD2 are part of the R-SMAD, and like SMAD2, are 
activated by the TGF-β-specific type I receptors (Massagué, Seoane et al. 2005). In 
ECs TGF-β has been shown to bind to TGF-βRI, ALK1, which induces SMAD1/5 
phosphorylation to potentiate angiogenic reactions; on the other hand, binding of 
TGF-β to ALK5, which is ubiquitously expressed in the majority of the cells, 
induces phosphorylation of SMAD2/3, thereby inhibiting proliferation, tube 
formation, and migration of ECs (Goumans, Valdimarsdottir et al. 2003). However, 
so far there are no studies reporting the role of SMAD3 in EC differentiation. 
Interestingly, in our system the inhibition of SMAD3 strongly reduced VE-cadherin 
expression, indicating the importance of the TGFβ-2/ SMAD3 pathway in the 
differentiation process of iPSCs.  
iPSCs were differentiated for 7 days on collagen IV and in DM with or without 
TGF-β2. From day 1 the cells were treated with 5µM SMAD3 inhibitor (SIS3) or 
DMSO as a control. Q-PCR results showed approximately two fold upregulation of 
VE-cadherin induced by TGF-β2 treatment. SMAD3 inhibition not only decreased 
the baseline expression level of VE-cadherin, but it also abolished the TGF-β2 





Figure 62 Inhibition of SMAD3 strongly reduces the baseline expression of VE-cadherin and 
abolished its induction by TGF-β2 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) containing 3ng/ml 
TGF-β2 or not. From day 1 the cells were treated with 5μM Smad3 inhibitor or DMSO as a control. 
Gene expression analysis was assessed by real-time PCR after 7 days. Results show the expression 
levels of VE-cadherin (VE-cad) in the presence or absence of TGF-β2 treatment and Smad3 
inhibition. The statistical analysis used is 1way ANOVA for multiple comparisons. Data are presented 
as mean ±SEM of 3 individual experiments. *P < 0.05 vs. iPSCs differentiated for 7 days on collagen 
IV and in DM and ***P < 0.001 vs. iPSCs differentiated for 7 days on collagen IV and in DM 
containing 3ng/ml TGF-β2. 
 
These data demonstrated that the effect of TGF-β2 on iPSC differentiation is 
mediated by Smad3 and highlighted the importance of the TGF-β2 pathway in the 
differentiation of iPSC into ECs. 
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3.3.4.5 TGF-β2 induces EC differentiation of iPSCs through the secretion of 
VEGF 
In order to elucidate how TGF-β2 induces iPSC differentiation into ECs, we 
hypothesized an indirect mechanism of VEGF secretion.  
We performed ELISAs in order to analyze the secretion of VEGF after 7 days of 
treatment with TGF-β2. At this point the cells were serum-deprived overnight, and 
then the supernatants were concentrated and loaded into an ELISA microplate to 
analyze the secretion level of VEGF. Results showed a significant induction of 1.6 




Figure 63 Analysis of VEGF secretion in iPSCs treated with TGF-β2 for 7 days 
iPSCs were seeded on collagen IV and cultured in differentiation medium (DM) containing 3ng/ml 
TGF-β2. After 7 days, the medium was removed and refreshed with serum free alpha MEM 
overnight. Cell supernatants were then harvested and 7.7 fold-concentrated using centrifugal filter 
units. Samples of concentrated supernatants were used to perform ELISAs. Results show relative 
VEGF secretion after TGF-β2 treatment, as compared to untreated cells in DM. The statistical 
analysis used is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 individual 




These data indicate that TGF-β2 promotes a specific and functional differentiation of 
iPSCs into ECs through induction of VEGF secretion. These results are in 
accordance with our previous data showing that miR-21 inhibition decreased VEGF 
gene expression, thus supporting the hypothesis of a link between miR-21, TGF-β2 
and VEGF pathways. 
To further confirm that VEGF secretion is required for TGF-β2 induced iPSC 
differentiation into ECs, we treated iPSCs for 7 days with TGF-β2 in the presence of 
0.1μg/ml VEGF neutralizing antibody or IgG as a control and analyzed the 
expression of the EC markers. 
Results of Western Blots showed that treatment with VEGF blocking antibody 
reduced the TGF-β2-dependent increase of VE-cadherin, as compared to control 
cells (Figure 64). 
 
 
Figure 64 Protein expression analysis of VE-cadherin in iPSCs treated with TGF-β2 and VEGF 
neutralizing antibody 
iPSCs were seeded on collagen IV and cultured in differentiation medium containing 3ng/ml TGF-β2 
or not for 7 days. From day one either 0.1µg/ml VEGF neutralizing antibody or IgG was added to the 
cells as a control. Protein expression was assessed by Western blot analysis after 7 days. Results are 




These results show that VEGF secretion is necessary for the TGF-β2 induced iPSC 




3.3.5 Conclusions  
In this section of the work we presented a screening of the in silico predicted and 
other potential targets of miR-21.  
MiR-21 has been found to induce the expression and the secretion of TGF-β2. TGF-
β2 has been identified as a downstream, indirect target of miR-21. 
Indeed, after neutralizing TGF-β2 in our differentiation system, miR-21 induction of 
EC marker expression was abolished. This data indicates that the TGF-β2 pathway is 
required for miR-21 inducing iPSC differentiation into ECs.  
The expression of TGF-β2 and its receptors TGF-βRIII and II has been shown to be 
strongly increased during VEGF induced iPSC differentiation into ECs, in particular 
after 5 and 7 days. These results demonstrate that TGF-β2 plays a role in the iPSC 
differentiation process. 
Furthermore, TGF-β2 treatment of iPSCs for 7 days induced the expression of EC 
markers at a gene and protein expression level, whereas it did not affect SMC marker 
expression. This data indicates that TGF-β2 regulation of iPSC differentiation acts 
specifically towards the EC lineage. In addition, treating iPSCs with TGF-β2 for 7 
days promoted the organization of the cells into tubular structures on Matrigel in 
vitro. 
To further confirm the importance of the TGF-β2 pathway in the EC differentiation 
of iPSCs, we inhibited SMAD3, a downstream effector of TGF-β2 and we analyzed 
the EC marker expression. Inhibition of SMAD3 not only repressed the baseline 
level of VE-cadherin, but it also abolished the induction of this marker observed 
after TGF-β2 treatment in the control cells. 
Finally, ELISAs performed on iPSCs treated for 7 days with TGF-β2 showed an 
induction of VEGF secretion from the cells. Furthermore, neutralization of VEGF 
secretion from the differentiation system repressed the TGF-β2-dependent increase 
in EC marker expression. These data might indicate that TGF-β2 indirectly regulates 




3.4 IDENTIFICATION OF THE MOLECULAR 
TARGETS OF miRNA-21: MiR-21 TARGETS THE 
PTEN/AKT PATHWAY, WHICH REGULATES 
iPSC DIFFERENTIATION INTO ECs 
 
3.4.1 MiR-21 targets the PTEN/AKT pathway  
 
3.4.1.1 PTEN is a direct target of miR-21 
After identifying TGF-β2 as a necessary downstream functional target of miR-21 
regulated iPSC differentiation into ECs, we aimed to identify the direct target of 
miR-21. 
One of the in silico predicted targets for miR-21 is PTEN. Recent studies indicated 
that miR-21 inhibited the tumor suppressor PTEN by binding to its 3’ UTR (Meng, 
Henson et al. 2007). 
MiR-21 has recently been shown to induce cell proliferation, migration and invasion 
by modulating tumor suppressor gene PTEN in human hepatocellular cancer (Meng 
and Henson, Gastroenterology 2007). Furthermore, inhibition of PTEN by miR-21 
has been shown to play a role in inducing tumor angiogenesis through AKT and 
ERK activation and HIF-1α expression (Liu L Z et al). However, the role of PTEN in 
miR-21 inducing endothelial cell differentiation remains to be elucidated.  
In iPSCs pre-differentiated in the presence of VEGF, overexpression of miR-21 
decreased the protein level of PTEN, as shown by Western Blot analysis (Figure 65, 
A). By contrast, inhibition of miR-21 expression increased PTEN protein level 






Figure 65 Protein expression analysis of PTEN in iPSCs differentiated with VEGF after miR-21 
overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Protein expression level of PTEN (A and B) was 
assessed after 48h by Western Blot analysis. GAPDH was used as a loading control (C and D). 
 
In order to confirm PTEN as a direct target of miR-21, we used a luciferase reporter 
vector encoding the complete 3’UTR of PTEN (WT PTEN 3’UTR) and a control 
vector containing mismatches in the predicted miR-21 binding site (Mut PTEN 
3’UTR). Co-transfection of the WT PTEN 3’UTR plasmid and LNA-21 in iPSCs 
differentiating with VEGF resulted in an approximately 1.4 fold increase in 
luciferase activity (Figure 66, A). This data suggests that PTEN mRNA is a direct 
target of miR-21. Importantly, mutations in the sequence targeted by miR-21 in 
PTEN 3’UTR abolished the observed up-regulation of luciferase activity by miR-21 
(Figure 66, B). This result confirmed PTEN as a direct target of miR-21 and 





Figure 66 Luciferase reporter assay confirms PTEN as a direct target for miR-21 
The wild type or mutated reporter plasmid pGL3 for PTEN 3’UTR (pGL3-PTEN-wt or pGL3-PTEN-
mut) was co-transfected with miR-21 inhibitor (LNA-21) and its control (LNA-Ctrl) in iPSCs 
differentiated for 3 days on collagen IV, in DM containing VEGF. 48h after transfection the luciferase 
activity was quantified. Results of relative luciferase activity are shown for pGL3-PTEN-wt (A) and 
pGL3-PTEN-mut (B). Renilla luciferase activity was used as a normalization control for transfection 
efficiency. The statistical analysis used is Student’s unpaired T-test. Data are shown as mean ±SEM 
of 3 individual experiments. *P < 0.05 vs. LNA-Ctrl. 
 
3.4.1.2 Phosphorylation of AKT is induced by miR-21  
PTEN is the antagonist of PI3K, which removes the 39 phosphate of 
Phosphatidylinositol 3-phosphate (PIP3), resulting in inhibition of the AKT 
signalling pathway (Jiang and Liu 2008). The PI3K/AKT signalling pathway plays a 
crucial role in many intracellular cascade events including tumor angiogenesis and 
tumor growth (Xia, Meng et al. 2006). Importantly, as already mentioned, the 
PI3K/AKT pathway has been shown to drive shear- and VEGF-induced stem cell 
differentiation into ECs (Zeng, Xiao et al. 2006). 
AKT (also known as protein kinase B), together with extracellular-signal regulated 
kinase (ERK), is one of the major signalling pathways regulating cell proliferation, 
survival and migration (Zhong, Chiles et al. 2000). 
Overexpression of miR-21 increased the phosphorylation of AKT at the Serine 473 
site (P-AKT), as compared to the negative control of precursor miRNA (Figure 67, 
A). On the other hand, inhibition of miR-21 reduced AKT phosphorylation, as 
compared to the negative control of an miRNA inhibitor (Figure 67, B). The total 
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level of AKT (AKT tot) was not significantly altered by miR-21 overexpression 
(Figure 67, C) or inhibition (Figure 67, D).  
 
 
Figure 67 Protein expression analysis of P-AKT and total AKT in iPSCs differentiated with 
VEGF, after miR-21 overexpression and inhibition 
iPSCs differentiated for 3 days on collagen IV and in differentiation medium containing VEGF were 
transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21) and the negative controls of the miR-
21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl). Protein expression level was assessed after 48h by 
Western Blot analysis of phosphorylated AKT (P-AKT, A and B) and total AKT (AKT tot, C and D). 
GAPDH was used as a loading control for Pre-miR (E) and LNA (F). 
 
Taken together, these data show that miR-21 inhibited PTEN expression, which in 






3.4.2 The PTEN/AKT pathway regulates iPSC differentiation into 
ECs 
 
3.4.2.1 PTEN inhibition leads to AKT activation in the VEGF-induced iPSC 
differentiation 
We then aimed to assess whether PTEN inhibition is required for the activation of 
AKT during the VEGF-induced iPSC differentiation process. 
PTEN shares the same active centre, the CX5R motif, with protein tyrosine 
phosphatases (PTPases) (Li, Ping et al. 2012); therefore, we inhibited PTEN using 
the chemical inhibitor bisperoxovanadium (bpV), a well-established PTPase 
inhibitor. BpV has been shown to target the phosphatidylinositol 3-phosphatase 
active site of PTEN (Schmid, Byrne et al. 2004); testing several different compounds 
in vitro, Scmid et al. showed that bpVs with polar N,O ligands had a strong 
preference towards the active site of PTEN, while bpVs with the neutral N,N ligands 
seemed to be more prone to target both PTPases and PTEN, although with distinct 
affinities. They concluded that all bpVs inhibit PTEN with 10- to 100-fold lower 
concentrations than PTPases (Bauters, Kumarswamy et al.). Although PTEN  shows 
dual phosphatase activity, dephosphorylating both protein and lipid substrates, it has 
a higher specificity towards 3-phosphorylated phosphoinositides (PI) such as 
PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3. In the above mentioned study of 
Schmid et al., after treatment with bpVs, the loss of PTEN activity has been 
monitored with an increase of PtdIns (3,4,5)P3 levels and therefore with a dose-
dependent increase of Ser473 phosphorylation of AKT, a well characterised 
downstream target of PTEN-dependent signalling (Bauters, Kumarswamy et al.). 
After 5 days of differentiation, iPSCs were starved for 4h and then treated with 5µM 
PTEN inhibitor for 30min, 2h and 24h and then harvested. Phosphorylation of AKT 
at the Ser-473 was increased after 30min and 24h of PTEN inhibition, as compared 
to the cells treated with DMSO as a control (Ctrl) (Figure 68, A). The protein level 




Figure 68 Protein expression analysis of P-AKT, total AKT and PTEN in iPSCs differentiated 
with VEGF, after PTEN chemical inhibition 
iPSCs were seeded on Collagen IV, in DM containing VEGF 50ng/ml up to day 5 when the medium 
was removed and refreshed with serum free alpha MEM for 4h. 5µM PTEN inhibitor was then added 
for 24h, 2h and 30’(minutes), after which time the cells were harvested. Cells were treated with 
DMSO for 2h as a control (Ctrl). Protein expression of phospho-Ser-473 AKT (P-AKT, A) and total 
AKT (AKT tot, B) was analyzed by Western Blot. GAPDH was used as a loading control (C). 
 
These data indicate that during the VEGF-induced iPSC differentiation process, 
inhibition of PTEN increases the AKT phosphorylation and its consequent 
activation.  
 
3.4.2.2 PTEN downregulation increases the EC marker expression in 
differentiating iPSCs 
After demonstrating that PTEN inhibition is required for AKT activation during the 
VEGF-induced iPSC differentiation, we aimed to clarify whether the PTEN/AKT 
pathway is essential for the EC differentiation of iPSCs. 
 
Since we found that prolonged exposure of iPSCs to bpV strongly diminished cell 
survival and in order to establish a stable knockdown of PTEN, we used specific 
shRNAs to shutdown its expression. We then assessed the effect of the knockdown 




iPSCs were differentiated for 3 days on collagen IV and in DM supplemented with 
50ng/ml VEGF and then infected with lentiviruses expressing shRNA specific for 
PTEN (shPTEN) or non targeting shRNAs (shNT), as a control. 48h later, the cells 
were harvested to analyze the gene expression level of PTEN and of the EC markers.  
 
Q-PCR results showed a significant and efficient repression of PTEN gene 




Figure 69 PTEN knockdown using lentiviral-mediated shRNA expression 
After 3 days of differentiation on collagen IV and in DM containing 50ng/ml VEGF, iPSCs were 
infected with shRNA specific for PTEN (shPTEN) or non targeting shRNAs (shNT), as a control. The 
gene expression level of PTEN was assessed 48h later by real time-PCR. The statistical analysis used 
is Student’s unpaired T-test. Data are presented as mean ±SEM of 3 individual experiments. ***P < 
0.001 vs. iPSCs infected with non targeting shRNA (shNT). 
 
After confirming the efficiency of the shRNA knockdown of PTEN, we analyzed the 
expression of the EC markers after shPTEN infection. Real time-PCR analysis 
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showed a 1.5-fold increase in the expression of VE-cadherin (VE-cad, Figure 70, A) 
and Flk1 (Figure 70, B) after shPTEN infection, as compared to shNT infection. 
 
Figure 70 Knockdown of PTEN induces EC marker upregulation in differentiating iPSCs 
iPSCs were differentiated for 3 days on collagen IV, in DM supplemented with 50ng/ml VEGF and 
then infected with shRNA specific for PTEN (shPTEN) or non targeting shRNAs (NT), as a control. 
Real time-PCR was performed 48h later to analyze the gene expression level of the EC markers VE-
cad (A) and Flk1 (B). The statistical analysis used is Student’s unpaired T-test. Data are shown as 
mean ±SEM of 3 individual experiments. ***P < 0.05 vs. iPSCs infected with non targeting shRNA 
(shNT). 
 
We can conclude that during the VEGF-induced iPSC differentiation, inhibition of 
PTEN with specific shRNAs is able to induce EC marker expression in 









3.4.3 Conclusions  
In summary, in the last part of the work we partially elucidated the signalling 
pathways through which miR-21 induces iPSC differentiation into ECs. 
We firstly confirmed PTEN as a direct target of miR-21 and validated its binding to 
the predicted binding site.   
Secondly, we showed that miR-21 regulates the AKT pathway by targeting PTEN 
and thus inducing AKT phosphorylation. 
Finally, we assessed the requirement of the PTEN/AKT pathway in the VEGF-
induced EC differentiation of iPSCs. 
Indeed, during the differentiation of iPSCs, shutdown of PTEN with specific 
shRNAs increased EC marker expression, thereby indicating that PTEN inhibition is 





















4.1 ROLE OF VEGF AND SHEAR STRESS IN 
STEM CELL DIFFERENTIATION INTO ECs 
 
The generation of an efficient, patient-specific vessel graft requires the identification 
of a suitable source of endothelial cells that can be derived from the patient in 
adequate number for clinical use. In this work we focused on the differentiation of 
iPSCs to ECs. Somatic cells from patients have the potential to be reprogrammed to 
iPSCs, which can be expanded in an undifferentiated state, or to be subjected to 
lineage specific differentiation in response to a stimulus. 
It is very important to establish an efficient and reproducible protocol of 
differentiation. We started from a protocol recently published from our lab to induce 
ESC differentiation towards ECs based on the use of collagen IV, VEGF and shear 
stress (Zeng, Xiao et al. 2006). Aiming to adapt this protocol to iPSCs 
differentiation, we tested many combinations, using different VEGF concentrations 
and time points. We also tried a combination of VEGF and shear stress firstly on 
ESCs, and then on iPSCs. After plating iPSCs on collagen IV, in DM containing 
VEGF, we first observed a different morphology as compared to the undifferentiated 
iPSCs on gelatine: the differentiating cells adhered to the plate and became flat and 
elongated, while the undifferentiated iPSCs appeared to cluster in round three-
dimensional colonies. 
We then aimed to find an optimal dose of VEGF able to obtain the best response of 
ECs differentiation generated by iPSCs. Zeng et al. stimulated Sca-1
+
 vascular 
progenitor cells derived from ESC with medium containing 10ng/ml VEGF. On the 
other hand, in the work of Narazaki et al., iPSC and ESC-derived Flk1
+
 progenitor 
cells were stimulated with 100ng/ml VEGF (Narazaki, Uosaki et al. 2008). In our 
study we aimed to test several concentrations ranging between these two extremes. 
Furthermore, we used we used undifferentiated iPSCs without pre-differentiating the 
cells or selecting for a specific population. The results of a dose-response curve 
experiment showed that concentrations of 20 and 50 ng/ml of VEGF were able to 
induce a robust upregulation of the EC markers VE-cadherin, Flk1 and vWF. 
Interestingly, immunostaining experiments of the differentiated cells revealed a 
homogeneous expression of the endothelial markers, showing a remarkably high 
193 
 
differentiation rate. Indeed, the cellular distribution of endothelial-specific proteins 
observed by immunostaining confirmed the presence of a clear pattern of VE-
cadherin expression at the cell junctions and eNOS and vWF at the 
cytoplasm/membrane of the cells. Therefore we confirmed that we had devised a 
protocol that bypassed the need of selecting for a specific marker. 
We also investigated the timeframe of differentiation by analysing the EC marker 
expression in cells treated with 20 and 50ng/ml of VEGF at different time points. 
Previously published protocols indicate that the peak of differentiation starts after 3-
day culture of iPSC–derived Flk1+ cells using 100 ng/ml VEGF (Narazaki, Uosaki et 
al. 2008), or after 7-day culture of ESC-derived Sca-1
+
 cells using 10 ng/ml VEGF 
(Zeng, Xiao et al. 2006). 
Our experiments showed that the highest upregulation of the EC markers (VE-
cadherin, Flk1 and vWF) was after 7 days. However, using 50ng/ml of VEGF for 7 
days, we observed an increased expression of the late EC marker VE-cad (20 fold), 
as compared to 20ng/ml VEGF (14 fold). Furthermore, VE-cad and vWF expression 
started at an early time, around day 3, as compared to the lower dose. 
In summary, we established that the treatment of iPSCs with increasing 
concentrations of VEGF had an effect on endothelial differentiation up to 50ng/ml, 
while higher concentrations did not achieve a better result. Furthermore, 50ng/ml 
achieved a quicker pattern of differentiation as compared to 20ng/ml and was 
therefore chosen for further experiments. Importantly, compared to previously 
described differentiation protocols, our protocol shows a higher scale of EC marker 
induction, up to a 100 fold increase in Flk1 expression, thus indicating better 
differentiation efficiency than existing protocols. For instance, Narazaki et al. 
showed that, in Flk1
+
 progenitor cells, the effect of VEGF only led to a 20 fold 
increase in  EC marker expression (Narazaki, Uosaki et al. 2008). 
In conclusion, our protocol allows the direct and efficient EC differentiation from 
undifferentiated iPSCs in a relative short time and at a highest level, as compared to 
the previously published protocols. 
In addition to phenotypical characterization, the functionality of the obtained 
endothelial cells was investigated using an in vitro angiogenesis assay. The 
194 
 
phenomenon that ECs rapidly form capillary-like structures in vitro when plated on a 
reconstituted basement membrane extracellular matrix, such as Matrigel, was 
demonstrated almost 20 years ago (Grant, Kinsella et al. 1995). This formation of 
capillary-like structures is specific to ECs and is used to assess EC functionality. 
Cells differentiated using our protocol showed the ability to organize into tube-like 
structures, confirming their endothelial nature. 
In conclusion, using such an optimized differentiation protocol for iPSCs we 
characterized the differentiated cells and established that they were highly positive 
for main endothelial markers at gene and protein level and resemble endothelial cells 
in their morphology and their ability to organise into tubular structures in vitro.  
A separate section of the work was dedicated to a set of experiments involving the 
use of shear stress. Shear stress has been shown by our group and others to play an 
important role in stem cell differentiation, in particular in the differentiation of the 
progenitor cell population Sca1
+
 (Zeng, Xiao et al. 2006). We first performed 
preliminary experiments on a better established population of progenitor cells, ckit
+
, 
which has been characterized in our laboratory and has been demonstrated to 
represent a novel vascular progenitor cell population.  
In the study of Yamamoto et al., ESC-derived Flk1
+
 progenitors exposed to shear 
stress (1.5 to 10 dynes/cm
2
) showed a significant induction in EC marker expression 
(Flk1, Flt-1, PECAM-1 and VE-cadherin) at both protein and mRNA levels, and had 
an increased tube formation capacity (Yamamoto, Sokabe et al. 2005).  
Furthermore, data from our group showed that exposing Sca1
+
 progenitor cells to 
laminar shear stress (12 dynes/cm
2
) for 24h increased their proliferation and 
differentiation. Sheared Sca1
+ 
cells displayed increased expression levels of Flk1, 
eNOS and VCAM-1, and showed improved tube-like structure formation on 
Matrigel (Xiao, Zeng et al. 2006). In the work of Xiao et al., the predifferentiated 





was determined by the flow rate and the channel dimensions, 
and was comparable with the physiological range in human major arteries. 





cells were exposed to short-term shear stress using an orbital shaker, and showed an 
increased EC marker expression (in revision, Campagnolo et al.).  
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Following the protocol described in the study of Xiao et al., we indeed differentiated 
ESCs on collagen IV and in DM for 4 days to obtain a mixed population of 
progenitor cells. Subsequently, we decided to isolate ckit
+
 progenitor cells, rather 
than Sca-1
+
, using immunomagnetic beads and to differentiate this progenitor 
population for a further 3 days in the same conditions. Shear stress was then applied, 
using an orbital shaker, for either 24h or 48h, after which cells were collected and 
endothelial marker expression analyzed. We could only observe some degree of 
upregulation of the EC markers after 24h of shear stress. 
Interestingly, previous data from our group demonstrated that shear stress and VEGF 
share a similar activation pathway (the Flk1–PI3K–AKT–HDAC3–p53–p21 
pathway) in the induction of EC differentiation of Sca1
+
 derived from ESCs  (Xiao, 
Zeng et al. 2006). We decided to combine shear stress stimulation with VEGF 
treatment, in order to increase the rate of EC differentiation. Results showed an 
enhanced expression of EC markers such as CD31, VE-cad, Flk1 and eNOS  after 24 
or 48h (about 2 folds), as compared to each stimuli applied alone. However the 
results were often quite inconsistent and poorly reproducible. 
After optimising the conditions for this differentiation protocol on ckit
+
 progenitor 
cells, we then applied the shear stress and VEGF treatment to iPSCs for 48h. 
Synergistic application of VEGF and shear stress to iPSCs has been never shown so 
far in the literature. We observed an approximately 3 fold induction in EC marker 
expression. Although it was possible to appreciate some effect of the synergistic 
action of shear stress and VEGF on the iPSC differentiation, we decided to focus 
only on the VEGF stimuli to study the mechanisms underlying iPSC differentiation. 
The shear stress application system, using an orbital shaker platform, presents too 




4.2 CHARACTERIZATION OF miRNA PROFILE 
DURING VEGF- AND SHEAR STRESS- INDUCED 
iPSC DIFFERENTIATION: MiRNA-21 
REGULATES VEGF-INDUCED iPSC 
DIFFERENTIATION INTO ECs 
 
The main aim in this thesis was to establish the molecular mechanisms driving the 
differentiation of iPSCs to ECs. . MiRNAs are small non-coding RNAs that have 
been shown the potential to regulate complex processes by targeting multiple 
proteins at the same time. For this reason we decided to investigate the miRNA 
signature of differentiated and undifferentiated iPSCs using a miRNA array. 
Previous work on embryonic stem cells has shown that pluripotent cells and cells 
differentiated to vascular ECs express different pools of miRNAs. In particular, 
some of the miRNAs found to be highly overexpressed by ESC-derived EC were 
previously found to be involved in angiogenesis (Kane, Meloni et al. 2010). 
To our knowledge, there are no studies investigating the miRNA profile during 
vascular differentiation of iPSCs though recent publications have characterized the 
miRNA profile of iPSCs during osteogenic differentiation (Okamoto, Matsumi et al. 
2012). We performed a miRNA array on iPSCs differentiated for 3 days with VEGF 
and in undifferentiated iPSCs, in order to compare their miRNA profiles. We found a 
pool of differentially expressed miRNAs and selected some of the most consistently 
up or downregulated miRNAs to validate their expression over a 7 day-long 
differentiation toward the endothelial lineage.  
We validated a total of 5 miRNAs, including miR-218, miR-133a, miR-29b, miR-
20b and miR-21.  Among the validated miRNAs, miR-218, showed an induction of 
up to 25 fold after 7 days of VEGF-induced differentiation. This miRNA has been 
mainly studied as a tumour suppressor in different types of cancer (Yamasaki, Seki 
et al. , Li, Ping et al. 2012). MiR-133a showed an upregulation of approximately 50 
fold after 7 days of differentiation; miR-133a has been shown to be mainly involved 
in cardiac and muscle remodelling and is a known biomarker expressed after 
myocardial infarction (Bauters, Kumarswamy et al.). MiR-133a was also shown to 
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be involved in myocardial and liver fibrosis (Castoldi, di Gioia et al. 2012, 
Roderburg, Luedde et al. 2013) and to promote cardiogenic differentiation (Lee, 
Ham et al. 2013). Another miRNA showing a strong induction, of approximately 35 
fold at day 5 of differentiation, was miR-29b. This miRNA plays a role in osteogenic 
differentiation (Trompeter, Dreesen et al. 2013) and acts as a tumour suppressor 
(Melo and Kalluri 2013), in particular repressing tumour angiogenesis, invasion and 
metastasis (Fang, Zhou et al. 2011). Additionally, miR-20b was found to be 
upregulated by 6 fold at day 3 of differentiation. Previous publications have shown 
that miR-20b has antiangiogenic properties  (Wu, Yang et al. 2009) being 
downregulated in hypoxic conditions and decreasing the expression of VEGF in 
carcinoma cell lines (Hua, Lv et al. 2006). Finally miR-21 was found to be 
upregulated by approximately 6 and 8 fold after 5 and 7 days, respectively. MiR-21 
has been shown to increase tumour progression in several types of tumours by 
targeting and inhibiting tumour suppression proteins such as phosphatase and tensin 
homolog (PTEN) (Meng, Henson et al. 2007). More relevant to our research, miR-21 
has been previously shown to induce tumour angiogenesis through the AKT and 
ERK pathway activation, increasing the expression of VEGF and HIF-1α (Liu, Li et 
al. 2011). Conversely, it has also been reported to exhibit antiangiogenic functions, 
by targeting RhoB in mature ECs (Sabatel, Malvaux et al. 2011). This double aspect 
of miR-21 in the context of angiogenesis led us to hypothesise a possible role in EC 
differentiation.  
After validating the expression of the above mentioned miRNAs, we decided to 
select the two most interesting candidates, in order to study their involvement in the 
mechanisms underlying iPSC differentiation into ECs. Although miRNAs 133a, 29b 
and 218 were highly upregulated during iPSC differentiation, we decided to focus on 
miRNAs which had previously been shown to be related to angiogenic processes, 
such as miR-20b and miR-21. Despite some studies relating these two miRNAs with 
tumour angiogenesis and mature EC biology, no studies have investigated their 
involvement in the VEGF-induced differentiation of iPSCs.  
Our initial aim was to establish a miRNA link between the differentiation pathway 
induced by VEGF and the pathway induced by shear stress. We therefore ran a 
parallel experiment of miRNA array to compare cells grown in static and shear stress 
conditions. Interestingly, miR-218, one of the most consistently overexpressed 
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miRNAs was also upregulated in the VEGF array, although at a lower level. We 
attempted to confirm this result by analysing its expression with real time PCR, but 
we could not validate it. We also attempted to validate other interesting miRNAs that 
emerged from the array, but the high variability and poor reproducibility of the 
conditions invalidated the results. 
The shear stress model that we used is an orbital shaker platform; in this model, the 
shear stress cannot be uniformly applied to the cells across the plate and the entity of 
the shear is difficult to define mathematically. It has been shown that  shear stress 
generated by an orbital shaker is low and oscillatory at the centre of the well, while 
at the periphery of the well it is directional and laminar as in atheroprotected 
physiological conditions (Chakraborty, Chakraborty et al. 2012). Therefore, in order 
to overcome this issue we systematically removed the cells in the centre of the well 
before collecting our samples. This expedient did not succeed in eliminating the 
problem.  This may be due to variability within the area we defined as the periphery. 
In a study based on the analysis of computational fluid dynamics (CFD), time and 
location dependent wall shear stress (WSS) generated by an orbital shaker was 
determined. WSS was shown to be uniform (0–1 dyne/cm2) across the bottom of the 
dish, when low orbital speed (50 rpm) was applied; however, using higher orbital 
speeds (100 and 150 rpm), the WSS remained uniform near the centre, but varied 
significantly (0–9 dyne/cm2) near the side walls of the dish (Dardik, Chen et al. 
2005). This variation can be thought of as similar to the pulsatile nature of shear 
stress experienced by native ECs. 
We applied an orbital speed of 120 rpm, which corresponds to a peak shear of 8 
dyne/cm
2
 (Dardik, Chen et al. 2005), but this level of shear stress was not necessarily 
sensed in a homogeneous pattern by the cells across the surface. Differentiating 
iPSCs at day 3 do not form a uniform monolayer, in contrast to the appearance of 
mature ECs, and this might prevent the cells from transmitting shear sensing 
mechanical signals to adjacent cells.  
These factors should be considered in the interpretation of the results of experiments 
performed with shear stress, which were not always consistent and reproducible. 
This may also explain why we were not able to validate the expression of the 
miRNAs found in the array performed with shear stress. For these reasons, we 
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decided to focus on the VEGF differentiation system, in order to study the 
involvement of miRNA candidates in the EC differentiation of iPSCs.  
In conclusion, we performed the first miRNA array during iPSC differentiation 
towards an EC lineage. Our miRNA characterization may open future studies: for 
instance, the role of the other validated miRNAs.  Study of these miRNAs was 
beyond the scope of this thesis but the role of these could be analyzed in future, thus 
elucidating new molecular pathways. 
As mentioned previously, we chose to investigate the involvement of miR-20b and 
miR-21 in the VEGF-induced iPSC differentiation towards ECs. We first altered the 
levels of miR-20b and miR-21 in iPSCs differentiated with VEGF for three days. 
The efficiency of transfection with miRNA precursor (Pre20b/21) and inhibitor 
(LNA-20b/21) was significantly high, as showed by the relative increase and 
decrease in the mature miRNA expression. However, the gene expression of the EC 
markers was not affected by miR-20b overexpression and inhibition. On the other 
hand, when the cells were differentiated for 3 days in presence of VEGF and 
transfected with Pre-21, we could observe an induction of approximately 5 and 3 
fold in the gene expression level of VE-cadherin and Flk1 respectively; however, 
miR-21 inhibition did not affect the gene expression of these markers. At a protein 
expression level, we could confirm an increase in EC markers after transfecting 
iPSCs with Pre-21; importantly, we could also observe a significant decrease in the 
protein expression of VE-cadherin and flk1 after inhibiting miR-21. The differences 
in the results of miR-21 inhibition observed at a gene and protein expression levels 
could be explained in two ways; firstly, the effect of the inhibitor may depend on the 
miRNA expression level at the time of transfection: if the miRNA is not expressed 
by the cells at a significant level, the LNA cannot efficiently bind to and inhibit the 
endogenous molecules of miRNA. Secondly, miRNA regulation is known to occur at 
a post-trascriptional level, and this may explain why we could see the miR-21 
inhibition effect on the EC markers at a protein expression level only. In order to 
understand wether VEGF was required in this miR-21 regulation of EC marker 
expression, we cultured the cells in the absence of VEGF and we performed the 
same experiment. Importantly, miR-21 was not able to affect the expression of the 
EC markers at a gene expression level. These data indicate the requirement of VEGF 
stimulation for the miR-21 induced EC marker induction. 
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At this point, in order to verify that miR-21 regulation of iPSC differentiation 
occurred specifically towards the endothelial lineage, we analyzed the expression of 
SMC and cardiac markers, which, like ECs, are derived from the mesoderm and 
additionally, the expression of endoderm and ectoderm markers. Importantly, we 
confirmed that the expression of all these markers was not affected by miR-21 
overexpression and inhibition. We therefore proved that miR-21 specifically 
regulates iPSC differentiation towards ECs and not towards any other cell lineage. 
The specificity of miR-21 regulation towards EC differentiation is a strong point in 
this work and will allow us to study the mechanisms involved in this process. 
We then assessed the miR-21 regulation on iPSC differentiation into functional ECs, 
using an angiogenesis assay in vitro. Overexpression of miR-21 in iPSCs 
differentiated with VEGF for four days induced the formation of tube-like structures. 
Accordingly, miR-21 inhibition decreased the tube formation ability on Matigel; 
these results further confirmed the effect of miRNA inhibition at a post-trascriptional 
level.  
We also aimed to study the effect of miR-21 regulation using an in vivo angiogenesis 





capillaries in the plugs seeded with miR-21 transfected cells, as compared 
to the control cells. Similarly to the results obtained in vitro, inhibition of miR-21 led 
to a decreased density of capillaries positive for the EC markers CD31 and VE-cad, 
as compared to LNA-Ctrl.  
In vivo assays that mimic human angiogenesis has been previously reported, for 
instance in the work of Skovseth et al., where native HUVECs are suspended in 
Matrigel, injected into immunodeficient mice, and develop into mature, functional 
vessels able to vascularize the Matrigel plug within 30 days (Skovseth, Küchler et al. 
2007). 
Moreover, in the study of Liu et al., human prostate cancer cells transfected with 
Pre-21, LNA-21 and the relative negative controls were resuspended in serum-free 
medium, and mixed with Matrigel; aliquots of the different mixture were then 
applied onto the chicken chorioallantoic membrane of 9-day-old embryos to assess 
tumour angiogenesis. The number of branches of microvessels were increased by 
miR-21 overexpression and viceversa decreased by miR-21 inhibition, indicating a 
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pro-angiogenic function of miR-21 (Liu, Li et al. 2011). This study indeed shows a 
direct role of miR-21 in inducing angiogenesis, thus supporting our findings.  
Our results of the in vivo angiogenesis assay suggested a potential use of miR-21 
inhibitor in the development of new antiangiogenesis therapies; for instance this may 
be used for the treatment of diseases like cancer, where angiogenesis plays an 
important role.   
Since in the in vivo angiogenesis assay we did not label the miR-21 transfected cells 
before the injection, we cannot exclude that the capillary structures observed in the 
matrigel plugs were also composed by the host ECs, and not only by the miR-21-
induced ECs. However, since the previously performed in vitro Matrigel assay 
showed that cells transfected with miR-21 were able to organize tube like structures, 
probably in the Matrigel plugs the same cells are able to promote the angiogenic 
process in vivo. There is a possibility that host cells are recruited by miR-21 
transfected cells and integrate with them to form new capillaries, following the 
inflammation process induced by Matrigel plug injection. In both the cases, either if 
the effect on the capillary formation is due to the injected cells only or to their 
interaction with the host cells, in vivo angiogenesis is promoted by miR-21 
transfected cells.  
In conclusion, we showed for the first time that miR-21 specifically regulates the 
VEGF-induced differentiation of iPSCs into functional ECs and that VEGF 
stimulation is required in this process. Interestingly, a link between miR-21 and 
VEGF expression has already been established in the work of Liu et al., where miR-
21 has been reported to induce tumour angiogenesis through AKT and ERK pathway 
activation, increasing the expression of VEGF and hypoxia-inducible factor 1-alpha 
(HIF-1α) (Liu, Li et al. 2011). The possibility of a mutual regulation between the 





4.3 IDENTIFICATION OF THE MOLECULAR 
TARGETS OF MiRNA-21: TGF-β2 PATHWAY IS 
A DOWNSTREAM TARGET OF MiR-21 AND 
DRIVES iPSC DIFFERENTIATION INTO ECs 
 
At this point we aimed to elucidate the molecular mechanisms that occur during 
miR-21 induced differentiation of iPSCs. We started by identifying the molecular 
targets of miR-21 in order to elucidate the signalling pathways involved in the 
differentiation process. This was a difficult process as miR-21 has been shown to 
target multiple genes, which have not yet been shown to have a role in stem cell 
differentiation towards the EC lineage. 
In order to start screening the molecular targets of miR-21 we used an miRNA target 
database (miRGEN), based on the intersection of four different prediction 
algorithms. From the lists of in silico predicted targets, we mainly focused on genes 
that may be involved in the angiogenic process. Among those, we focused on genes 
known to regulate EC functions and vessel growth, such as TGF-βRII, regulator of 
ERK activation Sprouty 1 (SPRY1), RhoGTPase RhoB and Sox7, and genes 
encoding for regulators of cell migration such as vinculin (Vcl). 
We also decided to include genes of the Wnt and the HIF1α/VEGF signalling 
pathways, which are known regulators of EC differentiation during embryogenesis 
and tumour growth (Logan and Nusse 2004, Dejana 2010). Furthermore, miR-21 is 
known to regulate HIF1α, and induce tumour angiogenesis, through stimulation of 
VEGF gene expression (Kong, Kong et al. 2012). Interestingly, we found that 
transfection with miR-21 inhibitor was able to reduce VEGF gene expression.  These 
results highlighted the connection between miR-21 and VEGF by showing that while 
miR-21 is regulated during VEGF-dependent differentiation, it is also important in 
the regulation of VEGF, since cells lacking miR-21expressed a reduced amount of 
VEGF mRNA. 
Despite the lack of variation in the other genes identified through miRGEN, we 
decided to expand our investigation stemming from the two predicted members of 
the TGF-β family, TGF-βRII and transforming TGF-βI, to the rest of the components 
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of the pathway. TGF-β is a multifunctional cytokine which regulates proliferation, 
migration, differentiation and survival of many different cell types (Munger, Harpel 
et al. 1997). In mammals there are three known isoforms, TGF-β1, TGF-β2 and 
TGF-β3, with distinct and shared functions. Deletions of different members of the 
TGF-β family, have been shown to cause vascular remodelling defect and absence of 
mural cell formation, leading to embryonic lethality (Pardali and Ten Dijke 2009), 
and mutations of other components of this family have been reported to lead to 
severe vascular disorders (Bertolino, Deckers et al. 2005, Lebrin, Deckers et al. 
2005).  
Interestingly, TGF-β2 was found to be upregulated by miR-21 overexpression. 
Importantly, this observation was matched by increased levels of secreted protein, 
showing that miR-21 was not only able to influence TGF-β2 at a transcriptional 
level, but also that this resulted in an increase of the functional protein. Furthermore, 
protein levels in the supernatant were reduced by the treatment with miR-21 
inhibitor, despite no apparent change in RNA levels. This inhibitory effect on TGF-
β2 protein secretion only might be due to the fact that miRNAs, as stated earlier, are 
known to act at a postranscriptional level. 
To confirm TGF-β2 as an essential downstream molecule mediating miR-21-
inducing EC differentiation, Pre-21-transfected iPSCs were treated with TGFβ-2 
neutralizing antibody. TGF-β2 neutralization inhibited the miR-21-induced EC 
marker induction, as compared to IgG control, at both gene and protein expression 
level. This experiment was relevant to assess for the first time the existence of a link 
between miR-21 and TGF-β2 during iPSCs differentiation, thus attesting that TGF-
β2 secretion is an essential step in the miR-21 induced EC differentiation. 
We therefore aimed to analyze TGF-β2 expression during the VEGF-induced iPSC 
differentiation. Our results showed a strong upregulation of TGF-β2 gene 
expression, up to 200 fold after 7 days of differentiation, while the expression of 
TGF-β1 was much lower, with a peak of 10 fold induction after 7 days. Interestingly 
and supporting our previous results, TGF-β2 expression appeared to be concomitant 
with miR-21 expression, after 5 and 7 days of VEGF-induced iPSC differentiation; 
these data further support the connection between miR-21 and TGF-β2 in the iPSC 
differentiation process. Next, we analyzed the expression of receptors of TGF-β 
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signalling during VEGF-induced iPSC differentiation. Consistently with the 
expression of the ligands, we found a strong upregulation of TGF-βRII and III. 
Although a trend was visible, TGF-βRI gene was upregulated to a lesser extent and 
not always consistently. TGF-βRIII was the most highly upregulated, reaching 200 
fold induction after 7 days. This result may be explained by considering that TGF-
β2, which has a low affinity for TGF-βRII, requires the accessory receptor TGF-
βRIII or β-glycan, for high-affinity interaction with the heteromeric-signalling 
receptor complex; binding of TGF-β2 to TGF-βRII then leads to activation of TGF-
βRI for the signal transduction (Goumans, Liu et al. 2009).  
After indentifying TGF-β2 as an important downstream effector of miR-21, and after 
showing its expression during VEGF-induced iPSC differentiation, we aimed to 
clarify the role of TGF-β2 in this process. We therefore treated iPSCs for up to 7 
days with TGF-β2 to analyze the expression of EC markers. Results showed an 
upregulation of approximately 2.3 and 2 fold in the gene expression of VE-cadherin 
and Flk1 respectively. Importantly, after TGF-β2 treatment, we could not see any 
effect on the SMC markers. In contrast, it has previously been demonstrated that 
TGF-β induces ESC differentiation into SMCs via Notch or SMAD2 and SMAD3 
signalling (Yamashita, Takano et al. 2005, Kurpinski, Lam et al. 2010); additionally, 
in a neural crest stem cell line Chen et al. showed a TGF-β induction of SMC 
markers and phenotype (Chen and Lechleider 2004). Here, we report for the first 
time that TGF-β2 treatment is able to specifically induce iPSC differentiation 
towards EC lineage, without affecting SMC marker expression.  
From the ELISA results iPSCs secretion of TGF-β2 appeared to be in the scale of 
pg/ml, indeed at a low concentration level; however, since iPSCs continuously 
secrete TGF-β2, which probably exerts a paracrine action on neighbouring cells, that 
concentration was enough to be effective in iPSC differentiation. However, in order 
to study the response of the cells to TGF-β2 treatment for a defined time of 7 days, 
we had to use a significantly higher dose of the cytokine; we chose 3ng/ml TGF-β2 
which has previously been shown to induce EMT in epithelial cells (Hatanaka, 
Koizumi et al. 2012).  
Importantly, results of protein expression analysis confirmed the induction of the EC 
markers observed at a transcriptional level. Moreover, TGF-β2 regulation of the 
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functional iPSC differentiation was attested by in vitro angiogenesis assay; TGF-β2 
treated cells showed a significantly increased tube formation capacity, as compared 
to untreated cells. Notably, so far there are no other studies reporting the role of 
TGF-β2 on stem cell functional differentiation towards ECs.  
It has previously been shown that the TGF-β family exerts its action on cells via 
specific intracellular transcription factors, such as RhoA/ROCK and SMAD. The 
ROCK pathway has been shown to play a negative role in stem cell differentiation, 
since its suppression promotes differentiation and expansion of ECs from ESC-
derived Flk1
+
 cells (Yamasaki, Seki et al.). On the other hand, in ECs TGF-β has 
been shown to bind to TGF-βRI, and to induce phosphorylation of SMAD2/3, 
thereby inhibiting proliferation, tube formation, and migration of ECs (Goumans, 
Valdimarsdottir et al. 2003). However, so far there are no studies reporting the role 
of SMAD3 in stem cell differentiation into ECs. Indeed, in order to clarify the 
molecular mechanisms through which TGF-β2 is able to drive iPSC differentiation 
into ECs, we decided to investigate the role of the TGF-β2/SMAD3 pathway in this 
process. We therefore treated iPSCs differentiated for 7 days in the presence or 
absence of TGF-β2, with a SMAD3 inhibitor. Q-PCR results showed that the 
SMAD3 inhibitor significantly abolished TGF-β2 induction of EC markers, as 
compared to untreated cells. These data confirm the importance of the TGF-
β2/SMAD3 pathway in the iPSC differentiation process. Interestingly, our results 
also showed that inhibition of SMAD3 significantly reduced the baseline expression 
level of VE-cadherin, in the absence of TGF-β2 stimulation; this result may be 
explained by considering that SMAD3 is at the centre of other molecular pathways 
and it is not only a TGF-β2 downstream effector. For instance activin, a member of 
the TGF-β superfamily, has been shown to share some biological activities with 
TGF-β and to signal through SMAD proteins, such as SMAD3 (Massagué and Chen 
2000). Moreover, it has been reported that SMAD2/3 is a downstream effector of 
Activin/Nodal signalling, which binds and directly controls the activity of the Nanog 
gene to mantain pluripotency in hESCs (Singh, Reynolds et al. 2012). Furthermore, 
studies conducted in EC-specific SMAD2/3 double KO (SMAD2/3KO) mice 
embryos, revealed hemorrhage leading to embryonic lethality around E12.5 and 
incomplete vascular maturation because of inadequate assembly of mural cells in the 
vasculature. In the vasculature of EC-SMAD2/3KO mice it is possible to observe 
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wide gaps between ECs and mural cells, because of the reduced expression of N-
cadherin and sphingosine-1-phosphate receptor-1 (S1PR1) in ECs. Indeed the 
SMAD2/3 signalling has been reported to be essential in ECs to keep the vascular 
integrity through regulating N-cadherin, VE-cadherin, and S1PR1 expressions (Itoh, 
Itoh et al. 2012). This last study could also explain why the baseline level of VE-
cadherin expression was affected after SMAD3 inhibition in our system. 
In conclusion, our results demonstrated that SMAD3 mediates the effect of TGF-β2 
on iPSC differentiation and for the first time highlighted the importance of the TGF-
β2/SMAD3 pathway in the differentiation of iPSCs into ECs.  
At this point, we aimed to elucidate the mechanisms behind the TGF-β2 induction of 
iPSC differentiation into ECs. Our results showed so far that miR-21 inhibition 
reduces VEGF gene expression, and that VEGF stimulation is required in the miR-
21 regulation of iPSC differentiation into ECs. We indeed hypothesized an indirect 
mechanism of VEGF secretion induced by TGF-β2 treatment. 
We therefore performed ELISAs in order to analyze the secretion of VEGF after 7 
days of treatment with TGF-β2. Our results showed a significant induction of 1.6 
folds in the secretion of VEGF after TGF-β2 treatment, as compared to untreated 
cells; this data indicates that TGF-β2 promotes a specific and functional 
differentiation of iPSCs into ECs through induction of VEGF secretion. Other 
studies previously conducted in different cellular contests showed that VEGF 
secretion can be induced by TGF-β2, thus supporting our findings. For instance, 
VEGF secretion has been shown to play an important role in retinal and choroidal 
neovascularisation; induction of VEGF secretion by TGF-β2 in human retinal 
pigment epithelium is mediated by MEK, p38, JNK, PI3K and NF-kappaB and by 
many other important signalling intermediates, such as PKC, PTK and ROS (Bian, 
Elner et al. 2007). Moreover, in the work of Ma et al. it has been reported that TGF-
β2 stimulation increases VEGF mRNA expression and secretion; both VEGF and 
TGF-β2 were in fact able to induce retinal pigment epithelium cell-mediated 
collagen gel contraction in vitro through upregulation of α-SMA expression (Ma, 
Zhang et al. 2012). 
To further confirm our hypothesis that VEGF secretion is required for TGF-β2 
induced iPSC differentiation into ECs, we treated iPSCs for 7 days with TGF-β2 in 
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the presence of VEGF neutralizing antibody or IgG as a control and we analyzed the 
expression of the EC markers. Western Blot results showed that treatment with 
VEGF blocking antibody reduced the TGF-β2-dependent increase of VE-cadherin, 
as compared to control cells. These results indeed strongly support our data from the 
ELISAs and indicate for the first time that VEGF secretion is required for the TGF-
β2 induced iPSC differentiation into ECs. Indeed, our data so far demonstrated that 
TGF-β2 expression and secretion were increased during the VEGF- and miR-21-
induced iPSC differentiation and vice versa VEGF secretion was induced by TGF-β2 
treatment; after neutralizing VEGF secretion, there was a decrease in the TGF-β2 
induction of the EC markers. Indeed, we could conclude that there is an evident link 
between the miR-21, TGF-β2 and VEGF pathways, which appears to be a mutual 
regulation.  
 
4.4 IDENTIFICATION OF THE MOLECULAR 
TARGETS OF miRNA-21: MiR-21 TARGETS THE 
PTEN/AKT PATHWAY, WHICH REGULATES 
iPSC DIFFERENTIATION INTO ECs 
In the last part of this work, after identifying TGF-β2 as an essential downstream 
functional target of the miR-21 regulated iPSC differentiation into ECs, we focused 
on the research of the direct target of miR-21. We also aimed to elucidate the 
molecular pathway underlying the miR-21 regulation of iPSC differentiation. 
One of the in silico predicted targets for miR-21 is PTEN. Recent studies indicated 
that miR-21 inhibited the tumour suppressor PTEN by binding to its 3’ UTR (Meng, 
Henson et al. 2007). Modulation of the tumour suppressor gene PTEN by miR-21 in 
human hepatocellular cancer has recently been shown to induce cell proliferation, 
migration and invasion (Meng and Henson, Gastroenterology 2007), and inhibition 
of PTEN by miR-21 has been reported to induce tumour angiogenesis through AKT 
and ERK activation and HIF-1α expression (Liu L Z et al). However, so far the role 
of PTEN in miR-21 induction of endothelial cell differentiation has not yet been 
elucidated. We aimed to clarify it. 
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We first confirmed PTEN as a direct target of miR-21 at a protein expression level. 
In iPSCs pre-differentiated in the presence of VEGF for 3 days, transfection with 
Pre-21 caused a significant reduction of PTEN protein expression, whereas 
transfection with LNA-21 led to a significant induction of PTEN.  
To further confirm this result, we performed a luciferase assay, which has the 
consistency of a gene expression analysis, but is more specific since it assesses the 
binding of miRNA to mRNA, using wild type and mutated 3’ UTR sequences. Co-
transfection of the WT PTEN 3’UTR plasmid and LNA-21 in iPSCs differentiating 
with VEGF resulted in an approximately 1.4 fold increase in luciferase activity. 
Importantly, mutations in the sequence targeted by miR-21 in PTEN 3’UTR 
abolished the observed up-regulation of luciferase activity by miR-21. This result 
confirmed PTEN as a direct target of miR-21 and validated its specific binding to the 
predicted binding site.   
At this point, since PTEN is known to be the antagonist of PI3K, which removes the 
39 phosphate of PIP3, resulting in inhibition of the AKT signalling pathway (Jiang 
and Liu 2008), we aimed to assess whether PTEN inhibition is required for the 
activation of AKT during the VEGF-induced iPSC differentiation process. In order 
to do so, in iPSCs differentiated for 5 days with VEGF, we inhibited PTEN using the 
chemical inhibitor bisperoxovanadium (bpV) for 30min, 2h and 24h. BpV is a well-
established PTPase inhibitor, which binds to the phosphatidylinositol 3-phosphatase 
active site of PTEN through competitive inhibition, with 10- to 100-fold lower 
concentrations than the other PTPase inhibitors (Bauters, Kumarswamy et al.). 
PTEN  shows dual phosphatase activity, dephosphorylating both protein and lipid 
substrates, with a higher specificity towards 3-phosphorylated phosphoinositides (PI) 
such as PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3; indeed loss of PTEN activity 
can be monitored with an increase of PtdIns (3,4,5)P3 levels and therefore with a 
dose-dependent increase of Ser473 phosphorylation of AKT (Bauters, Kumarswamy 
et al.). 
Our results showed that phosporylation of AKT at the Ser-473 was increased after 
30min and 24h of PTEN inhibition, as compared to the cells treated with DMSO as a 
control; the protein level of total AKT was instead not altered by PTEN inhibition. 
With this experiment we proved that during the VEGF-induced iPSC differentiation 
209 
 
process, inhibition of PTEN increases the AKT phosphorylation and its consequent 
activation.  
Interestingly it has been shown that the PI3K/AKT signalling pathway plays a 
crucial role in many intracellular cascade events including tumour angiogenesis and 
tumour growth (Xia, Meng et al. 2006) and, in particular, the PI3K/AKT pathway 
has been reported to drive the shear- and VEGF-induced stem cell differentiation 
into ECs (Zeng, Xiao et al. 2006). We therefore decided to assess whether the 
PTEN/AKT pathway was essential in driving iPSC differentiation into EC. We 
indeed aimed to inhibit PTEN in iPSCs differentiating in presence of VEGF, in order 
to analyze the expression of the EC markers. Knockdown of genes using specific 
shRNAs is optimal for differentiation studies, since it has a long term and stable 
action on gene inhibition. Furthermore, we found that prolonged expositions of 
iPSCs to the PTEN chemical inhibitor bpV strongly diminished the cell survival, and 
it was indeed only possible to treat the cells with bpV for a short time. Therefore, in 
iPSCs differentiated with VEGF, in order to establish a stable knockdown of PTEN 
we used specific shRNAs to shutdown its expression and we then assessed the effect 
of the knockdown on EC marker expression. PTEN gene expression showed a 
significant repression in iPSCs infected with shPTEN, as compared to cells infected 
with shNT, confirming the efficiency of the shRNA knockdown of PTEN. 
Importantly, VE-cadherin and Flk1 showed a 1.5-fold increase in the gene 
expression after shPTEN infection, as compared to shNT infection. 
Our results indeed highlight for the first time that PTEN inhibition is required to 
induce EC marker expression in iPSCs differentiated with VEGF.  
To conclude our mechanistic studies, after linking the inhibition of PTEN to AKT 
activation and therefore to EC differentiation of iPSCs, we finally wanted to confirm 
it in the miR-21-induced iPSC differentiation system. We indeed showed that miR-
21 overexpression increased the phosphorylation of AKT at the Serine 473 site, 
whereas inhibition of miR-21 reduced AKT phosphorylation, as compared to the 
relative negative controls. The total level of AKT was not significantly altered by 
miR-21 overexpression or inhibition. In conclusion, these data show that miR-21 
inhibits PTEN expression, which in turn increases AKT phosphorylation. 
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All together our results show for the first time that miR-21 inhibits PTEN, therefore 
inducing AKT activation, and stimulates the secretion of TGF-β2, in order to drive 
iPSC differentiation into ECs, through VEGF stimulation.  
We established a new link between miR-21, TGF-β2 and VEGF, which, as 
mentioned before, appears to act through a mutual regulation. Elucidation of the 
molecular pathway involved in the miR-21 induced iPSC differentiation into ECs 
might provide the basic information for stem cell therapy of vascular diseases, e.g. 
tissue engineering and endothelial repair in damaged vessels. 
 
4.5 CONCLUSIONS AND FUTURE WORK 
The work presented in this thesis was based on the hypothesis that specific miRNAs 
and their targets may be able to drive the VEGF-induced iPSC differentiation 
towards EC lineage. 
Indeed, we have demonstrated that differentiation of iPSCs in presence of VEGF 
induces miR-21expression and that miR-21 is able to induce TGF-β2 expression and 
secretion, which in turn increases iPSC differentiation. Moreover TGF-β2 is 
expressed during the VEGF-induced iPSC differentiation and iPSCs treatment with 
the cytokine induces functional endothelial differentiation. We have then proved that 
TGF-β2 regulates EC differentiation of iPSCs through induction of VEGF secretion; 
moreover, miR-21 inhibition decreases VEGF expression in iPSCs. Indeed we have 
showed that the miR-21, TGF-β2 and VEGF pathways are tightly linked by a mutual 
regulation during iPSC differentiation into ECs. Finally, we have partially elucidated 
an additional signalling pathway through which miR-21 induces iPSC differentiation 
by validating PTEN/AKT pathway as a direct target of miR-21 and demonstrating 
that the PTEN/AKT pathway is required in the VEGF-induced EC differentiation of 
iPSCs. 
Evidences presented in this thesis suggest that endothelial lineage differentiation 
from iPSCs is regulated by miR-21/AKT and TGF-β2 pathways. 
Moreover, further elucidation of the molecular targets/pathways involved in the 
iPSC differentiation process regulated by VEGF, miR-21 and TGF-β2, will be useful 
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to fulfil the therapeutic potential of these enhanced ECs. For instance, the 
downstream targets of TGF-β2 need still to be elucidated in order to complete the 
mechanistic study of the miR-21/TGF-β2-regulated differentiation of iPSC. 
Interestingly, in a study from Kato et al. it has been reported that TGF-β can increase 
FoxO3a phosphorylation and transcriptional inactivation via PI3K/AKT; this study 
suggests that AKT/FoxO pathway regulation by TGF-β may be a new mechanism in 
inducing mesangial cell survival and oxidant stress in diabetic kidney disease (Kato, 
Yuan et al. 2006). Even though this mechanism has been described in a different cell 
type, it might be worth investigating it in our differentiation, since the forkhead box 
(Fox) family of transcription factors plays an important role in regulating the 
expression of genes involved in cell growth, proliferation, differentiation, and 
longevity (Tuteja and Kaestner 2007). 
Moreover, for possible future applications, iPSCs can be modified with the 
overexpression or knockdown of miR-21 and/or its targets, such as PTEN/AKT and 
TGF-β2, to improve their endothelial differentiation potential in order to obtain more 
homogeneous EC populations. 
Improvement in EC differentiation will be assessed in in vivo settings. In particular, 
enhanced ECs will be used for tissue engineering of decellularized vessels, in order 
to reduce the stenosis occurrence in vessel grafts. Furthermore, ECs obtained will be 
used for cell transplantation purposes to repair the damaged lumen in a model of 






Figure 71 Endothelial lineage differentiation from iPSCs is regulated by miR-21/AKT and 
TGF-β2 pathways 
A. Differentiation of iPSCs in presence of collagen IV and VEGF induces miR-21expression. miR-21 
induces iPSC differentiation into EC by inhibiting PTEN and therefore inducing AKT 
phosphorylation; moreover miR-21 is able to induce TGF-β2 expression and secretion, which in turn 
increases iPSC differentiation into ECs, through induction of VEGF secretion. 
B. TGF-β2 expression is induced by VEGF during iPSC differentiation and iPSCs treatment with 
TGF-β2 induces functional endothelial differentiation through induction of VEGF secretion. 
Inhibition of miR-21, whose expression is induced by VEGF during iPSC differentiation, decreases 
VEGF expression in iPSCs. Moreover, miR-21 induces TGF-β2 expression and secretion. Indeed, 
miR-21, TGF-β2 and VEGF pathways are tightly linked by a mutual regulation during iPSC 
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